aminolevulinic acid has been researched along with Bladder Cancer in 331 studies
Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.
5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To confirm the reproducibility of the effectiveness and safety in photodynamic diagnosis of non-muscle-invasive bladder cancer using 5-aminolevulinic acid in a prospective multicenter non-randomized phase III trial." | 9.27 | Oral 5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: A multicenter phase III study. ( Fujimoto, K; Furuse, H; Inoue, K; Matsuyama, H; Miyake, M; Nagao, K; Nakai, Y; Oyama, M; Ozono, S; Shimamoto, T; Shuin, T; Tsuzuki, T, 2018) |
| "To examine the utility and safety of photodynamic diagnosis (PDD) after oral administration of 5-aminolevulinic acid (5-ALA) (ALA-PDD) of non-muscle-invasive bladder cancer (NMIBC) using fluorescent-light (FL)-cystoscopy." | 9.22 | The clinical trial on the safety and effectiveness of the photodynamic diagnosis of non-muscle-invasive bladder cancer using fluorescent light-guided cystoscopy after oral administration of 5-aminolevulinic acid (5-ALA). ( Azuma, H; Fujimoto, K; Hirao, Y; Inoue, K; Ito, YM; Matsubara, A; Matsuyama, H; Mimata, H; Nagase, Y; Oyama, M; Ozono, S; Shiina, H; Shuin, T; Sugimura, Y; Ueno, M; Watanabe, H, 2016) |
| "Photodynamic diagnosis (PDD) of non-muscle-invasive bladder cancer (NMIBC) following transurethral administration of a hexalated form of 5-aminolevulinic acid (5-ALA), 5-ALA hexyl ester, is widely performed in Western countries." | 9.20 | Oral 5-aminolevulinic acid mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: A randomized, double-blind, multicentre phase II/III study. ( Anai, S; Fujimoto, K; Fukuhara, H; Furuse, H; Hara, T; Hirao, Y; Inoue, K; Kai, F; Matsuyama, H; Narukawa, M; Oyama, M; Ozono, S; Shuin, T; Ueno, M, 2015) |
| "Several studies have shown that 5-aminolevulinic acid (5-ALA)-induced fluorescence cystoscopy improves the detection of superficial bladder cancer." | 9.12 | Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. ( Burger, M; Denzinger, S; Filbeck, T; Knuechel, R; Roessler, W; Walter, B; Wieland, WF, 2007) |
| "We determined whether neoplastic disease, which was missed under white light can be found during transurethral resection of bladder cancer by 5-aminolevulinic acid-induced porphyrin fluorescence." | 9.09 | Transurethral resection and surveillance of bladder cancer supported by 5-aminolevulinic acid-induced fluorescence endoscopy. ( Baumgartner, R; Hofstetter, A; Knuechel, R; Kriegmair, M; Stepp, H; Zaak, D, 1999) |
| "5-Aminolevulinic acid facilitates detection of neoplastic disease during transurethral resection of bladder cancer and increases the accuracy of diagnosis." | 9.09 | Transurethral resection and surveillance of bladder cancer supported by 5-aminolevulinic acid-induced fluorescence endoscopy. ( Baumgartner, R; Hofstetter, A; Knuechel, R; Kriegmair, M; Stepp, H; Zaak, D, 1999) |
| "1) To determine whether fluorescence cystoscopy after intravesical administration of 5-aminolevulinic acid (5-ALA) is more sensitive in detection of dysplasia and bladder cancer when compared with conventional cystoscopy." | 9.09 | Cystoscopic diagnosis of bladder cancer by intravesical instillation of 5-aminolevulinic acid induced porphyrin fluorescence--the Singapore experience. ( Cheng, CW; Lau, WK; Olivo, M; Tan, PH, 2000) |
| "We conducted a meta-analysis assessing the effect of photodynamic diagnosis (PDD) -guided transurethral resection of the bladder tumor (TURB) on the recurrence-free survival in patients with non-muscle invasive bladder cancer within prospective randomised trials that used 5-aminolevulinic acid as a photosensitizer." | 8.93 | [A systematic review and meta-analysis to assess the recurrence-free survival in non-muscle invasive bladder cancer after transurethral resection guided by 5-aminolevulinic acid-induced photodynamic diagnosis compared with white-light transurethral resect ( Evmenenko, AA; Rolevich, AI, 2016) |
| "Patient selection for transurethral resection of the bladder tumor using photodynamic diagnosis (PDD-TURBT) with oral 5-aminolevulinic acid (5-ALA) hydrochloride for non-muscle-invasive bladder cancer (NMIBC) is still unclear as to the best balance of risks (adverse events including hypotension) and benefits (reduction of intravesical recurrence)." | 8.31 | Risks and benefits of transurethral resection of the bladder tumor using photodynamic diagnosis with oral 5-aminolevulinic acid hydrochloride according to age and history of recurrence in patients with non-muscle invasive bladder cancer. ( Hirata, H; Hiroyoshi, T; Isoyama, N; Ito, H; Kobayashi, K; Matsumoto, H; Matsuyama, H; Misumi, T; Nakamura, K; Oka, S; Shiraishi, K, 2023) |
| "Photodynamic diagnosis (PDD) with administration of oral aminolevulinic acid (ALA) prior to transurethral resection of bladder tumor (TURBT) can now be used for non-muscle invasive bladder cancer (NMIBC) in clinical settings in Japan." | 8.12 | Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (2nd report): Reduced bladder recurrence after PDD-TURBT. ( Fukuhara, H; Furihata, M; Inoue, K; Karashima, T; Kurabayashi, A; Lai, HW; Yamamoto, S, 2022) |
| "Introducing 5-aminolevulinic acid-photodynamic diagnosis into transurethral resection reduces residual bladder cancer and improves the cumulative intravesical recurrence-free survival in patients with non-muscle-invasive bladder cancer, indicating its possible therapeutic benefits." | 8.12 | Photodynamic diagnosis-assisted transurethral resection using oral 5-aminolevulinic acid decreases residual cancer and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer. ( Harada, S; Honda, T; Kani, N; Kato, T; Matsuoka, Y; Okazoe, H; Sugimoto, M; Taoka, R; Tohi, Y; Tsunemori, H; Ueda, N; Yamasaki, M, 2022) |
| " The aim of the present study was to determine whether treatment with 5‑aminolevurinic acid (5‑ALA) has antitumor effects in bladder cancer, by reduction of mitochondrial iron without using an iron chelator, through activation of heme synthesis." | 8.12 | 5‑Aminolevurinic acid inhibits the proliferation of bladder cancer cells by activating heme synthesis. ( Fujii, T; Fujimoto, K; Hori, S; Iida, K; Miyake, M; Morizawa, Y; Nakai, Y; Oda, Y; Onishi, K; Onishi, S; Owari, T; Tanaka, N; Tatsumi, Y, 2022) |
| "To investigate risk factors for orally administered 5-aminolevulinic acid (ALA)-induced hypotension for bladder cancer patients receiving photodynamic diagnosis (PDD)-assisted transurethral resection of bladder tumor (TURBT)." | 8.02 | Identification of risk factors associated with oral 5-aminolevulinic acid-induced hypotension in photodynamic diagnosis for non-muscle invasive bladder cancer: a multicenter retrospective study. ( Fukuhara, H; Hatakeyama, Y; Hyodo, Y; Inoue, K; Matsuyama, H; Mizokami, A; Nishimoto, K; Nohara, T; Okuhara, Y; Oyama, M, 2021) |
| "Transurethral resection of bladder tumor (TUR-BT) using 5-aminolevulinic acid (5-ALA) is common; however, intraoperative hypotension is frequent." | 8.02 | Oral 5-aminolevulinic acid administration prior to transurethral resection of bladder tumor causes intraoperative hypotension: Propensity score analysis. ( Ida, M; Kawaguchi, M; Naito, Y; Nakatani, S; Wang, X, 2021) |
| "A 72-year-old man with end-stage renal disease (ESRD) undergoing transurethral resection of a bladder tumor experienced severe and prolonged hypotension after receiving oral 5-aminolevulinic acid (5-ALA)." | 7.96 | Severe and Prolonged Hypotension After Oral 5-Aminolevulinic Acid Administration in a Patient With End-Stage Renal Disease Undergoing Transurethral Resection of a Bladder Tumor: A Case Report. ( Kida, T; Kobashi, T; Kobayashi, K; Sumitomo, M; Usuda, Y, 2020) |
| " Because EAU Guidelines awarded a level of evidence of 1a to mitomycin C, the drug is widely used to treat bladder cancer." | 7.96 | Mitomycin C-induced cell cycle arrest enhances 5-aminolevulinic acid-based photodynamic therapy for bladder cancer. ( Hanazaki, K; Inoue, K; Ishii, T; Ishizuka, M; Karashima, T; Kawada, C; Nakayama, T; Namikawa, T; Nozawa, N; Ogura, SI; Yamamoto, S, 2020) |
| "5-Aminolevulinic acid (ALA)-mediated photodynamic diagnosis (PDD) has recently been approved in Japan for the management of non-muscle invasive bladder cancer." | 7.96 | Real-world experience with 5-aminolevulinic acid for the photodynamic diagnosis of bladder cancer: Diagnostic accuracy and safety. ( Fukuhara, H; Inoue, K; Karashima, T; Yamamoto, S, 2020) |
| "The mechanism underlying the increased levels of protoporphyrin IX in bladder cancer remains unclear." | 7.83 | Expression of ferrochelatase has a strong correlation in protoporphyrin IX accumulation with photodynamic detection of bladder cancer. ( Anai, S; Chihara, Y; Fujimoto, K; Hirao, Y; Kuwada, M; Miyake, M; Nakai, Y; Onishi, S; Tanaka, N; Tatsumi, Y, 2016) |
| "The expression of ferrochelatase has a strong correlation in protoporphyrin IX accumulation with photodynamic detection of bladder cancer." | 7.83 | Expression of ferrochelatase has a strong correlation in protoporphyrin IX accumulation with photodynamic detection of bladder cancer. ( Anai, S; Chihara, Y; Fujimoto, K; Hirao, Y; Kuwada, M; Miyake, M; Nakai, Y; Onishi, S; Tanaka, N; Tatsumi, Y, 2016) |
| "We evaluated the feasibility of photodynamic diagnosis of bladder cancer by spectrophotometric analysis of voided urine samples after extracorporeal treatment with 5-aminolevulinic acid (ALA)." | 7.81 | Protoporphyrin IX induced by 5-aminolevulinic acid in bladder cancer cells in voided urine can be extracorporeally quantified using a spectrophotometer. ( Anai, S; Chihara, Y; Fujimoto, K; Hirao, Y; Masaomi, K; Miyake, M; Nakai, Y; Onishi, S; Tanaka, N; Tatsumi, Y, 2015) |
| "We demonstrated that protoporphyrin IX levels in urinary cells treated with ALA could be quantitatively detected by spectrophotometer in patients with bladder cancer." | 7.81 | Protoporphyrin IX induced by 5-aminolevulinic acid in bladder cancer cells in voided urine can be extracorporeally quantified using a spectrophotometer. ( Anai, S; Chihara, Y; Fujimoto, K; Hirao, Y; Masaomi, K; Miyake, M; Nakai, Y; Onishi, S; Tanaka, N; Tatsumi, Y, 2015) |
| " The precursor of the photosensitiser Protoporphyrin IX, 5-aminolevulinic acid (ALA), has been used for PDT of bladder cancer." | 7.80 | The natural flavonoid silybin improves the response to Photodynamic Therapy of bladder cancer cells. ( Batlle, A; Casas, A; Di Venosa, G; Eiján, AM; Gándara, L; Mamone, L; Prack Mc Cormick, B; Rodriguez, L; Sandes, E, 2014) |
| "The aim of this study was to assess the photodynamic effect of nanoparticles loaded with a photosensitizing nanomedicine, 5-aminolevulinic acid (5-ALA), on T24 bladder cancer cells in vitro." | 7.79 | Photodynamic effect of 5-aminolevulinic acid-loaded nanoparticles on bladder cancer cells: a preliminary investigation. ( Al-Hayek, S; Guo, H; Huang, H; Yan, X; Zhu, W; Zhu, Z, 2013) |
| "This study was undertaken to evaluate the clinical value of photodynamic diagnosis (PDD) with intravesical and oral instillation of 5-aminolevulinic acid (ALA) (ALA-PDD), and transurethral resection of bladder tumor (TURBT) guided by ALA-PDD (PDD-TURBT) for nonmuscle invasive bladder cancer." | 7.78 | Comparison between intravesical and oral administration of 5-aminolevulinic acid in the clinical benefit of photodynamic diagnosis for nonmuscle invasive bladder cancer. ( Fukuhara, H; Furihata, M; Iiyama, T; Inoue, K; Kamada, M; Kurabayashi, A; Miyamura, M; Shimamoto, T; Shuin, T; Tanimura, M; Watanabe, H, 2012) |
| "To report our clinical experience with intravesical instillations of 5-aminolevulinic acid (5-ALA) for the photodynamic diagnosis of bladder cancer and to assess any side-effects of the diagnostic method." | 7.73 | [Clinical experience with intravesical instillations of 5-aminolevulinic acid (5-ALA) for the photodynamic diagnosis using fluorescence cystoscopy for bladder cancer]. ( Inoue, K; Kamada, M; Karashima, T; Kurabayashi, A; Ohtsuki, Y; Shuin, T, 2006) |
| "5-aminolevulinic acid mediated changes in tissue specific fluorescence were studied in bladder cancer." | 7.72 | Fluorescence confocal microscopy and image analysis of bladder cancer using 5-aminolevulinic acid. ( Christopher, C; Hoon, TP; Lau, W; Manivasager, V; Olivo, M, 2003) |
| "To investigate the hypothesis that sequential mitomycin C and 5-aminolaevulinic acid (ALA)-mediated photodynamic therapy (PDT) interact additively in both the J82 bladder cancer cell line and its mitomycin-C-resistant derivative, J82/MMC, and to assess the theoretical basis of this interaction by measuring the relative mitochondrial density of the respective cell lines, on the basis that the mitochondria are the intracellular site where ALA is metabolized to the active photosensitizer, protoporphyrin IX." | 7.72 | Investigation of sequential mitomycin C and photodynamic therapy in a mitomycin-resistant bladder cancer cell-line model. ( Allman, R; Datta, SN; French, AJ; Matthews, PN, 2004) |
| "We determined whether photodynamic therapy after the oral administration of 5-aminolevulinic acid in patients with superficial bladder cancer that cannot be controlled by transurethral resection and intravesical bacillus Calmette-Guerin (BCG) immunotherapy would preserve the bladder, while stopping tumor progression." | 7.71 | Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. ( Baumgartner, R; Hofstetter, A; Kriegmair, M; Stepp, H; Waidelich, R; Weninger, E, 2001) |
| "These initial clinical results suggest that photodynamic therapy with orally administered 5-aminolevulinic acid is effective as an organ preserving procedure for treating superficial bladder cancer even in patients with bacillus Calmette-Guerin refractory carcinoma." | 7.71 | Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. ( Baumgartner, R; Hofstetter, A; Kriegmair, M; Stepp, H; Waidelich, R; Weninger, E, 2001) |
| "5-Aminolevulinic acid induced fluorescence endoscopy has outstanding sensitivity for detecting early stage bladder cancer." | 7.71 | Quantification of 5-aminolevulinic acid induced fluorescence improves the specificity of bladder cancer detection. ( Baumgartner, R; Frimberger, D; Hofstetter, A; Knüchel, R; Kriegmair, M; Schneede, P; Siebels, M; Stepp, H; Wagner, S; Zaak, D, 2001) |
| "In 25 cases (53 biopsies) of a history of or suspicion for bladder cancer 5-aminolevulinic acid induced fluorescence endoscopy and fluorescence image quantification were performed." | 7.71 | Quantification of 5-aminolevulinic acid induced fluorescence improves the specificity of bladder cancer detection. ( Baumgartner, R; Frimberger, D; Hofstetter, A; Knüchel, R; Kriegmair, M; Schneede, P; Siebels, M; Stepp, H; Wagner, S; Zaak, D, 2001) |
| "We determined whether the sensitivity of detecting dysplasia or early bladder cancer can be improved by 5-aminolevulinic acid induced porphyrin fluorescence." | 7.69 | Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. ( Baumgartner, R; Hofstädter, F; Hofstetter, A; Knüchel, R; Kriegmair, M; Stepp, H, 1996) |
| "To report clinical experience with intravesical instillations of 5-aminolevulinic acid (ALA) for the photodynamic therapy of superficial bladder cancer and to assess any side-effects of the treatment." | 7.69 | Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer. ( Baumgartner, R; Hofstetter, A; Kriegmair, M; Lumper, W; Waidelich, R, 1996) |
| " Cell survival of ALA-mediated photodynamic therapy was measured in the J82 bladder cancer cell line, along with its mitomycin C-resistant counterpart J82/MMC." | 7.69 | Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line. ( Allman, R; Datta, SN; Loh, C; Mason, M; Matthews, PN, 1997) |
| "5-Aminolevulinic acid (20 mg/kg) was orally administered 3 h before transurethral resection of bladder tumors using white light or fluorescent light." | 6.87 | Oral 5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: A multicenter phase III study. ( Fujimoto, K; Furuse, H; Inoue, K; Matsuyama, H; Miyake, M; Nagao, K; Nakai, Y; Oyama, M; Ozono, S; Shimamoto, T; Shuin, T; Tsuzuki, T, 2018) |
| "Regarding safety, the adverse drug reactions were observed as grade 1 pruritus in 1 patient (0." | 6.82 | The clinical trial on the safety and effectiveness of the photodynamic diagnosis of non-muscle-invasive bladder cancer using fluorescent light-guided cystoscopy after oral administration of 5-aminolevulinic acid (5-ALA). ( Azuma, H; Fujimoto, K; Hirao, Y; Inoue, K; Ito, YM; Matsubara, A; Matsuyama, H; Mimata, H; Nagase, Y; Oyama, M; Ozono, S; Shiina, H; Shuin, T; Sugimura, Y; Ueno, M; Watanabe, H, 2016) |
| "ALA-PDD was shown to be safe and effective." | 6.82 | The clinical trial on the safety and effectiveness of the photodynamic diagnosis of non-muscle-invasive bladder cancer using fluorescent light-guided cystoscopy after oral administration of 5-aminolevulinic acid (5-ALA). ( Azuma, H; Fujimoto, K; Hirao, Y; Inoue, K; Ito, YM; Matsubara, A; Matsuyama, H; Mimata, H; Nagase, Y; Oyama, M; Ozono, S; Shiina, H; Shuin, T; Sugimura, Y; Ueno, M; Watanabe, H, 2016) |
| "Evaluation of residual tumor rate and recurrence free survival were defined as the two primary study endpoints." | 6.71 | [Reducing the risk of superficial bladder cancer recurrence with 5-aminolevulinic acid-induced fluorescence diagnosis. Results of a 5-year study]. ( Filbeck, T; Knuechel, R; Pichlmeier, U; Rössler, W; Wieland, WF, 2003) |
| "Significant reduction in the number of residual tumours was detected in 59% (p = 0." | 6.71 | [Clinical significance of macroscopic 5-aminolevulinic acid (ALA)-inducer fluorescence in transurethral resection of non-invasive bladder cancer]. ( Al-Shukri, S; Danil'chenko, DI; Koenig, F; Loening, SA; Riedl, K; Schnorr, D; Waldman, A, 2003) |
| "The risk of residual tumor after transurethral resection of transitional cell carcinoma is significantly decreased by 5-aminolevulinic acid fluorescence endoscopy." | 6.70 | Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. ( Eisenberger, F; Hofstetter, A; Jocham, D; Kriegmair, M; Rassweiler, J; Rothenberger, KH; Stenzl, A; Tauber, R; Zaak, D, 2002) |
| "Residual tumor was evaluated in the 2 groups by repeat transurethral resection 10 to 14 days later." | 6.70 | Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. ( Eisenberger, F; Hofstetter, A; Jocham, D; Kriegmair, M; Rassweiler, J; Rothenberger, KH; Stenzl, A; Tauber, R; Zaak, D, 2002) |
| "5-Aminolevulinic acid (ALA) is a precursor of protoporphyrin IX (PpIX) that is being evaluated for use in photodiagnosis and phototherapy of malignant and nonmalignant disorders." | 6.70 | Clinical pharmacokinetics of 5-aminolevulinic acid in healthy volunteers and patients at high risk for recurrent bladder cancer. ( Dalton, JT; Golub, AL; Marcus, SL; Meyer, MC; Straughn, A; Yates, CR; Yin, D, 2002) |
| " ALA terminal half-life was approximately 45 min after intravenous or oral administration." | 6.70 | Clinical pharmacokinetics of 5-aminolevulinic acid in healthy volunteers and patients at high risk for recurrent bladder cancer. ( Dalton, JT; Golub, AL; Marcus, SL; Meyer, MC; Straughn, A; Yates, CR; Yin, D, 2002) |
| " The purpose of these studies was to examine the systemic pharmacokinetics and elimination of ALA, the bioavailability of ALA after oral and intravesical doses, and the factors that affect ALA concentrations in the bladder during intravesical treatment." | 6.70 | Clinical pharmacokinetics of 5-aminolevulinic acid in healthy volunteers and patients at high risk for recurrent bladder cancer. ( Dalton, JT; Golub, AL; Marcus, SL; Meyer, MC; Straughn, A; Yates, CR; Yin, D, 2002) |
| "First, we utilized three bladder cancer cell lines to evaluate senescence-related indicators and establish a cell senescence model." | 5.91 | Cell senescence-associated porphyrin metabolism affects the efficacy of aminolevulinic acid-photodynamic diagnosis in bladder cancer. ( Fukuhara, H; Inoue, K; Lai, HW; Ogura, SI; Yamamoto, S, 2023) |
| "Hypotension is an adverse effect of 5-ALA; however, its incidence and morbidity rates are unknown." | 5.91 | Incidence of perioperative hypotension in patients undergoing transurethral resection of bladder tumor after oral 5-aminolevulinic acid administration: a retrospective multicenter cohort study. ( Echigo, N; Goto, T; Inagawa, G; Kida, T; Kondo, Y; Nagamine, Y; Sumitomo, M; Yoshida, M; Yoshikawa, N, 2023) |
| "This study compared tumor recurrence among NMIBC patients who underwent TURBT under either white light cystoscopy (WL) or PDD." | 5.72 | Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (2nd report): Reduced bladder recurrence after PDD-TURBT. ( Fukuhara, H; Furihata, M; Inoue, K; Karashima, T; Kurabayashi, A; Lai, HW; Yamamoto, S, 2022) |
| "The frequency of recurrence in NMIBC patients (cumulative number of recurrences/cumulative number of follow-up days, number of recurrences/10,000 days), including progression to muscle-invasive bladder cancer (MIBC), was 12." | 5.72 | Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (2nd report): Reduced bladder recurrence after PDD-TURBT. ( Fukuhara, H; Furihata, M; Inoue, K; Karashima, T; Kurabayashi, A; Lai, HW; Yamamoto, S, 2022) |
| "The frequency of recurrence was lower and the time to recurrence was longer in the PDD-TURBT group than in the WL-TURBT group." | 5.72 | Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (2nd report): Reduced bladder recurrence after PDD-TURBT. ( Fukuhara, H; Furihata, M; Inoue, K; Karashima, T; Kurabayashi, A; Lai, HW; Yamamoto, S, 2022) |
| "5-aminolevulinic acid is a protoporphyrin IX precursor used for photodynamic diagnosis." | 5.72 | Photodynamic diagnosis-assisted transurethral resection using oral 5-aminolevulinic acid decreases residual cancer and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer. ( Harada, S; Honda, T; Kani, N; Kato, T; Matsuoka, Y; Okazoe, H; Sugimoto, M; Taoka, R; Tohi, Y; Tsunemori, H; Ueda, N; Yamasaki, M, 2022) |
| "PDD can increase the detection rate of bladder cancer, compared to NBI, by greater than 10%." | 5.62 | Comparison between 5-aminolevulinic acid photodynamic diagnosis and narrow-band imaging for bladder cancer detection. ( Abe, Y; Hagimoto, H; Kawakita, M; Kokubun, H; Kubota, M; Makita, N; Mine, Y; Murata, S; Tsutsumi, N; Yamasaki, T, 2021) |
| " ALA-related adverse effects included vomiting (seven cases), hypotension (seven cases, two of which were severe), and liver toxicity (four cases)." | 5.56 | Real-world experience with 5-aminolevulinic acid for the photodynamic diagnosis of bladder cancer: Diagnostic accuracy and safety. ( Fukuhara, H; Inoue, K; Karashima, T; Yamamoto, S, 2020) |
| "Sixty-one patients with bladder cancer, confirmed histologically after the transurethral resection of a bladder tumor, were recruited as the bladder cancer group, and 50 outpatients without history of urothelial carcinoma or cancer-related findings were recruited as the control group." | 5.42 | Protoporphyrin IX induced by 5-aminolevulinic acid in bladder cancer cells in voided urine can be extracorporeally quantified using a spectrophotometer. ( Anai, S; Chihara, Y; Fujimoto, K; Hirao, Y; Masaomi, K; Miyake, M; Nakai, Y; Onishi, S; Tanaka, N; Tatsumi, Y, 2015) |
| "The differences in the bladder cancer group were significantly greater than those in the control group (p < 0." | 5.42 | Protoporphyrin IX induced by 5-aminolevulinic acid in bladder cancer cells in voided urine can be extracorporeally quantified using a spectrophotometer. ( Anai, S; Chihara, Y; Fujimoto, K; Hirao, Y; Masaomi, K; Miyake, M; Nakai, Y; Onishi, S; Tanaka, N; Tatsumi, Y, 2015) |
| "In the pairwise meta-analysis, 5-aminolevulinic acid (5-ALA) reduced the short-term and long-term recurrence rates of bladder cancer compared with white light cystoscopy (WLC); however, no statistical difference was observed in intermediate-term recurrence rates (RR=0." | 5.41 | Diagnostic and therapeutic effects of fluorescence cystoscopy and narrow-band imaging in bladder cancer: a systematic review and network meta-analysis. ( Fan, Z; Guo, X; Liu, Y; Luo, J; Shi, H; Wang, B; Yu, J, 2023) |
| "Urine samples from 58 patients with bladder cancer were centrifuged, and urine sediments were then treated with ALA." | 5.40 | Diagnostic approach for cancer cells in urine sediments by 5-aminolevulinic acid-based photodynamic detection in bladder cancer. ( Anai, S; Chihara, Y; Fujimoto, K; Hirao, Y; Kuwada, M; Miyake, M; Nakai, Y; Onishi, S; Tanaka, N; Tatsumi, Y, 2014) |
| "Cytotoxicity to T24 bladder cancer cells was assessed by coincubating 5-ALA-loaded nanoparticles of different concentrations with T24 bladder cancer cells." | 5.39 | Photodynamic effect of 5-aminolevulinic acid-loaded nanoparticles on bladder cancer cells: a preliminary investigation. ( Al-Hayek, S; Guo, H; Huang, H; Yan, X; Zhu, W; Zhu, Z, 2013) |
| "Mitomycin C appears to enhance ALA-mediated PDT when administered first." | 5.32 | Investigation of sequential mitomycin C and photodynamic therapy in a mitomycin-resistant bladder cancer cell-line model. ( Allman, R; Datta, SN; French, AJ; Matthews, PN, 2004) |
| "On 21 patients, skin phototoxicity was determined prior to as well as 4, 8 and 28 h after intravesical instillation of a 3% ALA solution by exposing small skin areas to a progressively graded series of defined UVA-light doses (n = 9; 5-80 J/cm(2))." | 5.31 | No generalized skin phototoxicity after intravesical application of 5-aminolevulinic acid for fluorescence diagnosis of superficial bladder cancer. ( Filbeck, T; Karrer, S; Pichlmeier, U; Rössler, W; Szeimies, RM; Wieland, WF; Wimmershoff, MB, 2000) |
| "Most lesions of superficial bladder cancer may be easily missed during conventional white light cystoscopy." | 5.31 | Significance of fluorescence cystoscopy for diagnosis of superficial bladder cancer after intravesical instillation of delta aminolevulinic acid. ( Ehsan, A; Engelmann, U; Haupt, G; Sommer, F, 2001) |
| "To confirm the reproducibility of the effectiveness and safety in photodynamic diagnosis of non-muscle-invasive bladder cancer using 5-aminolevulinic acid in a prospective multicenter non-randomized phase III trial." | 5.27 | Oral 5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: A multicenter phase III study. ( Fujimoto, K; Furuse, H; Inoue, K; Matsuyama, H; Miyake, M; Nagao, K; Nakai, Y; Oyama, M; Ozono, S; Shimamoto, T; Shuin, T; Tsuzuki, T, 2018) |
| "To assess the efficacy of two treatment options for non-muscle-invasive bladder cancer (NMIBC): (1) transurethral resection (TUR) guided by fluorescence cystoscopy (FC) with the use of 5-aminolevulinic acid (5-ALA) and (2) single early instillation of doxorubicin in a single-center open-label prospective randomized study with a 2 × 2 factorial design." | 5.24 | Results of a prospective randomized study assessing the efficacy of fluorescent cystoscopy-assisted transurethral resection and single instillation of doxorubicin in patients with non-muscle-invasive bladder cancer. ( Krasny, SA; Minich, AA; Mokhort, AA; Polyakov, SL; Rolevich, AI; Sukonko, OG; Vasilevich, VY; Zhegalik, AG, 2017) |
| "To examine the utility and safety of photodynamic diagnosis (PDD) after oral administration of 5-aminolevulinic acid (5-ALA) (ALA-PDD) of non-muscle-invasive bladder cancer (NMIBC) using fluorescent-light (FL)-cystoscopy." | 5.22 | The clinical trial on the safety and effectiveness of the photodynamic diagnosis of non-muscle-invasive bladder cancer using fluorescent light-guided cystoscopy after oral administration of 5-aminolevulinic acid (5-ALA). ( Azuma, H; Fujimoto, K; Hirao, Y; Inoue, K; Ito, YM; Matsubara, A; Matsuyama, H; Mimata, H; Nagase, Y; Oyama, M; Ozono, S; Shiina, H; Shuin, T; Sugimura, Y; Ueno, M; Watanabe, H, 2016) |
| "Photodynamic diagnosis (PDD) of non-muscle-invasive bladder cancer (NMIBC) following transurethral administration of a hexalated form of 5-aminolevulinic acid (5-ALA), 5-ALA hexyl ester, is widely performed in Western countries." | 5.20 | Oral 5-aminolevulinic acid mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: A randomized, double-blind, multicentre phase II/III study. ( Anai, S; Fujimoto, K; Fukuhara, H; Furuse, H; Hara, T; Hirao, Y; Inoue, K; Kai, F; Matsuyama, H; Narukawa, M; Oyama, M; Ozono, S; Shuin, T; Ueno, M, 2015) |
| "The benefits of fluorescent light (FL) cystoscopy with 5-aminolevulinic acid (5-ALA) or hexaminolevulinate (HAL) in non-muscle-invasive bladder cancer (NMIBC) have been mentioned in many trials." | 5.12 | Effects of fluorescent light cystoscopy in non-muscle-invasive bladder cancer: A systematic review and meta-analysis. ( Liu, B; Ma, X; Shen, H; Sun, J, 2021) |
| "Several studies have shown that 5-aminolevulinic acid (5-ALA)-induced fluorescence cystoscopy improves the detection of superficial bladder cancer." | 5.12 | Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. ( Burger, M; Denzinger, S; Filbeck, T; Knuechel, R; Roessler, W; Walter, B; Wieland, WF, 2007) |
| "To report a phase-1 study of patients with recurrent superficial bladder cancer treated with photodynamic therapy (PDT) using sequential mitomycin C and 5-aminolaevulinic acid (ALA)." | 5.11 | A phase-1 study of sequential mitomycin C and 5-aminolaevulinic acid-mediated photodynamic therapy in recurrent superficial bladder carcinoma. ( Allman, R; Datta, SN; French, AJ; Mason, MD; Matthews, PN; Skyrme, RJ, 2005) |
| "5 hours after intravesical administration of 17% 5-aminolevulinic acid in 12 patients with recurring, multifocal, Stage pTa, grade I to III, urothelial tumors of the bladder and carcinoma in situ." | 5.10 | Whole bladder photodynamic therapy with 5-aminolevulinic acid using a white light source. ( Baumgartner, R; Beyer, W; Hofstetter, A; Knüchel, R; Kriegmair, M; Schröder, J; Stepp, H; Waidelich, R, 2003) |
| "Our preliminary data show that whole bladder photodynamic therapy with intravesically applied 5-aminolevulinic acid using a white light source is effective in destroying flat malignant lesions of the bladder such as carcinoma in situ." | 5.10 | Whole bladder photodynamic therapy with 5-aminolevulinic acid using a white light source. ( Baumgartner, R; Beyer, W; Hofstetter, A; Knüchel, R; Kriegmair, M; Schröder, J; Stepp, H; Waidelich, R, 2003) |
| "In 208 consecutive patients with superficial bladder cancer 328 endoscopies were performed to compare the sensitivity of white light and 5-aminolevulinic acid induced fluorescence endoscopy." | 5.09 | Is everything all right if nothing seems wrong? A simple method of assessing the diagnostic value of endoscopic procedures when a gold standard is absent. ( Kriegmair, M; Schneeweiss, S; Stepp, H, 1999) |
| "We determined whether neoplastic disease, which was missed under white light can be found during transurethral resection of bladder cancer by 5-aminolevulinic acid-induced porphyrin fluorescence." | 5.09 | Transurethral resection and surveillance of bladder cancer supported by 5-aminolevulinic acid-induced fluorescence endoscopy. ( Baumgartner, R; Hofstetter, A; Knuechel, R; Kriegmair, M; Stepp, H; Zaak, D, 1999) |
| "5-Aminolevulinic acid facilitates detection of neoplastic disease during transurethral resection of bladder cancer and increases the accuracy of diagnosis." | 5.09 | Transurethral resection and surveillance of bladder cancer supported by 5-aminolevulinic acid-induced fluorescence endoscopy. ( Baumgartner, R; Hofstetter, A; Knuechel, R; Kriegmair, M; Stepp, H; Zaak, D, 1999) |
| "1) To determine whether fluorescence cystoscopy after intravesical administration of 5-aminolevulinic acid (5-ALA) is more sensitive in detection of dysplasia and bladder cancer when compared with conventional cystoscopy." | 5.09 | Cystoscopic diagnosis of bladder cancer by intravesical instillation of 5-aminolevulinic acid induced porphyrin fluorescence--the Singapore experience. ( Cheng, CW; Lau, WK; Olivo, M; Tan, PH, 2000) |
| "The initial encouraging results using 5-aminolevulinic acid (5-ALA) induced fluorescence endoscopy (AFE) have promised a procedure with an outstanding sensitivity for the detection of early stage bladder cancer." | 5.09 | Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies. ( Baumgartner, R; Corvin, S; Frimberger, D; Hofstetter, A; Knüchel, R; Kriegmair, M; Oberneder, R; Schneede, P; Stepp, H; Zaak, D, 2001) |
| " The usefulness of intracellularly accumulated endogenous protoporphyrin IX (PPIX), induced by 5-aminolevulinic acid (ALA), for diagnosis of early bladder cancer and the correlation with cystoscopic, microscopic, and fluorescence findings was investigated." | 5.07 | Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid. ( Baumgartner, R; Ehsan, A; Hofstädter, F; Hofstetter, A; Knuechel, R; Kriegmair, M; Lumper, W; Steinbach, P, 1994) |
| "We conducted a meta-analysis assessing the effect of photodynamic diagnosis (PDD) -guided transurethral resection of the bladder tumor (TURB) on the recurrence-free survival in patients with non-muscle invasive bladder cancer within prospective randomised trials that used 5-aminolevulinic acid as a photosensitizer." | 4.93 | [A systematic review and meta-analysis to assess the recurrence-free survival in non-muscle invasive bladder cancer after transurethral resection guided by 5-aminolevulinic acid-induced photodynamic diagnosis compared with white-light transurethral resect ( Evmenenko, AA; Rolevich, AI, 2016) |
| "Controversy exists regarding the therapeutic benefit and cost effectiveness of photodynamic diagnosis (PDD) with 5-aminolevulinic acid (5-ALA) or hexyl aminolevulinate (HAL) in addition to white-light cystoscopy (WLC) in the management of non-muscle-invasive bladder cancer (NMIBC)." | 4.89 | Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. ( Babjuk, M; Catto, JW; Jichlinski, P; Rink, M; Shariat, SF; Stenzl, A; Stepp, H; Witjes, JA; Zaak, D, 2013) |
| "The clinical benefit of photodynamic diagnosis (PDD) with 5-aminolevulinic acid or hexaminolevulinate in addition to white-light cystoscopy (WLC) in bladder cancer has been discussed controversially." | 4.86 | Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. ( Jacqmin, D; Jichlinski, P; Jocham, D; Kausch, I; Montorsi, F; Sommerauer, M; Stenzl, A; Vonthein, R; Ziegler, A, 2010) |
| "Hexyl aminolevulinate, the hexyl ester of 5-aminolevulinic acid, is a photosensitising agent designed to enhance the detection of bladder cancer tumours, in particular highly malignant carcinoma in situ (CIS)." | 4.83 | Hexyl aminolevulinate: in the detection of bladder cancer. ( Frampton, JE; Plosker, GL, 2006) |
| "Hexyl aminolevulinate [aminolevulinic acid hexyl ester, hexyl 5-aminolevulinate, 5-ALA hexylester, hexaminolevulinate, Hexvix, Hexvix PD, Hexvix PDT, P 1206] is being developed by PhotoCure, a Norwegian company, for the diagnosis and treatment of bladder cancer." | 4.82 | Hexyl aminolevulinate: 5-ALA hexylester, 5-ALA hexylesther, aminolevulinic acid hexyl ester, hexaminolevulinate, hexyl 5-aminolevulinate, P 1206. ( , 2005) |
| "Patient selection for transurethral resection of the bladder tumor using photodynamic diagnosis (PDD-TURBT) with oral 5-aminolevulinic acid (5-ALA) hydrochloride for non-muscle-invasive bladder cancer (NMIBC) is still unclear as to the best balance of risks (adverse events including hypotension) and benefits (reduction of intravesical recurrence)." | 4.31 | Risks and benefits of transurethral resection of the bladder tumor using photodynamic diagnosis with oral 5-aminolevulinic acid hydrochloride according to age and history of recurrence in patients with non-muscle invasive bladder cancer. ( Hirata, H; Hiroyoshi, T; Isoyama, N; Ito, H; Kobayashi, K; Matsumoto, H; Matsuyama, H; Misumi, T; Nakamura, K; Oka, S; Shiraishi, K, 2023) |
| "Photodynamic diagnosis (PDD) with administration of oral aminolevulinic acid (ALA) prior to transurethral resection of bladder tumor (TURBT) can now be used for non-muscle invasive bladder cancer (NMIBC) in clinical settings in Japan." | 4.12 | Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (2nd report): Reduced bladder recurrence after PDD-TURBT. ( Fukuhara, H; Furihata, M; Inoue, K; Karashima, T; Kurabayashi, A; Lai, HW; Yamamoto, S, 2022) |
| "Introducing 5-aminolevulinic acid-photodynamic diagnosis into transurethral resection reduces residual bladder cancer and improves the cumulative intravesical recurrence-free survival in patients with non-muscle-invasive bladder cancer, indicating its possible therapeutic benefits." | 4.12 | Photodynamic diagnosis-assisted transurethral resection using oral 5-aminolevulinic acid decreases residual cancer and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer. ( Harada, S; Honda, T; Kani, N; Kato, T; Matsuoka, Y; Okazoe, H; Sugimoto, M; Taoka, R; Tohi, Y; Tsunemori, H; Ueda, N; Yamasaki, M, 2022) |
| "Seven different inhibitors of the heme metabolic pathway were applied in combination with HAL to study the formation of PpIX in bladder cancer HT1197 and normal fibroblast HFFF2 cells ex vivo, specifically with the aim to increase the fluorescence contrast between cancer and non-cancer cells." | 4.12 | Effects of Supplemental Drugs on Hexaminolevulinate (HAL)-Induced PpIX Fluorescence in Bladder Cancer Cell Suspensions. ( Chan, KM; MacGregor, M; Vasilev, K, 2022) |
| " The aim of the present study was to determine whether treatment with 5‑aminolevurinic acid (5‑ALA) has antitumor effects in bladder cancer, by reduction of mitochondrial iron without using an iron chelator, through activation of heme synthesis." | 4.12 | 5‑Aminolevurinic acid inhibits the proliferation of bladder cancer cells by activating heme synthesis. ( Fujii, T; Fujimoto, K; Hori, S; Iida, K; Miyake, M; Morizawa, Y; Nakai, Y; Oda, Y; Onishi, K; Onishi, S; Owari, T; Tanaka, N; Tatsumi, Y, 2022) |
| "To investigate risk factors for orally administered 5-aminolevulinic acid (ALA)-induced hypotension for bladder cancer patients receiving photodynamic diagnosis (PDD)-assisted transurethral resection of bladder tumor (TURBT)." | 4.02 | Identification of risk factors associated with oral 5-aminolevulinic acid-induced hypotension in photodynamic diagnosis for non-muscle invasive bladder cancer: a multicenter retrospective study. ( Fukuhara, H; Hatakeyama, Y; Hyodo, Y; Inoue, K; Matsuyama, H; Mizokami, A; Nishimoto, K; Nohara, T; Okuhara, Y; Oyama, M, 2021) |
| "Hexaminolevulinate (HAL) induced Protoporphyrin IX (PpIX) fluorescence is commonly used to differentiate cancer cells from normal cells in vivo, as for instance in blue light cystoscopy for bladder cancer diagnosis." | 4.02 | Improving hexaminolevulinate enabled cancer cell detection in liquid biopsy immunosensors. ( Chan, KM; Gleadle, J; Li, J; MacGregor, M; Michl, TD; Vasilev, K, 2021) |
| "Transurethral resection of bladder tumor (TUR-BT) using 5-aminolevulinic acid (5-ALA) is common; however, intraoperative hypotension is frequent." | 4.02 | Oral 5-aminolevulinic acid administration prior to transurethral resection of bladder tumor causes intraoperative hypotension: Propensity score analysis. ( Ida, M; Kawaguchi, M; Naito, Y; Nakatani, S; Wang, X, 2021) |
| "Photodynamic diagnosis (PDD) using 5-aminolevulinic acid (5-ALA) is expected to be useful in preventing oversight of non-muscle-invasive bladder cancer (NMIBC) and in reducing the intravesical recurrence rate after transurethral resection of bladder tumor (TURBT)." | 4.02 | [Initial Experience of Photodynamic Diagnosis-Assisted Transurethral Resection of Bladder Tumor (PDD-TURBT)]. ( Inoue, T; Kanda, H; Kato, M; Masui, S; Nishikawa, K; Sasaki, T; Sugimura, Y; Sugino, Y; Yoshio, Y, 2021) |
| "A 72-year-old man with end-stage renal disease (ESRD) undergoing transurethral resection of a bladder tumor experienced severe and prolonged hypotension after receiving oral 5-aminolevulinic acid (5-ALA)." | 3.96 | Severe and Prolonged Hypotension After Oral 5-Aminolevulinic Acid Administration in a Patient With End-Stage Renal Disease Undergoing Transurethral Resection of a Bladder Tumor: A Case Report. ( Kida, T; Kobashi, T; Kobayashi, K; Sumitomo, M; Usuda, Y, 2020) |
| "To investigate the diagnostic accuracy of 5- aminolevulinic acid-mediated photodynamic diagnosis (ALA-PDD) for upper urinary tract tumor (UTUC) including carcinoma in situ (CIS) lesions using flexible fluorescence ureterorenoscopy." | 3.96 | 5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence ureterorenoscopy for urinary upper tract urothelial carcinoma ∼Preliminary prospective single centre trial∼. ( Fukuhara, H; Furihata, M; Inoue, K; Kurabayashi, A; Murakami, K; Setuda, S; Takahashi, K; Tanaka, T, 2020) |
| "Photodynamic diagnosis (PDD) of non-muscle invasive bladder cancer using 5-aminolevulinic acid (5-ALA) has recently attracted attention as a diagnostic method for observing cancer lesions based on fluorescence emission using a fluorescent endoscope." | 3.96 | Inverted papilloma of the urinary bladder shows fluorescence on photodynamic diagnosis using 5-aminolevulinic acid. ( Akiyama, Y; Kawai, T; Kume, H; Makino, K; Miyakawa, J; Miyama, Y; Nakamura, M; Oshina, T; Sato, Y; Suzuki, M; Ushiku, T; Yamada, D; Yamada, Y, 2020) |
| " Because EAU Guidelines awarded a level of evidence of 1a to mitomycin C, the drug is widely used to treat bladder cancer." | 3.96 | Mitomycin C-induced cell cycle arrest enhances 5-aminolevulinic acid-based photodynamic therapy for bladder cancer. ( Hanazaki, K; Inoue, K; Ishii, T; Ishizuka, M; Karashima, T; Kawada, C; Nakayama, T; Namikawa, T; Nozawa, N; Ogura, SI; Yamamoto, S, 2020) |
| "5-Aminolevulinic acid (ALA)-mediated photodynamic diagnosis (PDD) has recently been approved in Japan for the management of non-muscle invasive bladder cancer." | 3.96 | Real-world experience with 5-aminolevulinic acid for the photodynamic diagnosis of bladder cancer: Diagnostic accuracy and safety. ( Fukuhara, H; Inoue, K; Karashima, T; Yamamoto, S, 2020) |
| " We introduce 5-aminolevulinic acid-based photodynamic diagnosis for bladder cancer." | 3.88 | [Navigation Surgery for Bladder Cancer by ALA-PDD]. ( Fukuhara, H; Inoue, K, 2018) |
| " To evaluate the feasibility of using CLE with two fluorophores: fluorescein (FLUO) and hexylaminolevulinate (HAL) to determine histologic and cytologic bladder cancer criteria." | 3.85 | Urothelial Tumors and Dual-Band Imaging: A New Concept in Confocal Laser Endomicroscopy. ( Bonnal, JL; Francois, C; Gosset, P; Maadarani, KE; Marien, A; Mauroy, B; Rock, A, 2017) |
| "The mechanism underlying the increased levels of protoporphyrin IX in bladder cancer remains unclear." | 3.83 | Expression of ferrochelatase has a strong correlation in protoporphyrin IX accumulation with photodynamic detection of bladder cancer. ( Anai, S; Chihara, Y; Fujimoto, K; Hirao, Y; Kuwada, M; Miyake, M; Nakai, Y; Onishi, S; Tanaka, N; Tatsumi, Y, 2016) |
| "The expression of ferrochelatase has a strong correlation in protoporphyrin IX accumulation with photodynamic detection of bladder cancer." | 3.83 | Expression of ferrochelatase has a strong correlation in protoporphyrin IX accumulation with photodynamic detection of bladder cancer. ( Anai, S; Chihara, Y; Fujimoto, K; Hirao, Y; Kuwada, M; Miyake, M; Nakai, Y; Onishi, S; Tanaka, N; Tatsumi, Y, 2016) |
| "We evaluated the feasibility of photodynamic diagnosis of bladder cancer by spectrophotometric analysis of voided urine samples after extracorporeal treatment with 5-aminolevulinic acid (ALA)." | 3.81 | Protoporphyrin IX induced by 5-aminolevulinic acid in bladder cancer cells in voided urine can be extracorporeally quantified using a spectrophotometer. ( Anai, S; Chihara, Y; Fujimoto, K; Hirao, Y; Masaomi, K; Miyake, M; Nakai, Y; Onishi, S; Tanaka, N; Tatsumi, Y, 2015) |
| "We demonstrated that protoporphyrin IX levels in urinary cells treated with ALA could be quantitatively detected by spectrophotometer in patients with bladder cancer." | 3.81 | Protoporphyrin IX induced by 5-aminolevulinic acid in bladder cancer cells in voided urine can be extracorporeally quantified using a spectrophotometer. ( Anai, S; Chihara, Y; Fujimoto, K; Hirao, Y; Masaomi, K; Miyake, M; Nakai, Y; Onishi, S; Tanaka, N; Tatsumi, Y, 2015) |
| " The precursor of the photosensitiser Protoporphyrin IX, 5-aminolevulinic acid (ALA), has been used for PDT of bladder cancer." | 3.80 | The natural flavonoid silybin improves the response to Photodynamic Therapy of bladder cancer cells. ( Batlle, A; Casas, A; Di Venosa, G; Eiján, AM; Gándara, L; Mamone, L; Prack Mc Cormick, B; Rodriguez, L; Sandes, E, 2014) |
| "The aim of this study was to assess the photodynamic effect of nanoparticles loaded with a photosensitizing nanomedicine, 5-aminolevulinic acid (5-ALA), on T24 bladder cancer cells in vitro." | 3.79 | Photodynamic effect of 5-aminolevulinic acid-loaded nanoparticles on bladder cancer cells: a preliminary investigation. ( Al-Hayek, S; Guo, H; Huang, H; Yan, X; Zhu, W; Zhu, Z, 2013) |
| "This study was undertaken to evaluate the clinical value of photodynamic diagnosis (PDD) with intravesical and oral instillation of 5-aminolevulinic acid (ALA) (ALA-PDD), and transurethral resection of bladder tumor (TURBT) guided by ALA-PDD (PDD-TURBT) for nonmuscle invasive bladder cancer." | 3.78 | Comparison between intravesical and oral administration of 5-aminolevulinic acid in the clinical benefit of photodynamic diagnosis for nonmuscle invasive bladder cancer. ( Fukuhara, H; Furihata, M; Iiyama, T; Inoue, K; Kamada, M; Kurabayashi, A; Miyamura, M; Shimamoto, T; Shuin, T; Tanimura, M; Watanabe, H, 2012) |
| "This study shows that PVP-hypericin appears to have great potential as a photodynamic agent against non-muscle-invasive bladder cancers after intravesical administration, with a limited risk of affecting the deeper layers of the bladder." | 3.77 | Biodistribution of PVP-hypericin and hexaminolevulinate-induced PpIX in normal and orthotopic tumor-bearing rat urinary bladder. ( de Witte, PA; Hettinger, K; Van Cleynenbreugel, B; Van Poppel, H; Vandepitte, J, 2011) |
| "To study the differential effects of bacillus Calmette-Guérin (BCG) and mitomycin C (MMC) intravesical therapy on the false-positive rate of PDD of bladder cancer." | 3.76 | Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Guérin immunotherapy and mitomycin C intravesical therapy. ( Bosch, JL; Draga, RO; Grimbergen, MC; Jonges, TN; Kok, ET; van Swol, CF, 2010) |
| "Sixty specimens of bladder mucosa were collected from 20 patients who were suspected of having carcinoma in situ by fluorescence cystoscopy with 5-aminolevulinic acid." | 3.75 | Cytogenetic analysis of false-positive mucosa by photodynamic diagnosis using 5-aminolevulinic acid - possible existence of premalignant genomic alterations examined by in vitro experiment. ( Matsuyama, H; Nagao, K; Ohmi, C; Sakano, S; Sasaki, K; Yamamoto, Y, 2009) |
| " In bladder cancer diagnosis, fluorescence-guided endoscopy with 5-aminolevulinic acid (5-ALA) has gained interest as a technique that can provide such spatial differentiation, thus improving early detection and more complete removal of superficial tumors." | 3.75 | Raman spectroscopy of bladder tissue in the presence of 5-aminolevulinic acid. ( Grimbergen, MC; Mahadevan-Jansen, A; Stone, N; Uff, J; van Moorselaar, RJ; van Swol, CF, 2009) |
| "To report our clinical experience with intravesical instillations of 5-aminolevulinic acid (5-ALA) for the photodynamic diagnosis of bladder cancer and to assess any side-effects of the diagnostic method." | 3.73 | [Clinical experience with intravesical instillations of 5-aminolevulinic acid (5-ALA) for the photodynamic diagnosis using fluorescence cystoscopy for bladder cancer]. ( Inoue, K; Kamada, M; Karashima, T; Kurabayashi, A; Ohtsuki, Y; Shuin, T, 2006) |
| "5-aminolevulinic acid mediated changes in tissue specific fluorescence were studied in bladder cancer." | 3.72 | Fluorescence confocal microscopy and image analysis of bladder cancer using 5-aminolevulinic acid. ( Christopher, C; Hoon, TP; Lau, W; Manivasager, V; Olivo, M, 2003) |
| "To investigate the hypothesis that sequential mitomycin C and 5-aminolaevulinic acid (ALA)-mediated photodynamic therapy (PDT) interact additively in both the J82 bladder cancer cell line and its mitomycin-C-resistant derivative, J82/MMC, and to assess the theoretical basis of this interaction by measuring the relative mitochondrial density of the respective cell lines, on the basis that the mitochondria are the intracellular site where ALA is metabolized to the active photosensitizer, protoporphyrin IX." | 3.72 | Investigation of sequential mitomycin C and photodynamic therapy in a mitomycin-resistant bladder cancer cell-line model. ( Allman, R; Datta, SN; French, AJ; Matthews, PN, 2004) |
| "We determined whether photodynamic therapy after the oral administration of 5-aminolevulinic acid in patients with superficial bladder cancer that cannot be controlled by transurethral resection and intravesical bacillus Calmette-Guerin (BCG) immunotherapy would preserve the bladder, while stopping tumor progression." | 3.71 | Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. ( Baumgartner, R; Hofstetter, A; Kriegmair, M; Stepp, H; Waidelich, R; Weninger, E, 2001) |
| "These initial clinical results suggest that photodynamic therapy with orally administered 5-aminolevulinic acid is effective as an organ preserving procedure for treating superficial bladder cancer even in patients with bacillus Calmette-Guerin refractory carcinoma." | 3.71 | Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. ( Baumgartner, R; Hofstetter, A; Kriegmair, M; Stepp, H; Waidelich, R; Weninger, E, 2001) |
| "5-Aminolevulinic acid induced fluorescence endoscopy has outstanding sensitivity for detecting early stage bladder cancer." | 3.71 | Quantification of 5-aminolevulinic acid induced fluorescence improves the specificity of bladder cancer detection. ( Baumgartner, R; Frimberger, D; Hofstetter, A; Knüchel, R; Kriegmair, M; Schneede, P; Siebels, M; Stepp, H; Wagner, S; Zaak, D, 2001) |
| "In 25 cases (53 biopsies) of a history of or suspicion for bladder cancer 5-aminolevulinic acid induced fluorescence endoscopy and fluorescence image quantification were performed." | 3.71 | Quantification of 5-aminolevulinic acid induced fluorescence improves the specificity of bladder cancer detection. ( Baumgartner, R; Frimberger, D; Hofstetter, A; Knüchel, R; Kriegmair, M; Schneede, P; Siebels, M; Stepp, H; Wagner, S; Zaak, D, 2001) |
| "We determined whether the sensitivity of detecting dysplasia or early bladder cancer can be improved by 5-aminolevulinic acid induced porphyrin fluorescence." | 3.69 | Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. ( Baumgartner, R; Hofstädter, F; Hofstetter, A; Knüchel, R; Kriegmair, M; Stepp, H, 1996) |
| "To report clinical experience with intravesical instillations of 5-aminolevulinic acid (ALA) for the photodynamic therapy of superficial bladder cancer and to assess any side-effects of the treatment." | 3.69 | Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer. ( Baumgartner, R; Hofstetter, A; Kriegmair, M; Lumper, W; Waidelich, R, 1996) |
| "Aqueous solutions of 5-aminolevulinic acid (ALA) prepared for intravesical instillation in the framework of a clinical study on the fluorescence diagnosis of urothelial bladder cancer were found to be unstable." | 3.69 | Chemical instability of 5-aminolevulinic acid used in the fluorescence diagnosis of bladder tumours. ( Diddens, H; Hüttmann, G; Novo, M, 1996) |
| " Cell survival of ALA-mediated photodynamic therapy was measured in the J82 bladder cancer cell line, along with its mitomycin C-resistant counterpart J82/MMC." | 3.69 | Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line. ( Allman, R; Datta, SN; Loh, C; Mason, M; Matthews, PN, 1997) |
| "To determine the effect of photodynamic therapy mediated by 5-aminolevulinic acid (ALA) on a range of bladder cancer cell lines, including a squamous cancer cell line and a multi-drug resistant cell line." | 3.69 | Photodynamic therapy of bladder cancer cell lines. ( Allman, R; Datta, SN; Loh, CS; Mason, M; Matthews, PN, 1997) |
| "Non-muscle invasive bladder cancers are more suitable for PDT than muscle invasive and metastatic bladder cancers." | 3.01 | Photodynamic Therapy for Bladder Cancers, A Focused Review ( Foster, BA; Giram, P; Rahman, KMM; You, Y, 2023) |
| "Bladder cancer is the first cancer for which PDT was clinically approved in 1993." | 3.01 | Photodynamic Therapy for Bladder Cancers, A Focused Review ( Foster, BA; Giram, P; Rahman, KMM; You, Y, 2023) |
| "Most patients had nonmuscle-invasive bladder cancer." | 3.01 | Diagnostic and therapeutic effects of fluorescence cystoscopy and narrow-band imaging in bladder cancer: a systematic review and network meta-analysis. ( Fan, Z; Guo, X; Liu, Y; Luo, J; Shi, H; Wang, B; Yu, J, 2023) |
| " None of the 12 adverse events during surveillance were serious." | 2.87 | Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study. ( Bivalacqua, T; Daneshmand, S; DeCastro, J; Downs, T; Huang, W; Jones, J; Jones, JS; Kamat, A; Konety, B; Lotan, Y; O'Donnell, M; Patel, S; Pohar, K; Resnick, M; Schoenberg, M; Steinberg, G; Trabulsi, E; Woods, M, 2018) |
| "Office based blue light flexible cystoscopy significantly improves the detection of patients with recurrent bladder cancer and it is safe when used for surveillance." | 2.87 | Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study. ( Bivalacqua, T; Daneshmand, S; DeCastro, J; Downs, T; Huang, W; Jones, J; Jones, JS; Kamat, A; Konety, B; Lotan, Y; O'Donnell, M; Patel, S; Pohar, K; Resnick, M; Schoenberg, M; Steinberg, G; Trabulsi, E; Woods, M, 2018) |
| "5-Aminolevulinic acid (20 mg/kg) was orally administered 3 h before transurethral resection of bladder tumors using white light or fluorescent light." | 2.87 | Oral 5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: A multicenter phase III study. ( Fujimoto, K; Furuse, H; Inoue, K; Matsuyama, H; Miyake, M; Nagao, K; Nakai, Y; Oyama, M; Ozono, S; Shimamoto, T; Shuin, T; Tsuzuki, T, 2018) |
| "Diagnosis of bladder cancer is based on urine cytology and white-light cystoscopy (WLC) performed for patients with suspected bladder mass and÷or hematuria." | 2.84 | Improved diagnosis and long-term recurrence rate reduction for non-muscle-invasive bladder cancer patients undergoing fluorescent hexylaminolevulinate photodynamic diagnosis. ( Drăgoescu, NAM; Drăgoescu, PO; Drocaş, AI; Meşină, C; Mititelu, CD; Mitroi, G; Mohamed, G; Pănuş, A; Stănculescu, AD; Tomescu, PI; Tudorache, Ş, 2017) |
| "5-Aminolevulinic acid is a new-generation photosensitizer with high tumor specificity." | 2.82 | Current status of photodynamic technology for urothelial cancer. ( Fukuhara, H; Furihata, M; Hanazaki, K; Inoue, K; Karashima, T; Kurabayashi, A; Lai, HW; Ogura, SI; Yamamoto, S, 2022) |
| "Regarding safety, the adverse drug reactions were observed as grade 1 pruritus in 1 patient (0." | 2.82 | The clinical trial on the safety and effectiveness of the photodynamic diagnosis of non-muscle-invasive bladder cancer using fluorescent light-guided cystoscopy after oral administration of 5-aminolevulinic acid (5-ALA). ( Azuma, H; Fujimoto, K; Hirao, Y; Inoue, K; Ito, YM; Matsubara, A; Matsuyama, H; Mimata, H; Nagase, Y; Oyama, M; Ozono, S; Shiina, H; Shuin, T; Sugimura, Y; Ueno, M; Watanabe, H, 2016) |
| "ALA-PDD was shown to be safe and effective." | 2.82 | The clinical trial on the safety and effectiveness of the photodynamic diagnosis of non-muscle-invasive bladder cancer using fluorescent light-guided cystoscopy after oral administration of 5-aminolevulinic acid (5-ALA). ( Azuma, H; Fujimoto, K; Hirao, Y; Inoue, K; Ito, YM; Matsubara, A; Matsuyama, H; Mimata, H; Nagase, Y; Oyama, M; Ozono, S; Shiina, H; Shuin, T; Sugimura, Y; Ueno, M; Watanabe, H, 2016) |
| "Patients with a history of bladder cancer were excluded." | 2.78 | Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasi ( Chandra, A; Chatterton, K; Khan, MS; O'Brien, T; Ray, E; Thomas, K, 2013) |
| "Recurrent bladder cancer was confirmed histologically in 14/18 (78%) patients." | 2.74 | Hexylaminolevulinate photodynamic diagnosis for multifocal recurrent nonmuscle invasive bladder cancer. ( Chandra, A; Chatterton, K; Khan, MS; O'Brien, TS; Ray, ER; Thomas, K, 2009) |
| "In patients with bladder cancer hexaminolevulinate fluorescence cystoscopy with blue light can diagnose carcinoma in situ that may be missed with white light cystoscopy." | 2.73 | A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. ( Albala, D; Cookson, M; Droller, MJ; Fradet, Y; Gomella, L; Grossman, HB; Lerner, S, 2007) |
| "Twelve patients with known bladder cancer received a 2-hour administration of 50 mL of phosphate-buffered saline containing 4 mmol/L, 8 mmol/L or 16 mmol/L of hexylaminolevulinate." | 2.72 | An open pharmacokinetic study of hexylaminolevulinate-induced photodiagnosis after intravesical administration. ( Aymon, D; Collaud, S; Gurny, R; Jichlinski, P; Lange, N; Marti, A, 2006) |
| "Evaluation of residual tumor rate and recurrence free survival were defined as the two primary study endpoints." | 2.71 | [Reducing the risk of superficial bladder cancer recurrence with 5-aminolevulinic acid-induced fluorescence diagnosis. Results of a 5-year study]. ( Filbeck, T; Knuechel, R; Pichlmeier, U; Rössler, W; Wieland, WF, 2003) |
| "Significant reduction in the number of residual tumours was detected in 59% (p = 0." | 2.71 | [Clinical significance of macroscopic 5-aminolevulinic acid (ALA)-inducer fluorescence in transurethral resection of non-invasive bladder cancer]. ( Al-Shukri, S; Danil'chenko, DI; Koenig, F; Loening, SA; Riedl, K; Schnorr, D; Waldman, A, 2003) |
| "20 patients with known or suspected bladder cancer were included in a comparative within patient controlled Phase II study." | 2.71 | Comparison of hexaminolevulinate based flexible and rigid fluorescence cystoscopy with rigid white light cystoscopy in bladder cancer: results of a prospective Phase II study. ( Moonen, PM; van der Heijden, AG; Witjes, JA, 2005) |
| "The risk of residual tumor after transurethral resection of transitional cell carcinoma is significantly decreased by 5-aminolevulinic acid fluorescence endoscopy." | 2.70 | Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. ( Eisenberger, F; Hofstetter, A; Jocham, D; Kriegmair, M; Rassweiler, J; Rothenberger, KH; Stenzl, A; Tauber, R; Zaak, D, 2002) |
| "Residual tumor was evaluated in the 2 groups by repeat transurethral resection 10 to 14 days later." | 2.70 | Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. ( Eisenberger, F; Hofstetter, A; Jocham, D; Kriegmair, M; Rassweiler, J; Rothenberger, KH; Stenzl, A; Tauber, R; Zaak, D, 2002) |
| "A major problem diagnosing bladder cancer using conventional white-light cystoscopy is that flat and tiny papillary neoplasms can be overlooked." | 2.70 | Diagnostic efficacy of fluorescence cystoscopy for detection of urothelial neoplasms. ( Chai, SE; Choi, HY; Hong, JH; Jeon, SS; Kang, I, 2001) |
| "A series of 62 patients with suspected bladder cancer were investigated by fluorescence cystoscopy." | 2.70 | Diagnostic efficacy of fluorescence cystoscopy for detection of urothelial neoplasms. ( Chai, SE; Choi, HY; Hong, JH; Jeon, SS; Kang, I, 2001) |
| "5-Aminolevulinic acid (ALA) is a precursor of protoporphyrin IX (PpIX) that is being evaluated for use in photodiagnosis and phototherapy of malignant and nonmalignant disorders." | 2.70 | Clinical pharmacokinetics of 5-aminolevulinic acid in healthy volunteers and patients at high risk for recurrent bladder cancer. ( Dalton, JT; Golub, AL; Marcus, SL; Meyer, MC; Straughn, A; Yates, CR; Yin, D, 2002) |
| " ALA terminal half-life was approximately 45 min after intravenous or oral administration." | 2.70 | Clinical pharmacokinetics of 5-aminolevulinic acid in healthy volunteers and patients at high risk for recurrent bladder cancer. ( Dalton, JT; Golub, AL; Marcus, SL; Meyer, MC; Straughn, A; Yates, CR; Yin, D, 2002) |
| " The purpose of these studies was to examine the systemic pharmacokinetics and elimination of ALA, the bioavailability of ALA after oral and intravesical doses, and the factors that affect ALA concentrations in the bladder during intravesical treatment." | 2.70 | Clinical pharmacokinetics of 5-aminolevulinic acid in healthy volunteers and patients at high risk for recurrent bladder cancer. ( Dalton, JT; Golub, AL; Marcus, SL; Meyer, MC; Straughn, A; Yates, CR; Yin, D, 2002) |
| "Pain was assessed using a linear analogue scale from 0 to 10." | 2.70 | Photodynamic therapy for superficial bladder cancer under local anaesthetic. ( Betts, CD; Briggs, C; Clarke, NW; Gilhooley, A; Moore, JV; O'Flynn, KJ; Shackley, DC; Whitehurst, C, 2002) |
| "A better understanding of why cancer cells fluoresce with 5-ALA would improve its use in cancer diagnostics and therapies." | 2.61 | In order for the light to shine so brightly, the darkness must be present-why do cancers fluoresce with 5-aminolaevulinic acid? ( Gleadle, JM; MacGregor, MN; McNicholas, K, 2019) |
| "The recurrence rate of some bladder cancers can be decreased by the implementation of either PDD- and NBI-assisted TUR; in real settings, clinicians should consider replacing WLC as the standard imaging technology to guide TUR." | 2.52 | A network meta-analysis of therapeutic outcomes after new image technology-assisted transurethral resection for non-muscle invasive bladder cancer: 5-aminolaevulinic acid fluorescence vs hexylaminolevulinate fluorescence vs narrow band imaging. ( Cho, KS; Choi, YD; Ham, WS; Jung, HD; Kang, DH; Kwon, JK; Lee, JY; Oh, CK, 2015) |
| "Non-muscle-invasive bladder cancer (NMIBC) is associated with a high recurrence risk, partly because of the persistence of lesions following transurethral resection of bladder tumour (TURBT) due to the presence of multiple lesions and the difficulty in identifying the exact extent and location of tumours using standard white-light cystoscopy (WLC)." | 2.50 | Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations. ( Babjuk, M; Gontero, P; Jacqmin, D; Karl, A; Kruck, S; Mariappan, P; Palou Redorta, J; Stenzl, A; van Velthoven, R; Witjes, JA; Zaak, D, 2014) |
| "Bladder cancer is the most common tumor of the urinary tract, with a worldwide incidence of 8." | 2.49 | Innovations in the endoscopic management of bladder cancer: is the era of white light cystoscopy over. ( Ambrosini, E; Frea, B; Giona, S; Gontero, P; Gurioli, A; Oderda, M; Peraldo, F; Soria, F, 2013) |
| "The drugs used in the treatment of bladder cancer are represented by the products referred to diagnosis (hexyl aminolevulinate), the intravesical instillations for the treatment of tumors not infiltrating the muscle and the infiltrating tumor chemotherapy (neo-adjuvant treatment or metastatic tumors)." | 2.49 | [Medical treatment of bladder carcinoma]. ( Bastide, C; Bay, JO; Bruyere, F; Guy, L; Karsenty, G; Mahammedi, H, 2013) |
| "Residual tumour was significantly less often found after PDD (odds ratio: 0." | 2.46 | Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. ( Jacqmin, D; Jichlinski, P; Jocham, D; Kausch, I; Montorsi, F; Sommerauer, M; Stenzl, A; Vonthein, R; Ziegler, A, 2010) |
| "Although bladder cancer occurs frequently, early diagnosis and complete removal of malignant lesions usually lead to good clinical outcomes." | 2.45 | Hexyl aminolevulinate fluorescence cystoscopy in bladder cancer. ( Kruck, S; Sievert, KD, 2009) |
| "Non-muscle invasive bladder cancer is one of the most prevalent and incident neoplastic conditions in the Western world." | 2.45 | [Photodynamic diagnosis (PDD) in non-muscle invasive bladder cancer. Literature review]. ( Oliva Encina, J; Rioja Sanz, C, 2009) |
| "Non-muscle invasive bladder cancer is the most expensive cancer to manage on a per patient basis due to the high recurrence rate, low mortality and the need for long term, often lifelong surveillance." | 2.44 | The economic benefit of photodynamic diagnosis in non-muscle invasive bladder cancer. ( Bunce, CJ; Dindyal, S; Nitkunan, T, 2008) |
| "In flat bladder cancer and carcinoma in situ, and in multifocal papillary cancer, some smaller lesions may be overlooked at cystoscopy." | 2.44 | Recent developments in fluorescence cystoscopy: do novel agents bring a benefit? ( Marberger, M; Schmidbauer, J, 2007) |
| "Non-muscle-invasive bladder cancer is labor intensive and costly to manage." | 2.44 | The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer. ( Douglass, J; Witjes, JA, 2007) |
| "Bladder cancer is a frequent disease and represents the second most common genitourinary neoplasm." | 2.44 | [Fluorescence cystoscopy at bladder cancer: present trials]. ( Burger, M; Karl, A; Knuechel, R; Stepp, H; Stief, C; Tilki, D; Tritschler, S; Zaak, D, 2007) |
| "The current standard diagnosis of bladder cancer involves cystoscopic examination of urine and bladder washings and is combined with biopsy for better detection of low-grade malignancies." | 2.43 | Hexyl aminolevulinate: 5-ALA hexylester, 5-ALA hexylesther, aminolevulinic acid hexyl ester, hexaminolevulinate, hexyl 5-aminolevulinate, P 1206. ( , 2005) |
| "Bladder cancer is a frequent disease and represents the second most common genitourinary neoplasm." | 2.43 | Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy. ( Bachmann, A; Hartmann, A; Karl, A; Knüchel, R; Popken, G; Reich, O; Siebels, M; Stepp, H; Stief, C; Zaak, D, 2005) |
| "With regard to bladder cancer, advances in drug development and modern light delivery techniques mean that photodynamic therapy shows promise in the treatment of superficial bladder cancer resistant to conventional treatments." | 2.41 | Photodynamic therapy for superficial bladder cancer. ( Betts, CD; Briggs, C; Clarke, NW; Moore, JV; O'Flynn, KJ; Shackley, DC; Whitehurst, C, 2001) |
| "Recurrent bladder cancer is due to tumor cell implantation, incomplete resection, and multicentric neoplastic changes throughout the bladder." | 2.41 | Endoscopic fluorescence diagnosis and laser treatment of transitional cell carcinoma of the bladder. ( Frimberger, D; Hofstetter, A; Zaak, D, 2000) |
| "Management of non-muscle-invasive bladder cancer (NMIBC) significantly impacts healthcare resource utilization due to requirements for ongoing surveillance." | 1.91 | Clinical and economic impact of blue light cystoscopy in the management of NMIBC at US ambulatory surgical centers: what is the site-of-service disparity? ( Gavaghan, MB; Shore, ND, 2023) |
| "First, we utilized three bladder cancer cell lines to evaluate senescence-related indicators and establish a cell senescence model." | 1.91 | Cell senescence-associated porphyrin metabolism affects the efficacy of aminolevulinic acid-photodynamic diagnosis in bladder cancer. ( Fukuhara, H; Inoue, K; Lai, HW; Ogura, SI; Yamamoto, S, 2023) |
| "Hypotension is an adverse effect of 5-ALA; however, its incidence and morbidity rates are unknown." | 1.91 | Incidence of perioperative hypotension in patients undergoing transurethral resection of bladder tumor after oral 5-aminolevulinic acid administration: a retrospective multicenter cohort study. ( Echigo, N; Goto, T; Inagawa, G; Kida, T; Kondo, Y; Nagamine, Y; Sumitomo, M; Yoshida, M; Yoshikawa, N, 2023) |
| "A total of 133 patients diagnosed with bladder cancer who underwent TURBT from April 2020 to March 2022 were included in the study." | 1.91 | Investigation on the Usefulness of Photodynamic Diagnosis-assisted Targeted Bladder Biopsy: Japanese Real-world Study. ( Arai, T; Goto, Y; Ichikawa, T; Imamura, Y; Oka, R; Sakamoto, S; Sato, H; Sazuka, T; Tsukamoto, R, 2023) |
| "This study compared tumor recurrence among NMIBC patients who underwent TURBT under either white light cystoscopy (WL) or PDD." | 1.72 | Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (2nd report): Reduced bladder recurrence after PDD-TURBT. ( Fukuhara, H; Furihata, M; Inoue, K; Karashima, T; Kurabayashi, A; Lai, HW; Yamamoto, S, 2022) |
| "The frequency of recurrence in NMIBC patients (cumulative number of recurrences/cumulative number of follow-up days, number of recurrences/10,000 days), including progression to muscle-invasive bladder cancer (MIBC), was 12." | 1.72 | Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (2nd report): Reduced bladder recurrence after PDD-TURBT. ( Fukuhara, H; Furihata, M; Inoue, K; Karashima, T; Kurabayashi, A; Lai, HW; Yamamoto, S, 2022) |
| "The frequency of recurrence was lower and the time to recurrence was longer in the PDD-TURBT group than in the WL-TURBT group." | 1.72 | Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (2nd report): Reduced bladder recurrence after PDD-TURBT. ( Fukuhara, H; Furihata, M; Inoue, K; Karashima, T; Kurabayashi, A; Lai, HW; Yamamoto, S, 2022) |
| "5-aminolevulinic acid is a protoporphyrin IX precursor used for photodynamic diagnosis." | 1.72 | Photodynamic diagnosis-assisted transurethral resection using oral 5-aminolevulinic acid decreases residual cancer and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer. ( Harada, S; Honda, T; Kani, N; Kato, T; Matsuoka, Y; Okazoe, H; Sugimoto, M; Taoka, R; Tohi, Y; Tsunemori, H; Ueda, N; Yamasaki, M, 2022) |
| " Adverse events (AEs) were recorded, and the safety of repeat use of HAL was determined by comparing the proportion of patients with AEs considered causally related to HAL in the surveillance examination compared to the OR examination." | 1.72 | Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study. ( Bivalacqua, TJ; Daneshmand, S; DeCastro, J; Downs, T; Huang, WC; Jones, J; Jones, JS; Kamat, AM; Konety, B; Lotan, Y; O'Donnell, M; Patel, S; Pohar, KS; Resnick, MJ; Schoenberg, M; Steinberg, G; Taylor, J; Trabulsi, E; Woods, M, 2022) |
| "Repeat use of HAL is safe even when administered within a few weeks of receiving a dose of intravesical therapy." | 1.72 | Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study. ( Bivalacqua, TJ; Daneshmand, S; DeCastro, J; Downs, T; Huang, WC; Jones, J; Jones, JS; Kamat, AM; Konety, B; Lotan, Y; O'Donnell, M; Patel, S; Pohar, KS; Resnick, MJ; Schoenberg, M; Steinberg, G; Taylor, J; Trabulsi, E; Woods, M, 2022) |
| "Bladder cancer is a common malignant disease in developed countries." | 1.72 | 5-Aminolevulinic acid-based photodynamic diagnosis for detection of urothelial carcinoma cells in bladder washing sediment suspension: A pilot study. ( Chu-Su, Y; Horita, S; Iizuka, J; Ishizuka, T; Nagashima, Y; Takagi, T; Tanabe, K; Toguchi, M; Tokuoka, Y; Yokoyama, T, 2022) |
| "Bladder cancer is common and has one of the highest recurrence rates." | 1.62 | Cancer cell detection device for the diagnosis of bladder cancer from urine. ( Belcher, S; Brown, MP; Chan, KM; Chong, M; Di Fiore, A; Gleadle, JM; Grochowski, A; Jay, A; Kashani, MN; Li, J; MacGregor, M; McNicholas, K; Michl, TD; Ostrikov, K; Robb, S; Safizadeh Shirazi, H; Staudacher, AH; Vasilev, K; Zhalgasbaikyzy, A, 2021) |
| "PDD can increase the detection rate of bladder cancer, compared to NBI, by greater than 10%." | 1.62 | Comparison between 5-aminolevulinic acid photodynamic diagnosis and narrow-band imaging for bladder cancer detection. ( Abe, Y; Hagimoto, H; Kawakita, M; Kokubun, H; Kubota, M; Makita, N; Mine, Y; Murata, S; Tsutsumi, N; Yamasaki, T, 2021) |
| "The ability to detect and diagnose bladder cancer early and precisely is crucial for effective treatment." | 1.56 | Evaluation of autofluorescence and photodynamic diagnosis in assessment of bladder lesions. ( Aebisher, D; Bochynek, K; Cieślar, G; Gasiorek, M; Kawczyk-Krupka, A, 2020) |
| "Bladder cancer is the eleventh most commonly diagnosed cancer worldwide." | 1.56 | Hexaminolevulinate blue light cystoscopy (Hal) assisted transurethral resection of the bladder tumour vs white light transurethral resection of the bladder tumour in non-muscle invasive bladder cancer (NMIBC) : a retrospective analysis. ( Bracale, U; Buonopane, R; Califano, G; Capece, M; Creta, M; Crocetto, F; Di Meo, S; Fusco, F; Imbimbo, C; Imperatore, V; La Rocca, R; Longo, N; Mirone, V; Napolitano, L; Palmieri, A; Sodo, M; Spirito, L; Verze, P, 2020) |
| "The study proposes to improve bladder cancer diagnosis by photodynamic diagnosis (PDD) using red-light excitation (632." | 1.56 | Two diagnostic criteria of optical spectroscopy for bladder tumor detection: Clinical study using 5-ALA induced fluorescence and mathematical modeling. ( Amouroux, M; Blondel, W; Daul, C; Kalyagina, N; Kudashev, B; Loschenov, V; Loshchenov, M, 2020) |
| "Two modalities of bladder cancer spectral diagnosis are presented: conventional PDD and intensity assessment of the diffusely reflected laser light by fiber-optic spectroscopy." | 1.56 | Two diagnostic criteria of optical spectroscopy for bladder tumor detection: Clinical study using 5-ALA induced fluorescence and mathematical modeling. ( Amouroux, M; Blondel, W; Daul, C; Kalyagina, N; Kudashev, B; Loschenov, V; Loshchenov, M, 2020) |
| " ALA-related adverse effects included vomiting (seven cases), hypotension (seven cases, two of which were severe), and liver toxicity (four cases)." | 1.56 | Real-world experience with 5-aminolevulinic acid for the photodynamic diagnosis of bladder cancer: Diagnostic accuracy and safety. ( Fukuhara, H; Inoue, K; Karashima, T; Yamamoto, S, 2020) |
| "The accumulation of PpIX in bladder cancer cells was significantly higher than in non-cancer cells, both cultured monolayer cells and cells in suspension." | 1.51 | Biosensor device for the photo-specific detection of immuno-captured bladder cancer cells using hexaminolevulinate: An ex-vivo study. ( Chan, KM; Gleadle, J; Li, J; MacGregor, M; McNicholas, K; Shirazi, HS; Vasilev, K, 2019) |
| "Patients with suspected bladder cancer (positive cytology with negative WLC) or history of previous high-grade NMIBC or CIS were included in the study." | 1.46 | Blue light cystoscopy with hexylaminolevulinate: Our 7 years experience. ( Beatrici, V; Cantoro, D; Cantoro, U; Cervelli, B; Cicetti, A; Gabrielloni, G; Lacetera, V; Milella, D; Montesi, L; Montesi, M; Morcellini, R; Parri, G; Recanatini, E, 2017) |
| "This study included 50 patients with bladder cancer that was confirmed histologically after transurethral resection (bladder cancer group) and 50 outpatients without a history of urothelial carcinoma or cancer-related findings (no malignancy group)." | 1.46 | Spectrophotometric photodynamic detection involving extracorporeal treatment with hexaminolevulinate for bladder cancer cells in voided urine. ( Fujimoto, K; Hori, S; Miyake, M; Mizuno, F; Morizawa, Y; Nakai, Y; Onishi, S; Owari, T; Ozawa, T; Tanaka, N; Tatsumi, Y; Tsuruta, D, 2017) |
| "This bladder cancer detection method is easy and cost-effective, and has the potential for clinical use." | 1.46 | Spectrophotometric photodynamic detection involving extracorporeal treatment with hexaminolevulinate for bladder cancer cells in voided urine. ( Fujimoto, K; Hori, S; Miyake, M; Mizuno, F; Morizawa, Y; Nakai, Y; Onishi, S; Owari, T; Ozawa, T; Tanaka, N; Tatsumi, Y; Tsuruta, D, 2017) |
| "To evaluate the residual tumor rate, the bladder was inspected after its removal and normal appearing mucosa sampled for histologic analysis." | 1.46 | Diagnostic Accuracy of Hexaminolevulinate in a Cohort of Patients Undergoing Radical Cystectomy. ( Alba, S; Buscarini, M; Carrieri, G; Cormio, L; Di Stasi, S; Gallone, MF; Minafra, P; Pagliarulo, V; Petitti, T, 2017) |
| "Sensitivity and specificity was calculated." | 1.42 | Effectiveness of hexaminolevulinate fluorescence cystoscopy for the diagnosis of non-muscle-invasive bladder cancer in daily clinical practice: a Spanish multicentre observational study. ( Abascal, JM; Abascal, R; Burgués, JP; Cabrera, JA; Conde, G; Gutiérrez, C; Hernández, C; Herranz, F; Iborra, I; Oliva, J; Palou, J; Rioja, C; Rodríguez, O; Solsona, E, 2015) |
| "We evaluated the detection rate of bladder cancer lesions by WLC and BLC with hexaminolevulinate, overall and by tumour stage and compared with histological examination of the biopsied lesions." | 1.42 | Effectiveness of hexaminolevulinate fluorescence cystoscopy for the diagnosis of non-muscle-invasive bladder cancer in daily clinical practice: a Spanish multicentre observational study. ( Abascal, JM; Abascal, R; Burgués, JP; Cabrera, JA; Conde, G; Gutiérrez, C; Hernández, C; Herranz, F; Iborra, I; Oliva, J; Palou, J; Rioja, C; Rodríguez, O; Solsona, E, 2015) |
| "Sixty-one patients with bladder cancer, confirmed histologically after the transurethral resection of a bladder tumor, were recruited as the bladder cancer group, and 50 outpatients without history of urothelial carcinoma or cancer-related findings were recruited as the control group." | 1.42 | Protoporphyrin IX induced by 5-aminolevulinic acid in bladder cancer cells in voided urine can be extracorporeally quantified using a spectrophotometer. ( Anai, S; Chihara, Y; Fujimoto, K; Hirao, Y; Masaomi, K; Miyake, M; Nakai, Y; Onishi, S; Tanaka, N; Tatsumi, Y, 2015) |
| "The differences in the bladder cancer group were significantly greater than those in the control group (p < 0." | 1.42 | Protoporphyrin IX induced by 5-aminolevulinic acid in bladder cancer cells in voided urine can be extracorporeally quantified using a spectrophotometer. ( Anai, S; Chihara, Y; Fujimoto, K; Hirao, Y; Masaomi, K; Miyake, M; Nakai, Y; Onishi, S; Tanaka, N; Tatsumi, Y, 2015) |
| "5-Aminolevulinic acid (ALA) is a widely used photodynamic therapy (PDT) prodrug in the clinic." | 1.42 | Immobilization of ALA-Zn(II) Coordination Polymer Pro-photosensitizers on Magnetite Colloidal Supraparticles for Target Photodynamic Therapy of Bladder Cancer. ( Guo, J; Sun, C; Tan, J; Wang, C; Xu, K, 2015) |
| "Urine samples from 58 patients with bladder cancer were centrifuged, and urine sediments were then treated with ALA." | 1.40 | Diagnostic approach for cancer cells in urine sediments by 5-aminolevulinic acid-based photodynamic detection in bladder cancer. ( Anai, S; Chihara, Y; Fujimoto, K; Hirao, Y; Kuwada, M; Miyake, M; Nakai, Y; Onishi, S; Tanaka, N; Tatsumi, Y, 2014) |
| " Between 41% and 58% of the patients had at least 1 adverse event (AE), although predominantly mild to moderate." | 1.40 | Safety of hexaminolevulinate for blue light cystoscopy in bladder cancer. A combined analysis of the trials used for registration and postmarketing data. ( Chang, SS; Gomella, LG; Grossman, HB; Stenzl, A; Witjes, JA; Zaak, D, 2014) |
| "This combined and detailed analysis of patients from 6 HAL-BLC studies with very comparable criteria shows that HAL-BLC is safe and poses very little additional risks other than expected for WL cystoscopy for bladder tumor resection in this specific patient population." | 1.40 | Safety of hexaminolevulinate for blue light cystoscopy in bladder cancer. A combined analysis of the trials used for registration and postmarketing data. ( Chang, SS; Gomella, LG; Grossman, HB; Stenzl, A; Witjes, JA; Zaak, D, 2014) |
| "Rats bearing orthotopic bladder tumors were instilled with hexyl-aminolevulinate and illuminated with red light at a high vs low (100 vs 15 mW/cm(2)) fluence rate." | 1.39 | How to avoid local side effects of bladder photodynamic therapy: impact of the fluence rate. ( Bezdetnaya, L; Bressenot, A; D'Hallewin, MA; François, A; Guillemin, F; Salvadori, A, 2013) |
| "Cytotoxicity to T24 bladder cancer cells was assessed by coincubating 5-ALA-loaded nanoparticles of different concentrations with T24 bladder cancer cells." | 1.39 | Photodynamic effect of 5-aminolevulinic acid-loaded nanoparticles on bladder cancer cells: a preliminary investigation. ( Al-Hayek, S; Guo, H; Huang, H; Yan, X; Zhu, W; Zhu, Z, 2013) |
| "In patients with non-muscle invasive bladder cancer, fluorescence cystoscopy can improve the detection and ablation of bladder tumors." | 1.38 | Blue light cystoscopy for detection and treatment of non-muscle invasive bladder cancer. ( Gelpi-Hammerschmidt, F; Gomella, LG; Mark, JR; Trabulsi, EJ, 2012) |
| "5-Aminolevulinic acid (5-ALA) was first suggested for photodynamic diagnosis (PDD) of transitional cell cancer (TCC) of the bladder in 1992." | 1.38 | Oral 5-aminolevulinic acid in simultaneous photodynamic diagnosis of upper and lower urinary tract transitional cell carcinoma - a prospective audit. ( Aboumarzouk, O; Ahmad, S; Kata, SG; Nabi, G; Somani, B, 2012) |
| "The mean time to bladder cancer recurrence for all recurrences within 0-18 months was 11." | 1.38 | The quality of 5-aminolevulinic acid-induced photodynamic diagnosis and transurethral resection of bladder tumors: does the urologist play a role?. ( Bosch, RJ; Draga, RO; Grimbergen, MC; Jonges, TN; Kok, ET; van Swol, CF, 2012) |
| "Orthotopic bladder cancer model in rats mimics human bladder cancer with respect to urothelial tumorigenesis and progression." | 1.37 | Tissue responses to hexyl 5-aminolevulinate-induced photodynamic treatment in syngeneic orthotopic rat bladder cancer model: possible pathways of action. ( Arum, CJ; Chen, D; Gederaas, OA; Hjelde, A; Krokan, HE; Larsen, EL; Randeberg, LL; Svaasand, LO; Zhao, CM, 2011) |
| "RESULTS Recurrent bladder cancer was detected in 11 of the 32 (34%) examinations." | 1.36 | Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guérin. ( Chandra, A; Chatterton, K; Dasgupta, P; Khan, MS; O'Brien, TS; Ray, ER; Thomas, K, 2010) |
| "PDD during initial TUR-BT in T1G3 bladder cancer seems to reduce significantly the rate of recurrence in our study population." | 1.36 | Photodynamic diagnosis in patients with T1G3 bladder cancer: influence on recurrence rate. ( Karl, A; Knüchel, R; Stadler, T; Stanislaus, P; Stief, CG; Tritschler, S; Zaak, D, 2010) |
| "Urothelial cancer of the bladder is a frequent disease, and urinary cytology often is used as a routine diagnostic tool." | 1.34 | [Fluorescence cytology. Improvement of urinary cytology]. ( Karl, A; Meier, R; Stepp, H; Stief, CG; Tauber, S; Tritschler, S; Zaak, D, 2007) |
| "Mitomycin C appears to enhance ALA-mediated PDT when administered first." | 1.32 | Investigation of sequential mitomycin C and photodynamic therapy in a mitomycin-resistant bladder cancer cell-line model. ( Allman, R; Datta, SN; French, AJ; Matthews, PN, 2004) |
| "A total of 279 patients with suspected bladder tumors underwent transurethral resection using FD in addition to WL cystoscopy." | 1.31 | Do patients profit from 5-aminolevulinic acid-induced fluorescence diagnosis in transurethral resection of bladder carcinoma? ( Filbeck, T; Knuechel, R; Pichlmeier, U; Roessler, W; Wieland, WF, 2002) |
| " Lipophilicity is one of the key parameters defining the bioavailability of a topically applied drug." | 1.31 | 5-Aminolevulinic acid and its derivatives: physical chemical properties and protoporphyrin IX formation in cultured cells. ( Juillerat-Jeanneret, L; Lange, N; Uehlinger, P; van den Bergh, H; Wagnières, G; Zellweger, M, 2000) |
| "On 21 patients, skin phototoxicity was determined prior to as well as 4, 8 and 28 h after intravesical instillation of a 3% ALA solution by exposing small skin areas to a progressively graded series of defined UVA-light doses (n = 9; 5-80 J/cm(2))." | 1.31 | No generalized skin phototoxicity after intravesical application of 5-aminolevulinic acid for fluorescence diagnosis of superficial bladder cancer. ( Filbeck, T; Karrer, S; Pichlmeier, U; Rössler, W; Szeimies, RM; Wieland, WF; Wimmershoff, MB, 2000) |
| " The elimination half-life of 5-ALA amounted to 0." | 1.31 | Intravesical administration of 5-aminolevulinic acid (5-ALA). Safety and pharmacokinetics of 5-ALA and its metabolite protoporphyrin IX. ( Birkel, M; Popken, G; Schultze-Seemann, W; Seiler, KU; Wetterauer, U, 2000) |
| "Most lesions of superficial bladder cancer may be easily missed during conventional white light cystoscopy." | 1.31 | Significance of fluorescence cystoscopy for diagnosis of superficial bladder cancer after intravesical instillation of delta aminolevulinic acid. ( Ehsan, A; Engelmann, U; Haupt, G; Sommer, F, 2001) |
| "This was first shown for cancer of the bladder." | 1.31 | [Fluorescent endoscopy superior to white light endoscopy. Detecting cancers of the urinary bladder earlier]. ( Zaak, D, 2002) |
| "The prognosis of superficial bladder cancer in terms of recurrence and disease progression is related to bladder tumor multiplicity and the presence of concomitant "plane" tumors such as high-grade dysplasia and carcinoma in situ." | 1.30 | Clinical assessment of fluorescence cytoscopy during transurethral bladder resection in superficial bladder cancer. ( Forrer, M; Graber, P; Guillou, L; Jichlinski, P; Leisinger, HJ; Mizeret, J; Oswald, M; Schmidlin, F; Van den Bergh, H; Wagnières, G, 1997) |
| "The prognosis of superficial bladder cancer in terms of local recurrence and transformation into invasive cancer is related to the multiplicity of tumor sites and the concomitant presence of "flat" tumours, such as dysplasia and carcinoma in situ." | 1.30 | [The clinical value of fluorescence cystoscopy in the detection of superficial transitional epithelial cell carcinoma of the bladder]. ( Forrer, M; Graber, P; Guillou, L; Jichlinski, P; Leisinger, HJ; Mizeret, J; Schmidlin, F; Van den Bergh, H; Wagniéres, G, 1997) |
| "Rats bearing orthotopic bladder tumors were treated either intravesically or intravenously with graded doses of 5-aminolevulinic acid (ALA) or PII." | 1.30 | Biodistribution of Photofrin II and 5-aminolevulinic acid-induced protoporphyrin IX in normal rat bladder and bladder tumor models: implications for photodynamic therapy. ( Brown, KM; Lown, JW; McCallum, TJ; Miller, GG; Moore, RB; Tulip, J; Xiao, Z, 1998) |
| "Sixteen patients with papillary bladder cancer, and CIS and dysplasia were given low-dose ALA." | 1.30 | Fluorescence detection of flat transitional cell carcinoma after intravesical instillation of aminolevulinic acid. ( Baert, L; D'Hallewin, MA; Vanherzeele, H, 1998) |
| "This study used bladder cancer cells, incubated with ALA at various oxygen tensions and H+ ion concentrations, and assessed the effects on PpIX generation and PDT sensitivity." | 1.30 | The influence of hypoxia and pH on aminolaevulinic acid-induced photodynamic therapy in bladder cancer cells in vitro. ( Brown, NJ; Reed, MW; Wyld, L, 1998) |
| "5-Aminolevulinic acid (ALA) is a precursor of heme biosynthesis." | 1.29 | Biodistribution and phototoxicity of 5-aminolevulinic acid-induced PpIX in an orthotopic rat bladder tumor model. ( Bachor, R; Flotte, T; Hasan, T; Iinuma, S, 1995) |
| "Following transurethral resection of bladder cancer, the fate of patients is clearly related to the presence or absence of precancerous or malignant lesions in the remaining mucosa." | 1.29 | [Photodynamic diagnosis of urothelial neoplasms after intravesicular instillation of 5-aminolevulinic acid]. ( Baumgartner, R; Ehsan, A; Hofstädter, F; Hofstetter, A; Knüchel, R; Kriegmair, M; Lumper, W; Steinbach, P, 1994) |
| "5-Aminolevulinic acid was instilled prior to cystoscopy and biopsies were taken of lesions that were either fluorescing or nonfluorescing." | 1.29 | Intravesical instillation of 5-aminolevulinic acid: the fluorescent metabolite is limited to urothelial cells. ( Baumgartner, R; Hofstädter, F; Knüchel, R; Kriegmair, M; Steinbach, P, 1994) |
| "Aminolevulinic acid (ALA) is a precursor of protoporphyrin IX (PP IX), a potent photosensitizer." | 1.29 | Aminolevulinic acid for photodynamic therapy of bladder carcinoma cells. ( Bachor, R; Hautmann, R; Reich, E; Rück, A, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 41 (12.39) | 18.2507 |
| 2000's | 120 (36.25) | 29.6817 |
| 2010's | 119 (35.95) | 24.3611 |
| 2020's | 51 (15.41) | 2.80 |
| Authors | Studies |
|---|---|
| Inoue, K | 25 |
| Fukuhara, H | 18 |
| Yamamoto, S | 5 |
| Karashima, T | 8 |
| Kurabayashi, A | 8 |
| Furihata, M | 8 |
| Hanazaki, K | 3 |
| Lai, HW | 3 |
| Ogura, SI | 3 |
| Nohara, T | 3 |
| Nishimoto, K | 1 |
| Hatakeyama, Y | 1 |
| Hyodo, Y | 1 |
| Okuhara, Y | 1 |
| Oyama, M | 4 |
| Mizokami, A | 3 |
| Matsuyama, H | 7 |
| Abrahimi, P | 1 |
| McClure, T | 1 |
| Kamijima, T | 1 |
| Fukuda, R | 1 |
| Kano, H | 1 |
| Shimada, T | 1 |
| Nakano, T | 2 |
| Kato, Y | 2 |
| Kadomoto, S | 1 |
| Iwamoto, H | 2 |
| Yaegashi, H | 2 |
| Iijima, M | 2 |
| Kawaguchi, S | 2 |
| Shigehara, K | 2 |
| Izumi, K | 2 |
| Kadono, Y | 2 |
| Taoka, R | 2 |
| Matsuoka, Y | 2 |
| Yamasaki, M | 1 |
| Kani, N | 1 |
| Honda, T | 2 |
| Harada, S | 1 |
| Tohi, Y | 2 |
| Kato, T | 2 |
| Okazoe, H | 2 |
| Tsunemori, H | 1 |
| Ueda, N | 2 |
| Sugimoto, M | 2 |
| Pohar, KS | 3 |
| Patel, S | 4 |
| Lotan, Y | 8 |
| Trabulsi, E | 4 |
| Woods, M | 4 |
| Downs, T | 4 |
| Huang, WC | 1 |
| Jones, J | 4 |
| Taylor, J | 2 |
| O'Donnell, M | 4 |
| Bivalacqua, TJ | 2 |
| DeCastro, J | 3 |
| Steinberg, G | 5 |
| Kamat, AM | 4 |
| Resnick, MJ | 2 |
| Konety, B | 5 |
| Schoenberg, M | 3 |
| Jones, JS | 4 |
| Daneshmand, S | 7 |
| Chan, KM | 4 |
| Vasilev, K | 4 |
| MacGregor, M | 4 |
| Yokoyama, T | 1 |
| Toguchi, M | 1 |
| Iizuka, J | 1 |
| Horita, S | 1 |
| Ishizuka, T | 1 |
| Chu-Su, Y | 1 |
| Nagashima, Y | 1 |
| Takagi, T | 1 |
| Tanabe, K | 1 |
| Tokuoka, Y | 1 |
| Lee, S | 1 |
| Oh, J | 1 |
| Cho, M | 1 |
| Kim, JK | 1 |
| Nakai, Y | 9 |
| Tatsumi, Y | 5 |
| Hori, S | 5 |
| Morizawa, Y | 4 |
| Iida, K | 1 |
| Onishi, K | 1 |
| Miyake, M | 9 |
| Oda, Y | 2 |
| Owari, T | 4 |
| Fujii, T | 3 |
| Onishi, S | 5 |
| Tanaka, N | 7 |
| Fujimoto, K | 11 |
| Rahman, KMM | 1 |
| Giram, P | 1 |
| Foster, BA | 1 |
| You, Y | 1 |
| Zhao, H | 3 |
| Peng, P | 3 |
| Luo, Z | 3 |
| Liu, H | 4 |
| Sun, J | 4 |
| Wang, X | 4 |
| Jia, Q | 3 |
| Yang, Z | 3 |
| Shore, ND | 1 |
| Gavaghan, MB | 3 |
| Audenet, F | 1 |
| Neuzillet, Y | 2 |
| Rouprêt, M | 3 |
| Kobayashi, K | 2 |
| Oka, S | 1 |
| Nakamura, K | 1 |
| Misumi, T | 1 |
| Hiroyoshi, T | 1 |
| Ito, H | 1 |
| Isoyama, N | 1 |
| Hirata, H | 1 |
| Matsumoto, H | 2 |
| Shiraishi, K | 1 |
| Kondo, Y | 1 |
| Nagamine, Y | 1 |
| Yoshikawa, N | 1 |
| Echigo, N | 1 |
| Kida, T | 2 |
| Sumitomo, M | 2 |
| Yoshida, M | 1 |
| Inagawa, G | 1 |
| Goto, T | 1 |
| Yamada, K | 1 |
| Sawanobori, Y | 1 |
| Osaki, Y | 1 |
| Abe, Y | 2 |
| Naito, H | 1 |
| Arai, T | 1 |
| Sazuka, T | 1 |
| Oka, R | 1 |
| Tsukamoto, R | 1 |
| Sato, H | 1 |
| Goto, Y | 1 |
| Imamura, Y | 1 |
| Sakamoto, S | 1 |
| Ichikawa, T | 1 |
| Fan, Z | 1 |
| Shi, H | 1 |
| Luo, J | 1 |
| Guo, X | 1 |
| Wang, B | 1 |
| Liu, Y | 1 |
| Yu, J | 1 |
| Hoogeveen, F | 1 |
| Blanker, MH | 1 |
| Cauberg, E | 1 |
| Steffens, MG | 1 |
| Chang, S | 1 |
| Bermoy, ME | 1 |
| Chang, SS | 2 |
| Scarpato, KR | 1 |
| Luckenbaugh, AN | 1 |
| Kolouri, S | 1 |
| Bowden, AK | 1 |
| Shirazi, HS | 1 |
| McNicholas, K | 3 |
| Li, J | 3 |
| Gleadle, J | 2 |
| MacGregor, MN | 1 |
| Gleadle, JM | 2 |
| Nakagawa, T | 1 |
| Nakashima, K | 1 |
| Chen, C | 1 |
| Huang, H | 2 |
| Zhao, Y | 1 |
| Sylvester, R | 1 |
| Lin, T | 1 |
| Huang, J | 1 |
| Kobashi, T | 1 |
| Usuda, Y | 1 |
| Drejer, D | 1 |
| Moltke, AL | 1 |
| Nielsen, AM | 1 |
| Lam, GW | 1 |
| Jensen, JB | 1 |
| Setuda, S | 1 |
| Takahashi, K | 1 |
| Murakami, K | 1 |
| Tanaka, T | 4 |
| Yamamichi, G | 2 |
| Nakata, W | 2 |
| Yoshimura, A | 1 |
| Tsujimura, G | 2 |
| Tsujimoto, Y | 2 |
| Nin, M | 2 |
| Mimura, A | 2 |
| Miwa, H | 2 |
| Tsujihata, M | 2 |
| Bochynek, K | 1 |
| Aebisher, D | 1 |
| Gasiorek, M | 1 |
| Cieślar, G | 1 |
| Kawczyk-Krupka, A | 1 |
| Fahmy, UA | 1 |
| Fahmy, O | 2 |
| Capece, M | 1 |
| Spirito, L | 1 |
| La Rocca, R | 1 |
| Napolitano, L | 1 |
| Buonopane, R | 1 |
| Di Meo, S | 1 |
| Sodo, M | 1 |
| Bracale, U | 1 |
| Longo, N | 1 |
| Palmieri, A | 1 |
| Fusco, F | 1 |
| Verze, P | 1 |
| Califano, G | 1 |
| Crocetto, F | 1 |
| Imbimbo, C | 1 |
| Mirone, V | 1 |
| Imperatore, V | 1 |
| Creta, M | 1 |
| Oshina, T | 1 |
| Kawai, T | 1 |
| Sato, Y | 1 |
| Miyakawa, J | 1 |
| Miyama, Y | 1 |
| Makino, K | 1 |
| Akiyama, Y | 1 |
| Yamada, Y | 1 |
| Nakamura, M | 1 |
| Yamada, D | 1 |
| Suzuki, M | 1 |
| Ushiku, T | 1 |
| Kume, H | 1 |
| Kobza-Mroczkowska, D | 1 |
| Khot, MI | 1 |
| Kalyagina, N | 1 |
| Loshchenov, M | 1 |
| Amouroux, M | 1 |
| Daul, C | 1 |
| Kudashev, B | 1 |
| Blondel, W | 1 |
| Loschenov, V | 1 |
| Nakayama, T | 1 |
| Nozawa, N | 1 |
| Kawada, C | 2 |
| Ishii, T | 2 |
| Ishizuka, M | 2 |
| Namikawa, T | 1 |
| Chaplin, I | 1 |
| Ahmadi, H | 1 |
| Meng, X | 1 |
| Roberts, S | 1 |
| Ladi-Seyedian, S | 1 |
| Bagrodia, A | 1 |
| Margulis, V | 1 |
| Woldu, S | 1 |
| Safizadeh Shirazi, H | 1 |
| Ostrikov, K | 1 |
| Jay, A | 1 |
| Chong, M | 1 |
| Staudacher, AH | 1 |
| Michl, TD | 2 |
| Zhalgasbaikyzy, A | 1 |
| Brown, MP | 1 |
| Kashani, MN | 1 |
| Di Fiore, A | 1 |
| Grochowski, A | 1 |
| Robb, S | 1 |
| Belcher, S | 1 |
| Todenhöfer, T | 1 |
| Maas, M | 1 |
| Ketz, M | 1 |
| Kossack, N | 1 |
| Colling, C | 1 |
| Qvick, B | 2 |
| Stenzl, A | 17 |
| Nishimura, N | 1 |
| Ohnishi, S | 1 |
| Gotoh, D | 1 |
| Anai, S | 6 |
| Torimoto, K | 2 |
| Hirao, Y | 7 |
| Ma, X | 1 |
| Shen, H | 1 |
| Liu, B | 1 |
| Iwamoto, T | 1 |
| Hara, T | 2 |
| Ota, U | 2 |
| Kuniyasu, H | 1 |
| Nakatani, S | 1 |
| Ida, M | 1 |
| Naito, Y | 1 |
| Kawaguchi, M | 1 |
| Gierth, M | 1 |
| Breyer, J | 1 |
| Zeman, F | 1 |
| Fritsche, HM | 1 |
| Cordes, J | 1 |
| Karl, A | 11 |
| Zaak, D | 28 |
| von Schmeling, IK | 1 |
| Sommerhuber, A | 1 |
| Zierer, T | 1 |
| Burger, M | 16 |
| Mayr, R | 2 |
| Andersson, M | 1 |
| Berger, M | 1 |
| Zieger, K | 1 |
| Malmström, PU | 8 |
| Bläckberg, M | 2 |
| Williams, SB | 1 |
| Fernandez, A | 1 |
| Sugino, Y | 1 |
| Nishikawa, K | 1 |
| Kato, M | 2 |
| Sasaki, T | 1 |
| Masui, S | 1 |
| Yoshio, Y | 1 |
| Kanda, H | 1 |
| Sugimura, Y | 2 |
| Inoue, T | 1 |
| Marien, A | 1 |
| Rock, A | 1 |
| Maadarani, KE | 1 |
| Francois, C | 1 |
| Gosset, P | 1 |
| Mauroy, B | 1 |
| Bonnal, JL | 1 |
| Lacetera, V | 1 |
| Cantoro, U | 1 |
| Montesi, L | 1 |
| Cantoro, D | 1 |
| Cervelli, B | 1 |
| Cicetti, A | 1 |
| Gabrielloni, G | 1 |
| Milella, D | 1 |
| Montesi, M | 1 |
| Morcellini, R | 1 |
| Parri, G | 1 |
| Recanatini, E | 1 |
| Beatrici, V | 1 |
| Ozawa, T | 1 |
| Mizuno, F | 1 |
| Tsuruta, D | 1 |
| Jacqmin, D | 6 |
| Jichlinski, P | 16 |
| Molinier, L | 2 |
| de la Taille, A | 1 |
| Irani, J | 1 |
| Malavaud, B | 2 |
| Gallagher, KM | 1 |
| Gray, K | 1 |
| Anderson, CH | 1 |
| Lee, H | 1 |
| Stewart, S | 1 |
| Donat, R | 2 |
| Mariappan, P | 2 |
| Pohar, K | 3 |
| Huang, W | 3 |
| Bivalacqua, T | 2 |
| Kamat, A | 2 |
| Resnick, M | 3 |
| Drăgoescu, PO | 1 |
| Tudorache, Ş | 1 |
| Drocaş, AI | 1 |
| Mitroi, G | 1 |
| Pănuş, A | 2 |
| Drăgoescu, NAM | 1 |
| Meşină, C | 1 |
| Mititelu, CD | 1 |
| Stănculescu, AD | 1 |
| Mohamed, G | 1 |
| Tomescu, PI | 1 |
| Clinton, TN | 1 |
| Smith, AB | 1 |
| Tsuzuki, T | 1 |
| Shimamoto, T | 2 |
| Shuin, T | 12 |
| Nagao, K | 2 |
| Furuse, H | 2 |
| Ozono, S | 3 |
| Raharja, PAR | 1 |
| Hamid, ARAH | 1 |
| Mochtar, CA | 1 |
| Umbas, R | 1 |
| Tani, M | 1 |
| McKiernan, J | 1 |
| Sankin, A | 1 |
| Smith, A | 1 |
| Renninger, M | 1 |
| Schubert, T | 1 |
| Schmid, MA | 1 |
| Hassan, F | 1 |
| Gakis, G | 1 |
| Konecki, T | 1 |
| Kutwin, P | 1 |
| Łowicki, R | 1 |
| Juszczak, AB | 1 |
| Jabłonowski, Z | 1 |
| Kanehira, K | 1 |
| Yano, Y | 1 |
| Hasumi, H | 1 |
| Yao, M | 1 |
| Ferré, A | 1 |
| Cordonnier, C | 1 |
| Demailly, M | 1 |
| Hakami, F | 1 |
| Sevestre, H | 1 |
| Saint, F | 1 |
| Tsuda, M | 2 |
| Nagakawa, K | 1 |
| Fujita, H | 2 |
| Utsumi, K | 2 |
| Garfield, SS | 1 |
| Armstrong, SO | 1 |
| Grossman, HB | 9 |
| Droller, M | 1 |
| Schmidbauer, J | 5 |
| Hermann, G | 1 |
| Drăgoescu, O | 2 |
| Ray, E | 2 |
| Fradet, Y | 5 |
| Burgués, JP | 3 |
| Witjes, JA | 11 |
| Jocham, D | 10 |
| Cordeiro, ER | 1 |
| Anastasiadis, A | 1 |
| Bus, MT | 1 |
| Alivizatos, G | 1 |
| de la Rosette, JJ | 1 |
| de Reijke, TM | 1 |
| Soria, F | 1 |
| Gurioli, A | 1 |
| Peraldo, F | 1 |
| Oderda, M | 1 |
| Giona, S | 1 |
| Ambrosini, E | 1 |
| Frea, B | 1 |
| Gontero, P | 2 |
| Rink, M | 1 |
| Babjuk, M | 6 |
| Catto, JW | 1 |
| Shariat, SF | 1 |
| Stepp, H | 22 |
| Hagiya, Y | 1 |
| Matsumoto, K | 1 |
| Endo, Y | 1 |
| Nakajima, M | 1 |
| Okura, I | 2 |
| Ogura, S | 2 |
| O'Brien, T | 2 |
| Chatterton, K | 4 |
| Khan, MS | 4 |
| Chandra, A | 4 |
| Thomas, K | 5 |
| Guy, L | 1 |
| Mahammedi, H | 1 |
| Bastide, C | 1 |
| Bruyere, F | 1 |
| Karsenty, G | 1 |
| Bay, JO | 1 |
| Yang, LP | 1 |
| Gkritsios, P | 1 |
| Hatzimouratidis, K | 1 |
| Kazantzidis, S | 1 |
| Dimitriadis, G | 1 |
| Ioannidis, E | 1 |
| Katsikas, V | 1 |
| Terada, Y | 1 |
| Matsumoto, T | 1 |
| Ishihara, M | 1 |
| Hamada, K | 1 |
| Shimamura, Y | 1 |
| Ogata, K | 1 |
| Taniguchi, Y | 1 |
| Horino, T | 1 |
| Tamura, K | 1 |
| Fujimoto, S | 1 |
| Kuwada, M | 2 |
| Chihara, Y | 3 |
| Gándara, L | 1 |
| Sandes, E | 1 |
| Di Venosa, G | 1 |
| Prack Mc Cormick, B | 1 |
| Rodriguez, L | 1 |
| Mamone, L | 1 |
| Batlle, A | 1 |
| Eiján, AM | 1 |
| Casas, A | 1 |
| Gomella, LG | 6 |
| Kruck, S | 2 |
| Palou Redorta, J | 1 |
| van Velthoven, R | 1 |
| Methorst, C | 1 |
| Schneider, M | 1 |
| Lebret, T | 1 |
| Rouanne, M | 1 |
| Radulescu, C | 1 |
| Molinie, V | 1 |
| Dreyfus, JF | 1 |
| Pelcat, V | 1 |
| Botto, H | 1 |
| Griffiths, TR | 2 |
| Kockelbergh, RC | 2 |
| Lerner, SP | 1 |
| Goh, A | 1 |
| Schuckman, AK | 1 |
| Bochner, BH | 1 |
| Cookson, MS | 1 |
| Downs, TM | 2 |
| Konety, BR | 1 |
| Lee, CT | 1 |
| Pruthi, RS | 1 |
| Smith, ND | 1 |
| Schoenberg, MP | 1 |
| Steinberg, GD | 1 |
| Calvaresi, AE | 1 |
| Trabulsi, EJ | 2 |
| Sonzogni, M | 1 |
| Lallas, CD | 1 |
| Wachsmuth, KS | 1 |
| Palou, J | 1 |
| Hernández, C | 1 |
| Solsona, E | 1 |
| Abascal, R | 2 |
| Rioja, C | 1 |
| Cabrera, JA | 1 |
| Gutiérrez, C | 1 |
| Rodríguez, O | 1 |
| Iborra, I | 2 |
| Herranz, F | 1 |
| Abascal, JM | 2 |
| Conde, G | 2 |
| Oliva, J | 2 |
| Masaomi, K | 1 |
| Leleu, H | 1 |
| Blachier, M | 1 |
| Marteau, F | 1 |
| Kai, F | 1 |
| Ueno, M | 2 |
| Narukawa, M | 1 |
| Lee, JY | 1 |
| Cho, KS | 1 |
| Kang, DH | 1 |
| Jung, HD | 1 |
| Kwon, JK | 1 |
| Oh, CK | 1 |
| Ham, WS | 1 |
| Choi, YD | 1 |
| Rose, JB | 1 |
| Armstrong, S | 1 |
| Hermann, GG | 2 |
| Kjellberg, J | 1 |
| Kureishi, M | 1 |
| Khoda, T | 1 |
| Iketani, K | 1 |
| Orita, M | 1 |
| Tan, J | 1 |
| Sun, C | 1 |
| Xu, K | 1 |
| Wang, C | 1 |
| Guo, J | 1 |
| Watanabe, H | 3 |
| Shiina, H | 1 |
| Mimata, H | 1 |
| Azuma, H | 1 |
| Nagase, Y | 1 |
| Matsubara, A | 1 |
| Ito, YM | 1 |
| Dansk, V | 1 |
| Malmenäs, M | 1 |
| Castle, EP | 1 |
| Sfetsas, K | 1 |
| Mitropoulos, D | 1 |
| Bach, T | 1 |
| Bastian, PJ | 1 |
| Blana, A | 1 |
| Kaminsky, A | 1 |
| Keller, S | 1 |
| Knoll, T | 1 |
| Lang, C | 1 |
| Promnitz, S | 1 |
| Ubrig, B | 1 |
| Keller, T | 1 |
| Rolevich, AI | 2 |
| Zhegalik, AG | 1 |
| Mokhort, AA | 1 |
| Minich, AA | 1 |
| Vasilevich, VY | 1 |
| Polyakov, SL | 1 |
| Krasny, SA | 1 |
| Sukonko, OG | 1 |
| Lane, GI | 1 |
| Soubra, A | 1 |
| Rao, A | 1 |
| Hemsley, L | 1 |
| Laylan, C | 1 |
| Shi, F | 1 |
| Filonenko, EV | 1 |
| Kaprin, AD | 1 |
| Alekseev, BY | 1 |
| Apolikhin, OI | 1 |
| Slovokhodov, EK | 1 |
| Ivanova-Radkevich, VI | 1 |
| Urlova, AN | 1 |
| Pagliarulo, V | 1 |
| Alba, S | 1 |
| Gallone, MF | 1 |
| Di Stasi, S | 1 |
| Cormio, L | 1 |
| Petitti, T | 1 |
| Buscarini, M | 1 |
| Minafra, P | 1 |
| Carrieri, G | 1 |
| Evmenenko, AA | 1 |
| Abascal Junquera, JM | 1 |
| Hevia Suárez, M | 1 |
| Abascal García, JM | 1 |
| Estébanez, C | 1 |
| Astudillo, A | 1 |
| Petschl, S | 1 |
| Volkmer, BG | 1 |
| Berrahmoune, S | 1 |
| Fotinos, N | 1 |
| Bezdetnaya, L | 6 |
| Lange, N | 7 |
| Guedenet, JC | 1 |
| Guillemin, F | 7 |
| D'Hallewin, MA | 5 |
| Ray, ER | 3 |
| O'Brien, TS | 3 |
| Yamamoto, Y | 1 |
| Ohmi, C | 1 |
| Sakano, S | 1 |
| Sasaki, K | 1 |
| Hedelin, H | 1 |
| Thomas, YK | 1 |
| Thompson, GJ | 1 |
| Durrant, H | 1 |
| Furniss, J | 1 |
| Dindyal, S | 1 |
| Nitkunan, T | 1 |
| Bunce, CJ | 1 |
| Grimbergen, MC | 6 |
| van Swol, CF | 4 |
| van Moorselaar, RJ | 2 |
| Uff, J | 1 |
| Mahadevan-Jansen, A | 1 |
| Stone, N | 1 |
| Geavlete, B | 3 |
| Multescu, R | 3 |
| Georgescu, D | 3 |
| Geavlete, P | 3 |
| Mostafid, H | 2 |
| Bunce, C | 2 |
| Draga, RO | 4 |
| Bosch, JL | 3 |
| Sievert, KD | 1 |
| Remzi, M | 1 |
| Klatte, T | 1 |
| Waldert, M | 1 |
| Mauermann, J | 1 |
| Susani, M | 3 |
| Marberger, M | 4 |
| Kok, ET | 3 |
| Jonges, TN | 3 |
| Stief, CG | 5 |
| Wieland, WF | 10 |
| Otto, W | 2 |
| Denzinger, S | 6 |
| Dasgupta, P | 1 |
| Schumacher, MC | 1 |
| Holmäng, S | 1 |
| Davidsson, T | 1 |
| Friedrich, B | 1 |
| Pedersen, J | 1 |
| Wiklund, NP | 1 |
| Oliva Encina, J | 1 |
| Rioja Sanz, C | 1 |
| Kamada, M | 4 |
| Sasaki, J | 1 |
| Scarpa, RM | 1 |
| Cracco, CM | 1 |
| Kuno, T | 1 |
| Hamaguchi, T | 1 |
| Fukata, S | 1 |
| Sakakura, N | 1 |
| Kasahara, K | 1 |
| Kozai, T | 1 |
| Yasuda, M | 1 |
| Kataoka, S | 1 |
| Tanimura, M | 2 |
| Atsushi, K | 1 |
| Kausch, I | 2 |
| Sommerauer, M | 2 |
| Montorsi, F | 3 |
| Ziegler, A | 2 |
| Vonthein, R | 2 |
| Ayres, BE | 1 |
| Kelly, J | 1 |
| Persad, R | 1 |
| Kockelbergh, R | 1 |
| Redorta, JP | 1 |
| Sofras, F | 1 |
| Riedl, C | 3 |
| Conti, G | 1 |
| Arentsen, HC | 1 |
| Mostafid, AH | 1 |
| Bordier, B | 1 |
| Guillotreau, J | 1 |
| Vandepitte, J | 1 |
| Van Cleynenbreugel, B | 1 |
| Hettinger, K | 1 |
| Van Poppel, H | 1 |
| de Witte, PA | 1 |
| Stanislaus, P | 2 |
| Stadler, T | 1 |
| Tritschler, S | 5 |
| Knüchel, R | 13 |
| Jecu, M | 2 |
| Mynderse, LA | 2 |
| Soloway, MS | 2 |
| Kriegmair, M | 24 |
| Shen, Y | 1 |
| Vordos, D | 1 |
| Penkoff, H | 1 |
| Dajc-Sommerer, E | 1 |
| Zumbraegel, A | 2 |
| Hoeltl, L | 1 |
| Scholz, M | 1 |
| Bugelnig, J | 1 |
| Hobisch, A | 1 |
| Mikuz, G | 1 |
| Pichlmeier, U | 5 |
| Compérat, E | 1 |
| Conort, P | 1 |
| Camparo, P | 1 |
| Mazerolles, C | 1 |
| Arum, CJ | 1 |
| Gederaas, OA | 4 |
| Larsen, EL | 1 |
| Randeberg, LL | 1 |
| Hjelde, A | 3 |
| Krokan, HE | 3 |
| Svaasand, LO | 1 |
| Chen, D | 1 |
| Zhao, CM | 1 |
| Ekroll, IK | 1 |
| Helander, L | 2 |
| Melø, TB | 1 |
| Johnsson, A | 1 |
| Tomescu, P | 1 |
| Enache, M | 1 |
| Maria, C | 1 |
| Stoica, L | 1 |
| Pleşea, IE | 1 |
| Baglo, Y | 1 |
| Sousa, MM | 1 |
| Slupphaug, G | 1 |
| Hagen, L | 1 |
| Håvåg, S | 1 |
| Zub, KA | 1 |
| Puertas, M | 1 |
| Ordoño, F | 1 |
| Stanescu, F | 1 |
| Iiyama, T | 1 |
| Miyamura, M | 1 |
| Isfoss, BL | 1 |
| Vom Dorp, F | 1 |
| Tschirdewahn, S | 1 |
| Olbricht, T | 1 |
| Szarvas, T | 1 |
| Rübben, H | 1 |
| Tauber, S | 6 |
| Brunken, C | 1 |
| Vierbuchen, M | 1 |
| Kamradt, J | 1 |
| Ohlmann, CH | 1 |
| Stöckle, M | 1 |
| Grabe, M | 1 |
| Haug, ES | 1 |
| Hellström, P | 1 |
| Mogensen, K | 1 |
| Raitanen, M | 1 |
| Wahlqvist, R | 2 |
| Bertrand, J | 1 |
| Soustelle, L | 1 |
| Grès, P | 1 |
| Wagner, L | 1 |
| Muyshondt, C | 1 |
| Boukaram, M | 1 |
| Ben Naoum, K | 1 |
| Costa, P | 1 |
| Droupy, S | 1 |
| Bader, MJ | 1 |
| Beyer, W | 2 |
| Pongratz, T | 1 |
| Sroka, R | 3 |
| Welschof, M | 1 |
| Tilki, D | 3 |
| Waidelich, R | 7 |
| Mark, JR | 1 |
| Gelpi-Hammerschmidt, F | 1 |
| Sagalowsky, AI | 1 |
| Gravas, S | 1 |
| Efstathiou, K | 1 |
| Zachos, I | 1 |
| Melekos, MD | 1 |
| Tzortzis, V | 1 |
| Lapini, A | 1 |
| Minervini, A | 1 |
| Masala, A | 1 |
| Schips, L | 1 |
| Pycha, A | 1 |
| Cindolo, L | 1 |
| Giannella, R | 1 |
| Martini, T | 1 |
| Vittori, G | 1 |
| Zani, D | 2 |
| Bellomo, F | 1 |
| Cosciani Cunico, S | 2 |
| Ahmad, S | 1 |
| Aboumarzouk, O | 1 |
| Somani, B | 1 |
| Nabi, G | 1 |
| Kata, SG | 1 |
| Meng, MV | 1 |
| Karaolides, T | 1 |
| Skolarikos, A | 1 |
| Bourdoumis, A | 1 |
| Konandreas, A | 1 |
| Mygdalis, V | 1 |
| Thanos, A | 1 |
| Deliveliotis, C | 1 |
| François, A | 2 |
| Battah, S | 1 |
| MacRobert, AJ | 2 |
| Bosch, RJ | 1 |
| Nair, R | 1 |
| Coker, C | 1 |
| Salvadori, A | 1 |
| Bressenot, A | 1 |
| Yan, X | 1 |
| Al-Hayek, S | 1 |
| Zhu, Z | 1 |
| Zhu, W | 1 |
| Guo, H | 1 |
| Shackley, DC | 2 |
| Briggs, C | 2 |
| Whitehurst, C | 2 |
| Betts, CD | 2 |
| O'Flynn, KJ | 2 |
| Clarke, NW | 2 |
| Moore, JV | 2 |
| Rothenberger, KH | 1 |
| Rassweiler, J | 1 |
| Eisenberger, F | 1 |
| Tauber, R | 1 |
| Hofstetter, A | 24 |
| Marti, A | 4 |
| Leisinger, HJ | 7 |
| Hungerhuber, E | 4 |
| Schneede, P | 7 |
| Frimberger, D | 6 |
| Corvin, S | 2 |
| Schmeller, N | 4 |
| Knuechel, R | 16 |
| Knöchel, R | 1 |
| Bisson, JF | 1 |
| Christophe, M | 1 |
| Padilla-Ybarra, JJ | 1 |
| Notter, D | 4 |
| Vigneron, C | 3 |
| Filbeck, T | 8 |
| Roessler, W | 6 |
| Baumgartner, R | 20 |
| Hartmann, A | 5 |
| Künchel, R | 1 |
| Hohla, A | 1 |
| Xiao, Z | 2 |
| Brown, K | 1 |
| Tulip, J | 2 |
| Moore, RB | 4 |
| Manivasager, V | 2 |
| Heng, PW | 1 |
| Hao, J | 1 |
| Zheng, W | 1 |
| Soo, KC | 1 |
| Olivo, M | 3 |
| Lau, W | 1 |
| Hoon, TP | 1 |
| Christopher, C | 1 |
| Schröder, J | 1 |
| Berger, AP | 1 |
| Steiner, H | 1 |
| Akkad, T | 1 |
| Bartsch, G | 2 |
| Holtl, L | 1 |
| Landry, JL | 1 |
| Gelet, A | 1 |
| Bouvier, R | 1 |
| Dubernard, JM | 1 |
| Martin, X | 1 |
| Colombel, M | 1 |
| Liedl, B | 2 |
| Liesmann, F | 1 |
| Jirsa, M | 5 |
| Petrík, R | 5 |
| Dvorácek, J | 3 |
| Urban, M | 1 |
| Köhler, O | 1 |
| Guillou, L | 6 |
| Karlsen, SJ | 1 |
| Brennhovd, B | 1 |
| Johansson, E | 1 |
| Gärtner, T | 1 |
| van den Bergh, H | 8 |
| Jonges, TG | 1 |
| Boon, TA | 1 |
| Grönlund-Pakkanen, S | 2 |
| Wahlfors, J | 2 |
| Talja, M | 2 |
| Kosma, VM | 1 |
| Pakkanen, TM | 2 |
| Ala-Opas, M | 2 |
| Alhava, E | 2 |
| Ballini, JP | 1 |
| Kucera, P | 3 |
| Rössler, W | 3 |
| Witjes, F | 2 |
| French, AJ | 2 |
| Datta, SN | 5 |
| Allman, R | 4 |
| Matthews, PN | 5 |
| Hao, GY | 1 |
| Zhang, YH | 1 |
| Danil'chenko, DI | 1 |
| Koenig, F | 6 |
| Riedl, K | 1 |
| Schnorr, D | 3 |
| Waldman, A | 1 |
| Al-Shukri, S | 1 |
| Loening, SA | 3 |
| Bichler, KH | 1 |
| Krause, FS | 1 |
| Feil, G | 1 |
| Nelde, HJ | 1 |
| Daniltchenko, D | 2 |
| Daha, LK | 1 |
| Sachs, M | 1 |
| El Khatib, S | 1 |
| Didelon, J | 1 |
| Leroux, A | 1 |
| D'Hallewin, M | 1 |
| Moonen, PM | 1 |
| van der Heijden, AG | 1 |
| Loidl, W | 1 |
| Lipiński, MI | 1 |
| Jeromin, LM | 1 |
| Skyrme, RJ | 1 |
| Mason, MD | 1 |
| Jain, S | 1 |
| Reich, O | 1 |
| Bachmann, A | 2 |
| Siebels, M | 2 |
| Popken, G | 3 |
| Stief, C | 6 |
| Wagner, S | 2 |
| Zeylemaker, B | 1 |
| van Moorselaar, J | 1 |
| Grimm, MO | 1 |
| Muschter, R | 1 |
| König, F | 1 |
| Kurth, KH | 1 |
| Senior, K | 1 |
| Soukup, V | 2 |
| Brubakk, AO | 1 |
| Simeone, C | 1 |
| da Pozzo, GP | 1 |
| Pavlík, I | 1 |
| Pecen, L | 1 |
| Daniltchenko, DI | 1 |
| Riedl, CR | 3 |
| Sachs, MD | 1 |
| Daha, KL | 1 |
| Pflueger, H | 2 |
| Frampton, JE | 2 |
| Plosker, GL | 2 |
| Meier, R | 2 |
| Bone, A | 1 |
| Collaud, S | 1 |
| Aymon, D | 1 |
| Gurny, R | 1 |
| Ohtsuki, Y | 1 |
| Vaucher, L | 1 |
| Ritter-Schenk, C | 1 |
| Cunderlíková, B | 1 |
| Berner, A | 1 |
| Vasovic, V | 1 |
| Warloe, T | 1 |
| Nesland, JM | 1 |
| Peng, Q | 1 |
| Walter, B | 1 |
| Gomella, L | 2 |
| Morales, A | 1 |
| Presti, J | 1 |
| Ritenour, C | 1 |
| Nseyo, U | 1 |
| Droller, MJ | 2 |
| Lerner, S | 1 |
| Cookson, M | 1 |
| Albala, D | 1 |
| Hofstaedter, F | 2 |
| Wild, PJ | 1 |
| Stoehr, R | 1 |
| Douglass, J | 1 |
| Forster, TH | 1 |
| Wyler, S | 1 |
| Ruszat, R | 1 |
| Gasser, TC | 1 |
| Staehler, M | 1 |
| Strittmatter, F | 1 |
| Hofstädter, F | 5 |
| Riesenberg, R | 2 |
| Sassy, T | 1 |
| Stocker, S | 3 |
| Lumper, W | 5 |
| Unsöld, E | 1 |
| Mizeret, J | 4 |
| Forrer, M | 5 |
| Wagnière, G | 1 |
| Schmidlin, F | 4 |
| Graber, P | 4 |
| Iinuma, S | 3 |
| Bachor, R | 2 |
| Flotte, T | 1 |
| Hasan, T | 3 |
| Ehsan, A | 4 |
| Steinbach, P | 6 |
| Farshi, SS | 1 |
| Ortel, B | 1 |
| König, K | 1 |
| Schneckenburger, H | 1 |
| Rück, A | 2 |
| Steiner, R | 1 |
| Weingandt, H | 1 |
| Stepp, HG | 1 |
| Rick, K | 1 |
| Fuchs, C | 1 |
| Novo, M | 1 |
| Hüttmann, G | 1 |
| Diddens, H | 1 |
| Reich, E | 1 |
| Hautmann, R | 1 |
| Eder, I | 1 |
| Kostron, H | 1 |
| Klocker, H | 1 |
| Wagnières, G | 6 |
| Oswald, M | 1 |
| Glanzmann, T | 1 |
| Braichotte, D | 1 |
| Zimmer, G | 1 |
| Heil, P | 1 |
| Loh, C | 1 |
| Mason, M | 2 |
| Loh, CS | 2 |
| Miller, GG | 1 |
| McCallum, TJ | 1 |
| Brown, KM | 1 |
| Lown, JW | 1 |
| Vanherzeele, H | 1 |
| Baert, L | 1 |
| Wyld, L | 2 |
| Reed, MW | 2 |
| Brown, NJ | 2 |
| Smith, O | 1 |
| Lawry, J | 1 |
| Whatley, SD | 1 |
| Dvorák, E | 2 |
| Skoda, V | 2 |
| Stádník, B | 2 |
| Straub, M | 2 |
| Kiel, HJ | 2 |
| Schneeweiss, S | 2 |
| McGovern, FJ | 1 |
| Larne, R | 1 |
| Enquist, H | 1 |
| Schomacker, KT | 2 |
| Deutsch, TF | 1 |
| Li, G | 1 |
| Szewczuk, MR | 1 |
| Raptis, L | 1 |
| Johnson, JG | 1 |
| Weagle, GE | 1 |
| Pottier, RH | 1 |
| Kennedy, JC | 1 |
| Zellweger, M | 2 |
| Rajadhyaksha, M | 1 |
| Bamberg, M | 1 |
| Momma, T | 1 |
| Plas, E | 1 |
| Pflüger, H | 1 |
| Uehlinger, P | 1 |
| Juillerat-Jeanneret, L | 1 |
| Wimmershoff, MB | 1 |
| Karrer, S | 1 |
| Szeimies, RM | 1 |
| Cheng, CW | 1 |
| Lau, WK | 1 |
| Tan, PH | 1 |
| Schultze-Seemann, W | 1 |
| Seiler, KU | 1 |
| Birkel, M | 1 |
| Wetterauer, U | 1 |
| Marinkovic, SP | 1 |
| Badlani, GH | 1 |
| Simak, R | 1 |
| Oberneder, R | 1 |
| Cosserat-Gerardin, I | 2 |
| Seidl, J | 1 |
| Rauch, J | 1 |
| Krieg, RC | 1 |
| Appel, S | 1 |
| Knittel, J | 1 |
| Weninger, E | 1 |
| De Dominicis, C | 1 |
| Liberti, M | 1 |
| Perugia, G | 1 |
| De Nunzio, C | 1 |
| Sciobica, F | 1 |
| Zuccalà, A | 1 |
| Sarkozy, A | 1 |
| Iori, F | 1 |
| Liessmann, F | 1 |
| Jeon, SS | 1 |
| Kang, I | 1 |
| Hong, JH | 1 |
| Choi, HY | 1 |
| Chai, SE | 1 |
| Sommer, F | 1 |
| Haupt, G | 1 |
| Engelmann, U | 1 |
| Schlake, G | 1 |
| Pytel, A | 1 |
| Makinen, K | 1 |
| Dalton, JT | 1 |
| Yates, CR | 1 |
| Yin, D | 1 |
| Straughn, A | 1 |
| Marcus, SL | 1 |
| Golub, AL | 1 |
| Meyer, MC | 1 |
| Gilhooley, A | 1 |
| Lipinski, M | 1 |
| Jeromin, L | 1 |
| Hagimoto, H | 1 |
| Makita, N | 1 |
| Mine, Y | 1 |
| Kokubun, H | 1 |
| Murata, S | 1 |
| Kubota, M | 1 |
| Tsutsumi, N | 1 |
| Yamasaki, T | 1 |
| Kawakita, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Open, Comparative, Within Patient Controlled Multicenter Phase 3 Study of Blue Light Cystoscopy With Cysview and White Light Cystoscopy Using KARL STORZ D-Light C PDD Flexible Videoscope System in Detection of Bladder Cancer in Patients Wit[NCT02560584] | Phase 3 | 304 participants (Actual) | Interventional | 2015-10-01 | Completed | ||
| Blue Light Cystoscopy With Cysview® Registry[NCT02660645] | 4,400 participants (Anticipated) | Observational [Patient Registry] | 2014-04-30 | Recruiting | |||
| Safety Analysis and Oncological Outcomes in Endoscopic Bladder Tumor Resection With Laser Holmium Compared With Transurethral Resection: a Prospective and Randomized Study[NCT05833997] | 100 participants (Anticipated) | Interventional | 2020-12-10 | Recruiting | |||
| Endoscopic Resection of High Grade(TA, T1, Cis)Non-muscle Invasive Bladder Tumors: Modification of Usual Management of This Resection by Using the Blue Light and Evaluation of the Outcome: Should we Maintain the Dogma of Second Endoscopic Resection as a P[NCT01750970] | 68 participants (Actual) | Interventional | 2009-11-30 | Completed | |||
| Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer (Study ATEZOBLADDERPRESERVE)[NCT04186013] | Phase 2 | 39 participants (Anticipated) | Interventional | 2019-09-18 | Active, not recruiting | ||
| A Randomized, Comparative, Controlled Phase III, Multicenter Study of Hexvix Fluorescence Cystoscopy and White Light Cystoscopy in the Detection Of Papillary Bladder Cancer and the Early Recurrence Rate in Patients With Bladder Cancer[NCT00233402] | Phase 3 | 789 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02560584)
Timeframe: At time of cystoscopy procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Surveillance Examination | 6 |
| Surveillance + OR Examination | 3 |
In the subsection of patients with histologically confirmed malignancy, the proportion of patients detected only by the use of blue light cystoscopy with Cysview is measured. (NCT02560584)
Timeframe: At time of cystoscopy procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Cysview Arm | 13 |
In the subsection of patients with histologically confirmed CIS, the proportion of patients detected only by blue light cystoscopy with Cysview is measured. (NCT02560584)
Timeframe: At time of cystoscopy procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Cysview Arm | 9 |
(NCT00233402)
Timeframe: 9 months
| Intervention | percentage of participants (Number) |
|---|---|
| Hexvix Group | 47.2 |
| White Light Group | 56.1 |
"The false detection rate for Hexvix cystoscopy was calculated as the total number of false positive lesions (i.e. lesions that were suspected with blue light but had negative histology according to the Standard of Truth central panel read) divided by the total number of lesions that were suspected with blue light (i.e., false positive divided by false positive plus true positive).~The corresponding false detection rates were also calculated for white light cystoscopy for the two groups separately." (NCT00233402)
Timeframe: Day 0
| Intervention | Percetange of lesion (Number) |
|---|---|
| Hexvix Group | 12 |
| White Light Group | 10 |
(NCT00233402)
Timeframe: Day 0
| Intervention | percentage of participants (Number) |
|---|---|
| Hexvix Group | 16.4 |
(NCT00233402)
Timeframe: Day 0
| Intervention | percentage of participants (Number) |
|---|---|
| Hexvix Fluorescence Cystoscopy | 31.7 |
53 reviews available for aminolevulinic acid and Bladder Cancer
| Article | Year |
|---|---|
Current status of photodynamic technology for urothelial cancer.
Topics: Aminolevulinic Acid; Biomarkers, Tumor; Early Detection of Cancer; Humans; Photochemotherapy; Photos | 2022 |
Emerging Intraoperative Imaging Technologies in Urologic Oncology.
Topics: Aminolevulinic Acid; Biomedical Technology; Carcinoma, Renal Cell; Fluorescence; Gallium Isotopes; G | 2022 |
Photodynamic Therapy for Bladder Cancers, A Focused Review
Topics: Aminolevulinic Acid; Humans; Photochemotherapy; Photosensitizing Agents; Prodrugs; Protoporphyrins; | 2023 |
Comparison of hexaminolevulinate (HAL) -guided versus white light transurethral resection for NMIBC: A systematic review and meta-analysis of randomized controlled trials.
Topics: Aminolevulinic Acid; Cystoscopy; Humans; Neoplasm Recurrence, Local; Neoplasm, Residual; Photochemot | 2023 |
Comparison of hexaminolevulinate (HAL) -guided versus white light transurethral resection for NMIBC: A systematic review and meta-analysis of randomized controlled trials.
Topics: Aminolevulinic Acid; Cystoscopy; Humans; Neoplasm Recurrence, Local; Neoplasm, Residual; Photochemot | 2023 |
Comparison of hexaminolevulinate (HAL) -guided versus white light transurethral resection for NMIBC: A systematic review and meta-analysis of randomized controlled trials.
Topics: Aminolevulinic Acid; Cystoscopy; Humans; Neoplasm Recurrence, Local; Neoplasm, Residual; Photochemot | 2023 |
Comparison of hexaminolevulinate (HAL) -guided versus white light transurethral resection for NMIBC: A systematic review and meta-analysis of randomized controlled trials.
Topics: Aminolevulinic Acid; Cystoscopy; Humans; Neoplasm Recurrence, Local; Neoplasm, Residual; Photochemot | 2023 |
Diagnostic and therapeutic effects of fluorescence cystoscopy and narrow-band imaging in bladder cancer: a systematic review and network meta-analysis.
Topics: Aminolevulinic Acid; Cystoscopy; Humans; Network Meta-Analysis; Prospective Studies; Urinary Bladder | 2023 |
In order for the light to shine so brightly, the darkness must be present-why do cancers fluoresce with 5-aminolaevulinic acid?
Topics: Amino Acid Transport Systems; Aminolevulinic Acid; Brain Neoplasms; Coproporphyrinogens; Ferrochelat | 2019 |
Diagnostic performance of image technique based transurethral resection for non-muscle invasive bladder cancer: systematic review and diagnostic meta-analysis.
Topics: Aminolevulinic Acid; Cystoscopy; Humans; Image Interpretation, Computer-Assisted; Narrow Band Imagin | 2019 |
Blue Light Cystoscopy: Indications and Outcomes.
Topics: Administration, Intravesical; Aminolevulinic Acid; Cystoscopy; Disease Progression; Humans; Light; N | 2020 |
Effects of fluorescent light cystoscopy in non-muscle-invasive bladder cancer: A systematic review and meta-analysis.
Topics: Aminolevulinic Acid; China; Cystoscopy; Humans; Neoplasm Recurrence, Local; Photochemotherapy; Photo | 2021 |
The use of blue light flexible cystoscopy with hexaminolevulinate & the diagnosis of bladder cancer.
Topics: Aminolevulinic Acid; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Cystoscopes; Cystos | 2018 |
Recent advances in optical imaging technologies for the detection of bladder cancer.
Topics: Aminolevulinic Acid; Cystoscopy; Humans; Microscopy, Confocal; Molecular Imaging; Photosensitizing A | 2018 |
Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018.
Topics: Aminolevulinic Acid; Consensus Development Conferences as Topic; Cystectomy; Cystoscopes; Cystoscopy | 2019 |
Hexaminolevulinate in the Management of Nonmuscle Invasive Bladder Cancer: A Meta-Analysis.
Topics: Aminolevulinic Acid; Carcinoma in Situ; Cystoscopy; Humans; Neoplasm Invasiveness; Photosensitizing | 2019 |
Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.
Topics: Aminolevulinic Acid; Carcinoma in Situ; Cystoscopy; Humans; Kaplan-Meier Estimate; Neoplasm Invasive | 2013 |
Is photodynamic diagnosis ready for introduction in urological clinical practice?
Topics: Aminolevulinic Acid; Cystoscopy; Humans; Photochemotherapy; Photosensitizing Agents; Urinary Bladder | 2013 |
Innovations in the endoscopic management of bladder cancer: is the era of white light cystoscopy over.
Topics: Aminolevulinic Acid; Carcinoma in Situ; Carcinoma, Transitional Cell; Cystoscopy; False Negative Rea | 2013 |
Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature.
Topics: Aminolevulinic Acid; Cost-Benefit Analysis; Cystectomy; Cystoscopy; Disease-Free Survival; Health Ca | 2013 |
[Medical treatment of bladder carcinoma].
Topics: Aminolevulinic Acid; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BC | 2013 |
Hexaminolevulinate blue light cystoscopy: a review of its use in the diagnosis of bladder cancer.
Topics: Aminolevulinic Acid; Clinical Trials as Topic; Cystoscopy; Humans; Meta-Analysis as Topic; Microscop | 2014 |
Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
Topics: Aminolevulinic Acid; Cost-Benefit Analysis; Cystectomy; Cystoscopy; Disease Progression; Disease-Fre | 2014 |
Novel endoscopic diagnosis for bladder cancer.
Topics: Aminolevulinic Acid; Carcinoma; Carcinoma, Papillary; Clinical Trials, Phase III as Topic; Cystoscop | 2015 |
Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA.
Topics: Aminolevulinic Acid; Carcinoma, Transitional Cell; Consensus; Cystoscopy; Humans; Neoplasm Invasiven | 2014 |
A network meta-analysis of therapeutic outcomes after new image technology-assisted transurethral resection for non-muscle invasive bladder cancer: 5-aminolaevulinic acid fluorescence vs hexylaminolevulinate fluorescence vs narrow band imaging.
Topics: Aminolevulinic Acid; Cystoscopy; Humans; Image Interpretation, Computer-Assisted; Narrow Band Imagin | 2015 |
5-Aminolevulinic acid-mediated photodynamic therapy for bladder cancer.
Topics: Aminolevulinic Acid; Humans; Photochemotherapy; Photosensitizing Agents; Protoporphyrins; Treatment | 2017 |
[A systematic review and meta-analysis to assess the recurrence-free survival in non-muscle invasive bladder cancer after transurethral resection guided by 5-aminolevulinic acid-induced photodynamic diagnosis compared with white-light transurethral resect
Topics: Aminolevulinic Acid; Cystectomy; Disease-Free Survival; Humans; Neoplasm Recurrence, Local; Photosen | 2016 |
The economic benefit of photodynamic diagnosis in non-muscle invasive bladder cancer.
Topics: Aminolevulinic Acid; Carcinoma, Transitional Cell; Fluorescence; Humans; Neoplasm Invasiveness; Phot | 2008 |
Hexyl aminolevulinate fluorescence cystoscopy in bladder cancer.
Topics: Aminolevulinic Acid; Clinical Trials as Topic; Cystoscopy; Fluorescent Dyes; Humans; Neoplasm Recurr | 2009 |
[Photodynamic diagnosis (PDD) in non-muscle invasive bladder cancer. Literature review].
Topics: Aminolevulinic Acid; Carbon Radioisotopes; Diagnostic Techniques, Urological; Humans; Photosensitizi | 2009 |
Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies.
Topics: Aminolevulinic Acid; Cystectomy; Cystoscopy; Disease-Free Survival; Evidence-Based Medicine; Humans; | 2010 |
The role of hexylaminolaevulinate in the diagnosis and follow-up of non-muscle-invasive bladder cancer.
Topics: Aminolevulinic Acid; Cystoscopy; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Photosen | 2010 |
Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations.
Topics: Aminolevulinic Acid; Cystectomy; Cystoscopy; Disease-Free Survival; Evidence-Based Medicine; Humans; | 2010 |
[Fluorescence diagnosis in patients with non-muscle invasive bladder cancer: results of a metaanalysis].
Topics: Aminolevulinic Acid; Cystoscopy; Disease-Free Survival; Fluorescence; Humans; Neoplasm Invasiveness; | 2010 |
[Pathologic diagnosis and management of flat lesions of urothelium detected with aminolevulinic acid (Hexvix®)].
Topics: Aminolevulinic Acid; Carcinoma in Situ; Humans; Metaplasia; Urinary Bladder; Urinary Bladder Neoplas | 2011 |
The sensitivity of fluorescent-light cystoscopy for the detection of carcinoma in situ (CIS) of the bladder: a meta-analysis with comments on gold standard.
Topics: Aminolevulinic Acid; Carcinoma in Situ; Cystoscopy; Fluorescence; Humans; Lighting; Photosensitizing | 2011 |
[Photodynamic diagnostics of bladder carcinoma].
Topics: Aminolevulinic Acid; Carcinoma in Situ; Carcinoma, Transitional Cell; Cystoscopy; Fluorescence; Huma | 2011 |
[Current developments in the diagnostics and therapy of bladder carcinoma].
Topics: Aminolevulinic Acid; Carcinoma in Situ; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combin | 2011 |
Photodynamic therapy for superficial bladder cancer.
Topics: Aminolevulinic Acid; Carcinoma in Situ; Dose-Response Relationship, Radiation; Hematoporphyrins; Hum | 2001 |
Fluorescence detection of bladder cancer: a review.
Topics: Administration, Intravesical; Aminolevulinic Acid; Anthracenes; Carcinoma in Situ; Cystoscopy; Dihem | 2002 |
[Fluorescence technique on diagnosis of urinary bladder carcinoma].
Topics: Aminolevulinic Acid; Anthracenes; Fluorescence; Humans; Perylene; Urinary Bladder Neoplasms | 2003 |
The role of photodynamic diagnosis in the contemporary management of superficial bladder cancer.
Topics: Aminolevulinic Acid; Anthracenes; Antineoplastic Agents; Carcinoma, Transitional Cell; Cystoscopy; D | 2005 |
Hexyl aminolevulinate: 5-ALA hexylester, 5-ALA hexylesther, aminolevulinic acid hexyl ester, hexaminolevulinate, hexyl 5-aminolevulinate, P 1206.
Topics: Aminolevulinic Acid; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drugs, | 2005 |
Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy.
Topics: Aminolevulinic Acid; Costs and Cost Analysis; Cystoscopy; Humans; Microscopy, Fluorescence; Photosen | 2005 |
Photodynamic applications in superficial bladder cancer: facts and hopes!
Topics: Aminolevulinic Acid; Animals; Carcinoma, Transitional Cell; Clinical Trials as Topic; Cystoscopy; Di | 2006 |
Hexyl aminolevulinate: in the detection of bladder cancer.
Topics: Aminolevulinic Acid; Animals; Carcinoma; Cystoscopy; Humans; Photosensitizing Agents; Urinary Bladde | 2006 |
Improving the management of bladder cancer with fluorescence cystoscopy.
Topics: Administration, Intravesical; Aminolevulinic Acid; Cystoscopy; Esters; Fluorescence; Humans; Photoch | 2007 |
Recent developments in fluorescence cystoscopy: do novel agents bring a benefit?
Topics: Aminolevulinic Acid; Anthracenes; Carcinoma in Situ; Cystoscopy; Fluorescence; Fluorescent Dyes; Hum | 2007 |
The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer.
Topics: Aminolevulinic Acid; Carbon Radioisotopes; Cystoscopy; Fluorescent Dyes; Humans; Survival Rate; Urin | 2007 |
[Fluorescence cystoscopy at bladder cancer: present trials].
Topics: Aminolevulinic Acid; Biopsy; Carcinoma in Situ; Carcinoma, Transitional Cell; Cystoscopy; Fluorescen | 2007 |
["... The better to see you with"--phothodynamic diagnostic in superficial bladder cancer].
Topics: Administration, Intravesical; Aminolevulinic Acid; Animals; Carcinoma in Situ; Carcinoma, Papillary; | 2007 |
[Fluorescence diagnosis and photodynamic therapy in urology].
Topics: Aminolevulinic Acid; Carcinoma in Situ; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II | 2007 |
Endoscopic fluorescence diagnosis and laser treatment of transitional cell carcinoma of the bladder.
Topics: Aminolevulinic Acid; Carcinoma, Transitional Cell; Cystoscopy; Fluorescence; Humans; Laser Therapy; | 2000 |
Imaging of the lower urinary tract in adults.
Topics: Adult; Aminolevulinic Acid; Carcinoma, Transitional Cell; Erectile Dysfunction; Female; Humans; Magn | 2001 |
[Diagnosis and treatment of bladder tumors by photodynamic therapy].
Topics: Aminolevulinic Acid; Hematoporphyrins; Humans; Photochemotherapy; Photosensitizing Agents; Urinary B | 2001 |
64 trials available for aminolevulinic acid and Bladder Cancer
| Article | Year |
|---|---|
DaBlaCa-11: Photodynamic Diagnosis in Flexible Cystoscopy-A Randomized Study With Focus on Recurrence.
Topics: Aged; Aminolevulinic Acid; Carcinoma in Situ; Cystoscopy; Female; Humans; Image Enhancement; Male; N | 2020 |
The HELENA study: Hexvix
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Antineoplastic Ag | 2021 |
Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Female; Humans; Male; Middle Aged; | 2018 |
Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Female; Humans; Male; Middle Aged; | 2018 |
Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Female; Humans; Male; Middle Aged; | 2018 |
Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Female; Humans; Male; Middle Aged; | 2018 |
Improved diagnosis and long-term recurrence rate reduction for non-muscle-invasive bladder cancer patients undergoing fluorescent hexylaminolevulinate photodynamic diagnosis.
Topics: Aminolevulinic Acid; Female; Fluorescence; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Ph | 2017 |
Patient-reported outcomes of blue-light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre study.
Topics: Aged; Aminolevulinic Acid; Anxiety; Color; Cystoscopy; False Positive Reactions; Female; Fluorescent | 2019 |
Oral 5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: A multicenter phase III study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma in Situ; Cystoscopy; F | 2018 |
Transient liver toxicity as a result of the oral administration of 5-aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer.
Topics: Administration, Oral; Age Factors; Aged; Aminolevulinic Acid; Chemical and Drug Induced Liver Injury | 2019 |
Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasi
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Antibiotics, Anti | 2013 |
Hexaminolevulinate-guided transurethral resection of non-muscle-invasive bladder cancer does not reduce the recurrence rates after a 2-year follow-up: a prospective randomized trial.
Topics: Aged; Aminolevulinic Acid; Color; Contrast Media; Cystoscopy; Disease-Free Survival; False Positive | 2014 |
Porphyrins as urinary biomarkers for bladder cancer after 5-aminolevulinic acid (ALA) administration: the potential of photodynamic screening for tumors.
Topics: Adult; Aged; Aminolevulinic Acid; Biomarkers, Tumor; Chromatography, High Pressure Liquid; Early Det | 2013 |
Assessment of diagnostic gain with hexaminolevulinate (HAL) in the setting of newly diagnosed non-muscle-invasive bladder cancer with positive results on urine cytology.
Topics: Aged; Aminolevulinic Acid; Cystoscopy; Female; Humans; Male; Photochemotherapy; Photosensitizing Age | 2014 |
Oral 5-aminolevulinic acid mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: A randomized, double-blind, multicentre phase II/III study.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Dose-Response Relationship, Drug; D | 2015 |
The clinical trial on the safety and effectiveness of the photodynamic diagnosis of non-muscle-invasive bladder cancer using fluorescent light-guided cystoscopy after oral administration of 5-aminolevulinic acid (5-ALA).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Contrast Media; Cystoscop | 2016 |
Results of a prospective randomized study assessing the efficacy of fluorescent cystoscopy-assisted transurethral resection and single instillation of doxorubicin in patients with non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Antibiotics, Anti | 2017 |
5-Aminolevulinic acid in intraoperative photodynamic therapy of bladder cancer (results of multicenter trial).
Topics: Adult; Aged; Aminolevulinic Acid; Combined Modality Therapy; Cystectomy; Female; Humans; Male; Middl | 2016 |
Hexylaminolevulinate photodynamic diagnosis for multifocal recurrent nonmuscle invasive bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Biopsy; Carcinoma in Situ; Cystoscopy; Demograp | 2009 |
Hexaminolevulinate fluorescence cystoscopy and transurethral resection of the bladder in noninvasive bladder tumors.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; False Positive Reactions; Female; F | 2009 |
Fluorescence cystoscopy with high-resolution optical coherence tomography imaging as an adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladder.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; False Positive Reactions; Female; F | 2009 |
Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic Acid under visible and fluorescent light: results of a prospective, randomised, multicentre study.
Topics: Aged; Aminolevulinic Acid; Carcinoma, Transitional Cell; Cystectomy; Cystoscopy; Double-Blind Method | 2010 |
HAL blue-light cystoscopy in high-risk nonmuscle-invasive bladder cancer--re-TURBT recurrence rates in a prospective, randomized study.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carbon Radioisotopes; Cystoscopy; Female; Human | 2010 |
Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer.
Topics: Aged; Aminolevulinic Acid; Carbon Radioisotopes; Cystoscopy; Female; Fluorescence; Humans; Male; Neo | 2010 |
Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer.
Topics: Aged; Aminolevulinic Acid; Carbon Radioisotopes; Cystoscopy; Female; Fluorescence; Humans; Male; Neo | 2010 |
Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer.
Topics: Aged; Aminolevulinic Acid; Carbon Radioisotopes; Cystoscopy; Female; Fluorescence; Humans; Male; Neo | 2010 |
Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer.
Topics: Aged; Aminolevulinic Acid; Carbon Radioisotopes; Cystoscopy; Female; Fluorescence; Humans; Male; Neo | 2010 |
Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy : A multicenter randomized, double-blind, placebo-controlled trial.
Topics: Administration, Intravesical; Aged; Algorithms; Aminolevulinic Acid; Carcinoma; Cystoscopy; Disease- | 2011 |
Photodynamic diagnosis of non-muscle invasive bladder cancer using hexaminolevulinic acid.
Topics: Aminolevulinic Acid; Cystoscopy; Female; Humans; Kaplan-Meier Estimate; Light; Male; Middle Aged; Mu | 2011 |
Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Contrast Media; Cystoscopy; Disease Progression | 2012 |
Photodynamic therapy of bladder cancer - a phase I study using hexaminolevulinate (HAL).
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Dose-Response Relationship, Drug; D | 2013 |
Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy.
Topics: Aged; Aminolevulinic Acid; Canada; Carbon Radioisotopes; Cystoscopy; Diagnosis, Differential; Europe | 2012 |
A comparison of hexaminolevulinate (Hexvix(®)) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Female; Fluorescence; Humans; Light | 2012 |
Hexaminolevulinate-induced fluorescence versus white light during transurethral resection of noninvasive bladder tumor: does it reduce recurrences?
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystectomy; Female; Fluorescence; Humans; Light | 2012 |
Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Austria; Carcinoma, Transitional Cell; Cystosco | 2002 |
Whole bladder photodynamic therapy with 5-aminolevulinic acid using a white light source.
Topics: Administration, Intravesical; Aminolevulinic Acid; Biopsy; Carcinoma in Situ; Carcinoma, Transitiona | 2003 |
Hexvix. Hexvix PD, Hexvix PDT.
Topics: Aminolevulinic Acid; Antineoplastic Agents; Clinical Trials as Topic; Cystoscopy; Drugs, Investigati | 2003 |
Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer--a multicenter study.
Topics: Aged; Aminolevulinic Acid; Carcinoma in Situ; Cystoscopy; Female; Humans; Male; Middle Aged; Neoplas | 2003 |
Reduced specificity of 5-ALA induced fluorescence in photodynamic diagnosis of transitional cell carcinoma after previous intravesical therapy.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Transitional | 2003 |
Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Transitional | 2003 |
[Reducing the risk of superficial bladder cancer recurrence with 5-aminolevulinic acid-induced fluorescence diagnosis. Results of a 5-year study].
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma in Situ; Carcinoma, Transitional Cell | 2003 |
[Clinical significance of macroscopic 5-aminolevulinic acid (ALA)-inducer fluorescence in transurethral resection of non-invasive bladder cancer].
Topics: Aminolevulinic Acid; Cystectomy; Cystoscopy; Fluorescence; Humans; Light; Neoplasm, Residual; Photos | 2003 |
[The impact of ALA (5-aminolevulinic acid)-fluorescence detection on the prognosis of superficial bladder cancer].
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Female; Fluorescence; Follow-Up Stu | 2004 |
Comparison of hexaminolevulinate based flexible and rigid fluorescence cystoscopy with rigid white light cystoscopy in bladder cancer: results of a prospective Phase II study.
Topics: Aged; Aminolevulinic Acid; Cystoscopes; Cystoscopy; Equipment Design; Female; Fluorescence; Hemorrha | 2005 |
Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance?
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopes; Cystoscopy; Equipment Design; Fals | 2005 |
A phase-1 study of sequential mitomycin C and 5-aminolaevulinic acid-mediated photodynamic therapy in recurrent superficial bladder carcinoma.
Topics: Aged; Aminolevulinic Acid; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional C | 2005 |
Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Biopsy; Cystoscop | 2005 |
Photodynamic therapy for bladder cancer.
Topics: Aminolevulinic Acid; Antineoplastic Combined Chemotherapy Protocols; Humans; Mitomycin; Neoplasm Rec | 2005 |
5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer.
Topics: Aged; Aminolevulinic Acid; Carcinoma, Transitional Cell; Cystoscopy; Disease-Free Survival; Female; | 2005 |
[Fluorescence cystoscopy in the diagnostics and treatment of superficial urinary bladder tumors].
Topics: Aged; Aminolevulinic Acid; Carcinoma, Transitional Cell; Cystoscopy; Female; Fluorescence; Humans; M | 2005 |
Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Austria; Carcinoma in Situ; Cystect | 2005 |
An open pharmacokinetic study of hexylaminolevulinate-induced photodiagnosis after intravesical administration.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Drug Stabili | 2006 |
Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cost-Benefit Anal | 2007 |
Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Female; Fluorescence; Follow-Up Studies; Humans | 2007 |
A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer.
Topics: Aged; Aminolevulinic Acid; Carbon Radioisotopes; Carcinoma in Situ; Carcinoma, Transitional Cell; Cy | 2007 |
A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study.
Topics: Aged; Aminolevulinic Acid; Carbon Radioisotopes; Carcinoma in Situ; Cystoscopy; Female; Humans; Male | 2007 |
Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Femal | 1994 |
Electromotive diffusion (EMD) and photodynamic therapy with delta-aminolaevulinic acid (delta-ALA) for superficial bladder cancer.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Diffusion; Female; Humans; Hydrogen-Ion Concentration; | 1996 |
Is everything all right if nothing seems wrong? A simple method of assessing the diagnostic value of endoscopic procedures when a gold standard is absent.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Female; Humans; Male; M | 1999 |
Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study.
Topics: Aged; Aminolevulinic Acid; Female; Fluorescence; Humans; Male; Middle Aged; Photochemotherapy; Photo | 1999 |
Photodynamic cystoscopy for detection of bladder tumors.
Topics: Adenocarcinoma, Papillary; Administration, Intravesical; Aminolevulinic Acid; Biopsy; Cystoscopy; Di | 1999 |
Transurethral resection and surveillance of bladder cancer supported by 5-aminolevulinic acid-induced fluorescence endoscopy.
Topics: Adenocarcinoma, Papillary; Adolescent; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinom | 1999 |
Fluorescence detection of bladder tumors with 5-amino-levulinic acid.
Topics: Adult; Aged; Aminolevulinic Acid; Cystoscopy; Fluorescence; Humans; Middle Aged; Photosensitizing Ag | 1999 |
Cystoscopic diagnosis of bladder cancer by intravesical instillation of 5-aminolevulinic acid induced porphyrin fluorescence--the Singapore experience.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Biopsy, Needle; C | 2000 |
Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Endoscopy; Female; Fluorescence; Humans; Male; | 2001 |
Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies.
Topics: Administration, Intravesical; Adolescent; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Biops | 2001 |
Diagnostic efficacy of fluorescence cystoscopy for detection of urothelial neoplasms.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma in Situ; Cystoscopy; Female; Fluoresc | 2001 |
Clinical pharmacokinetics of 5-aminolevulinic acid in healthy volunteers and patients at high risk for recurrent bladder cancer.
Topics: Administration, Intravesical; Administration, Oral; Aminolevulinic Acid; Cross-Over Studies; Drug Ad | 2002 |
Photodynamic therapy for superficial bladder cancer under local anaesthetic.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Anesthesia, Local; Anesthetics, Local; Carcinoma, Tran | 2002 |
Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors.
Topics: Administration, Intravesical; Adult; Aged; Aminolevulinic Acid; Carcinoma, Transitional Cell; Cystos | 2002 |
214 other studies available for aminolevulinic acid and Bladder Cancer
| Article | Year |
|---|---|
Identification of risk factors associated with oral 5-aminolevulinic acid-induced hypotension in photodynamic diagnosis for non-muscle invasive bladder cancer: a multicenter retrospective study.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Anesthesia, General; Anesthesia, Spinal; Calcium Chann | 2021 |
Variations in photodynamic diagnosis for bladder cancer due to the quality of endoscopic equipment.
Topics: Aminolevulinic Acid; Cystoscopy; Humans; Photochemotherapy; Retrospective Studies; Urinary Bladder N | 2022 |
[Ⅰ. Diagnosis and Therapy for Non-Muscle Invasive Bladder Cancer Using Photodynamic Technique].
Topics: Aminolevulinic Acid; Humans; Neoplasm Invasiveness; Photochemotherapy; Photosensitizing Agents; Urin | 2022 |
Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (2nd report): Reduced bladder recurrence after PDD-TURBT.
Topics: Aminolevulinic Acid; Cystoscopy; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Photoche | 2022 |
Photodynamic diagnosis-assisted transurethral resection using oral 5-aminolevulinic acid decreases residual cancer and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer.
Topics: Aminolevulinic Acid; Disease Progression; Humans; Neoplasm Recurrence, Local; Neoplasm, Residual; Ph | 2022 |
Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study.
Topics: Aminolevulinic Acid; Cystectomy; Cystoscopy; Humans; Urinary Bladder Neoplasms | 2022 |
Effects of Supplemental Drugs on Hexaminolevulinate (HAL)-Induced PpIX Fluorescence in Bladder Cancer Cell Suspensions.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Fluorescence; Heme; Humans; Pharmaceutical Preparations; Phot | 2022 |
5-Aminolevulinic acid-based photodynamic diagnosis for detection of urothelial carcinoma cells in bladder washing sediment suspension: A pilot study.
Topics: Aminolevulinic Acid; Carcinoma, Transitional Cell; Humans; Photochemotherapy; Photosensitizing Agent | 2022 |
Fluorescence-Based Microendoscopic Sensing System for Minimally Invasive In Vivo Bladder Cancer Diagnosis.
Topics: Aminolevulinic Acid; Animals; Carcinogens; Cystoscopy; Microscopy, Fluorescence; Rats; Urinary Bladd | 2022 |
5‑Aminolevurinic acid inhibits the proliferation of bladder cancer cells by activating heme synthesis.
Topics: Aminolevulinic Acid; Animals; Cell Proliferation; Ferritins; Ferrochelatase; Heme; Iron; Mice; Proli | 2022 |
Clinical and economic impact of blue light cystoscopy in the management of NMIBC at US ambulatory surgical centers: what is the site-of-service disparity?
Topics: Aged; Aminolevulinic Acid; Biopsy; Cystoscopy; Humans; Medicare; United States; Urinary Bladder Neop | 2023 |
[Photodynamic-guided transurethral resection: Uncertainties brought to light].
Topics: Aminolevulinic Acid; Humans; Urinary Bladder Neoplasms; Urologic Surgical Procedures | 2023 |
Risks and benefits of transurethral resection of the bladder tumor using photodynamic diagnosis with oral 5-aminolevulinic acid hydrochloride according to age and history of recurrence in patients with non-muscle invasive bladder cancer.
Topics: Aminolevulinic Acid; Cystectomy; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Non-Musc | 2023 |
Cell senescence-associated porphyrin metabolism affects the efficacy of aminolevulinic acid-photodynamic diagnosis in bladder cancer.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Cellular Senescence; Humans; Photochemotherapy; Photosensitiz | 2023 |
Incidence of perioperative hypotension in patients undergoing transurethral resection of bladder tumor after oral 5-aminolevulinic acid administration: a retrospective multicenter cohort study.
Topics: Adult; Aged; Aminolevulinic Acid; Cohort Studies; Humans; Hypotension; Incidence; Kidney Diseases; R | 2023 |
Oral 5-aminolevulinic acid administration before transurethral resection of bladder tumor induces perioperative nausea and vomiting.
Topics: Administration, Oral; Aminolevulinic Acid; Antiemetics; Humans; Nausea; Photochemotherapy; Photosens | 2023 |
Investigation on the Usefulness of Photodynamic Diagnosis-assisted Targeted Bladder Biopsy: Japanese Real-world Study.
Topics: Aminolevulinic Acid; Biopsy; East Asian People; Humans; Photosensitizing Agents; Urinary Bladder; Ur | 2023 |
Recurrence of non-muscle invasive bladder carcinoma after transurethral resection with hexaminolevulinate photodynamic diagnosis or regular cystoscopy.
Topics: Aminolevulinic Acid; Carcinoma; Cystoscopy; Humans; Neoplasm Recurrence, Local; Retrospective Studie | 2023 |
Enhancing the image quality of blue light cystoscopy through green-hue correction and fogginess removal.
Topics: Aminolevulinic Acid; Cystectomy; Cystoscopy; Humans; Urinary Bladder Neoplasms | 2023 |
Biosensor device for the photo-specific detection of immuno-captured bladder cancer cells using hexaminolevulinate: An ex-vivo study.
Topics: Aminolevulinic Acid; Biosensing Techniques; Cell Line, Tumor; Cystoscopy; Humans; In Vitro Technique | 2019 |
Intraoperative hypotension caused by oral administration of 5-aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aminolevulinic Acid; Female; Humans; Hypotension; Int | 2019 |
Editorial Comment from Dr Matsumoto to Intraoperative hypotension caused by oral administration of 5-aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer.
Topics: Administration, Oral; Aminolevulinic Acid; Humans; Hypotension; Photosensitizing Agents; Urinary Bla | 2019 |
Editorial Comment from Dr Fukuhara to Intraoperative hypotension caused by oral administration of 5-aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer.
Topics: Administration, Oral; Aminolevulinic Acid; Humans; Hypotension; Photosensitizing Agents; Urinary Bla | 2019 |
Severe and Prolonged Hypotension After Oral 5-Aminolevulinic Acid Administration in a Patient With End-Stage Renal Disease Undergoing Transurethral Resection of a Bladder Tumor: A Case Report.
Topics: Administration, Oral; Aged; Aminolevulinic Acid; Humans; Hypotension; Kidney Failure, Chronic; Norep | 2020 |
5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence ureterorenoscopy for urinary upper tract urothelial carcinoma ∼Preliminary prospective single centre trial∼.
Topics: Administration, Oral; Aged; Aminolevulinic Acid; Carcinoma in Situ; Cystoscopy; Female; Fluorescence | 2020 |
High performance of 5-aminolevulinic acid-induced fluorescent selective upper tract urinary cytology.
Topics: Aged; Aminolevulinic Acid; Carcinoma, Transitional Cell; Cytodiagnosis; Female; Humans; Male; Ureter | 2020 |
Evaluation of autofluorescence and photodynamic diagnosis in assessment of bladder lesions.
Topics: Aminolevulinic Acid; Cystectomy; Cystoscopy; Humans; Photochemotherapy; Photosensitizing Agents; Sen | 2020 |
In vitro evaluation of cytotoxic properties of 5-Aminolevulinic acid (5-ALA) on bladder cancer cells.
Topics: Aminolevulinic Acid; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Humans; Photochemotherapy; | 2020 |
Hexaminolevulinate blue light cystoscopy (Hal) assisted transurethral resection of the bladder tumour vs white light transurethral resection of the bladder tumour in non-muscle invasive bladder cancer (NMIBC) : a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Disease-Free Survival; Female; Fluo | 2020 |
Inverted papilloma of the urinary bladder shows fluorescence on photodynamic diagnosis using 5-aminolevulinic acid.
Topics: Aged; Aminolevulinic Acid; Endoscopy, Gastrointestinal; Female; Humans; Levulinic Acids; Male; Middl | 2020 |
The current situation of 5-aminolevulinic acid mediated photodynamic therapy in bladder cancer.
Topics: Aminolevulinic Acid; Humans; Photochemotherapy; Photosensitizing Agents; Urinary Bladder Neoplasms | 2020 |
Two diagnostic criteria of optical spectroscopy for bladder tumor detection: Clinical study using 5-ALA induced fluorescence and mathematical modeling.
Topics: Aminolevulinic Acid; Fluorescence; Humans; Photochemotherapy; Photosensitizing Agents; Spectrometry, | 2020 |
Mitomycin C-induced cell cycle arrest enhances 5-aminolevulinic acid-based photodynamic therapy for bladder cancer.
Topics: Aminolevulinic Acid; Cell Cycle Checkpoints; Cell Line, Tumor; Humans; Mitomycin; Photochemotherapy; | 2020 |
Prospective evaluation of blue-light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Biopsy; Color; Cystoscopy; Disease Progression; Female | 2021 |
Real-world experience with 5-aminolevulinic acid for the photodynamic diagnosis of bladder cancer: Diagnostic accuracy and safety.
Topics: Aminolevulinic Acid; Cystoscopy; Humans; Japan; Photochemotherapy; Photosensitizing Agents; Urinary | 2020 |
Cancer cell detection device for the diagnosis of bladder cancer from urine.
Topics: Aminolevulinic Acid; Biosensing Techniques; Cystoscopy; Humans; Photosensitizing Agents; Pilot Proje | 2021 |
Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB.
Topics: Aged; Aminolevulinic Acid; Carcinoma; Cystectomy; Cystoscopy; Female; Germany; Health Care Costs; He | 2021 |
Hexylaminolevulinate-mediated fluorescent urine cytology with a novel automated detection technology for screening and surveillance of bladder cancer.
Topics: Aminolevulinic Acid; Cytodiagnosis; Early Detection of Cancer; Humans; Optical Imaging; Population S | 2021 |
Improving hexaminolevulinate enabled cancer cell detection in liquid biopsy immunosensors.
Topics: Aminolevulinic Acid; Biosensing Techniques; Cell Line, Tumor; Cells, Cultured; Humans; Immunologic T | 2021 |
The sustaining of fluorescence in photodynamic diagnosis after the administration of 5-aminolevulinic acid in carcinogen-induced bladder cancer orthotopic rat model and urothelial cancer cell lines.
Topics: Aminolevulinic Acid; Animals; Carcinogens; Cell Line; Fluorescence; Photochemotherapy; Photosensitiz | 2021 |
Oral 5-aminolevulinic acid administration prior to transurethral resection of bladder tumor causes intraoperative hypotension: Propensity score analysis.
Topics: Aminolevulinic Acid; Humans; Hypotension; Photochemotherapy; Photosensitizing Agents; Propensity Sco | 2021 |
The diagnostic challenge of suspicious or positive malignant urine cytology findings when cystoscopy findings are normal: an outpatient blue-light flexible cystoscopy may solve the problem.
Topics: Aminolevulinic Acid; Carcinoma in Situ; Carcinoma, Transitional Cell; Cystoscopy; Humans; Outpatient | 2021 |
Macro and microeconomics of blue light cystoscopy with CYSVIEW® in non-muscle invasive bladder cancer.
Topics: Aminolevulinic Acid; Cystoscopy; Humans; Neoplasm Invasiveness; Population Surveillance; Urinary Bla | 2022 |
[Initial Experience of Photodynamic Diagnosis-Assisted Transurethral Resection of Bladder Tumor (PDD-TURBT)].
Topics: Aged; Aminolevulinic Acid; Cystectomy; Cystoscopy; Humans; Neoplasm Invasiveness; Neoplasm Recurrenc | 2021 |
Urothelial Tumors and Dual-Band Imaging: A New Concept in Confocal Laser Endomicroscopy.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Aminolevulinic Acid; Cell Nucleus; Cross-Sect | 2017 |
Blue light cystoscopy with hexylaminolevulinate: Our 7 years experience.
Topics: Aged; Aminolevulinic Acid; Biopsy; Cystoscopy; Female; Humans; Light; Male; Predictive Value of Test | 2017 |
Spectrophotometric photodynamic detection involving extracorporeal treatment with hexaminolevulinate for bladder cancer cells in voided urine.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cytodiagnosis; Female; Fluorescence; Follow-Up | 2017 |
Observational Studies Requested by European Health Authorities: Governmental Interference or an Enhancement of Everyday Urological Practice? The Hexvix® Observational Patients Evaluation Study as an Example of What to Expect.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystectomy; Cystoscopy; Disease Progression; Di | 2017 |
'Real-life experience': recurrence rate at 3 years with Hexvix
Topics: Administration, Intravesical; Aged; Aminolevulinic Acid; Cystectomy; Cystoscopy; Female; Humans; Kap | 2017 |
Editorial Comment.
Topics: Aminolevulinic Acid; Cystoscopy; Humans; Urinary Bladder Neoplasms | 2018 |
Hexvix plus Chemo.
Topics: Administration, Intravesical; Aminolevulinic Acid; Antineoplastic Agents; Carbon Radioisotopes; Cyst | 2018 |
[Navigation Surgery for Bladder Cancer by ALA-PDD].
Topics: Aminolevulinic Acid; Humans; Photosensitizing Agents; Urinary Bladder Neoplasms; Urologic Surgical P | 2018 |
High diagnostic efficacy of 5-aminolevulinic acid-induced fluorescent urine cytology for urothelial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cytodiagnosis; Female; Fluorescence; Humans; Ma | 2019 |
The prognostic impact of hexaminolevulinate-based bladder tumor resection in patients with primary non-muscle invasive bladder cancer treated with radical cystectomy.
Topics: Administration, Intravesical; Aged; Aminolevulinic Acid; Antineoplastic Agents; Cystectomy; Female; | 2020 |
Fluorescence Enhancement Effect of TiO
Topics: Aminolevulinic Acid; Cell Line, Tumor; Fluorescence; Humans; Nanoparticles; Neoplasms; Polyethylene | 2019 |
[Bladder tumor targeting by Hexvix(®) fluorescence: 4 years results after prospective monocentric evaluation].
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Female; Fluorescence; France; Human | 2013 |
Photodynamic therapy involves an antiangiogenic mechanism and is enhanced by ferrochelatase inhibitor in urothelial carcinoma.
Topics: Aminolevulinic Acid; Angiogenesis Inhibitors; Animals; Apoptosis; Carcinoma, Transitional Cell; Cell | 2013 |
The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation.
Topics: Aged; Aminolevulinic Acid; Cost-Benefit Analysis; Cystoscopy; Female; Follow-Up Studies; Humans; Mal | 2013 |
Expression levels of PEPT1 and ABCG2 play key roles in 5-aminolevulinic acid (ALA)-induced tumor-specific protoporphyrin IX (PpIX) accumulation in bladder cancer.
Topics: Aminolevulinic Acid; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette T | 2013 |
Would the benefits of hexaminolevulinate fluorescence cystoscopy be eliminated if every patient received postoperative installation of intravesical chemotherapy?
Topics: Aminolevulinic Acid; Antibiotics, Antineoplastic; Cystoscopy; Female; Humans; Male; Mitomycin; Neopl | 2013 |
5-Aminolevulinic acid protects against cisplatin-induced nephrotoxicity without compromising the anticancer efficiency of cisplatin in rats in vitro and in vivo.
Topics: Acute Kidney Injury; Aminolevulinic Acid; Animals; Antineoplastic Agents; Apoptosis; Carcinoma; Casp | 2013 |
Diagnostic approach for cancer cells in urine sediments by 5-aminolevulinic acid-based photodynamic detection in bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma in Situ; Cell Line, Tumor; Cytologica | 2014 |
The natural flavonoid silybin improves the response to Photodynamic Therapy of bladder cancer cells.
Topics: Aminolevulinic Acid; Apoptosis; Cell Line, Tumor; Cell Movement; Drug Synergism; Drug Therapy, Combi | 2014 |
Safety of hexaminolevulinate for blue light cystoscopy in bladder cancer. A combined analysis of the trials used for registration and postmarketing data.
Topics: Aged; Aminolevulinic Acid; Controlled Clinical Trials as Topic; Cystoscopy; Drug Approval; Female; H | 2014 |
A green light for blue light … without single-dose chemotherapy.
Topics: Aminolevulinic Acid; Cystectomy; Cystoscopy; Health Care Costs; Humans; Urinary Bladder Neoplasms | 2014 |
Implementing hexaminolevulinate HCl blue light cystoscopy: a nursing perspective.
Topics: Aminolevulinic Acid; Cystoscopy; Education, Nursing, Continuing; Humans; Urinary Bladder Neoplasms | 2014 |
Effectiveness of hexaminolevulinate fluorescence cystoscopy for the diagnosis of non-muscle-invasive bladder cancer in daily clinical practice: a Spanish multicentre observational study.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Female; Humans; Male; Middle Aged; | 2015 |
Protoporphyrin IX induced by 5-aminolevulinic acid in bladder cancer cells in voided urine can be extracorporeally quantified using a spectrophotometer.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cell Line, Tumor; Female; Humans; Male; Middle | 2015 |
[Cost-effectiveness of transurethral resection of the bladder with blue light in patients with non muscle invasive bladder cancer in France].
Topics: Administration, Intravesical; Aged; Aminolevulinic Acid; Carcinoma, Transitional Cell; Cost Savings; | 2015 |
Fluorescence cystoscopy: the end of biopsies for carcinoma in situ detection?
Topics: Aminolevulinic Acid; Cystoscopy; Female; Humans; Male; Urinary Bladder Neoplasms | 2015 |
Expression of ferrochelatase has a strong correlation in protoporphyrin IX accumulation with photodynamic detection of bladder cancer.
Topics: Aminolevulinic Acid; Biomarkers, Tumor; Cell Line, Tumor; Cells, Cultured; Cystoscopy; Ferrochelatas | 2016 |
Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden.
Topics: Aminolevulinic Acid; Budgets; Costs and Cost Analysis; Cystoscopy; Disease Progression; Humans; Neop | 2016 |
The Utility of a Flexible Fluorescence-Cystoscope with a Twin Mode Monitor for the 5-Aminolevulinic Acid-Mediated Photodynamic Diagnosis of Bladder Cancer.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopes; Cystoscopy; False Positive Reactions; Fem | 2015 |
Immobilization of ALA-Zn(II) Coordination Polymer Pro-photosensitizers on Magnetite Colloidal Supraparticles for Target Photodynamic Therapy of Bladder Cancer.
Topics: Aminolevulinic Acid; Blotting, Western; Cell Death; Cell Line, Tumor; Colloids; Ferrosoferric Oxide; | 2015 |
Hexaminolevulinate hydrochloride blue-light flexible cystoscopy in the detection and follow-up of nonmuscle-invasive bladder cancer: cost consequences during outpatient surveillance in Sweden.
Topics: Aminolevulinic Acid; Costs and Cost Analysis; Cystectomy; Cystoscopy; Disease Progression; Follow-Up | 2016 |
Blue Light Cystoscopy Should be Used Routinely for Bladder Cancer Detection: Con.
Topics: Aminolevulinic Acid; Cystoscopy; Fluorescence; Humans; Urinary Bladder Neoplasms | 2016 |
Blue Light Cystoscopy Should be Used Routinely for Bladder Cancer Detection: Pro.
Topics: Aminolevulinic Acid; Cystectomy; Cystoscopy; Fluorescence; Humans; Neoplasm Recurrence, Local; Urina | 2016 |
Reducing understaging of bladder cancer with the aid of photodynamic cystoscopy.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma in Situ; Cystoscopy; Female; Fluoresc | 2016 |
Optimised photodynamic diagnosis for transurethral resection of the bladder (TURB) in German clinical practice: results of the noninterventional study OPTIC III.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma in Situ; Carcinoma, Transitional Cell; Cysto | 2017 |
Tolerability of Repeat Use of Blue Light Cystoscopy with Hexaminolevulinate for Patients with Urothelial Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma; Cystoscopy; Female; Humans; Male; Mi | 2017 |
Editorial Comment.
Topics: Aminolevulinic Acid; Carcinoma, Transitional Cell; Cystoscopy; Humans; Urinary Bladder Neoplasms | 2017 |
Diagnostic Accuracy of Hexaminolevulinate in a Cohort of Patients Undergoing Radical Cystectomy.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma in Situ; Carcinoma, Transitional Cell | 2017 |
[Initial experience in the diagnosis and treatment of superficial bladder tumors with Hexvix].
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carbon Radioisotopes; Cystoscopy; Female; Fluorescence | 2008 |
[Calculating the price of a new diagnostic or therapeutic option. Example of transurethral resection of bladder tumors using photodynamic diagnostics with hexaminolevulinic acid].
Topics: Aminolevulinic Acid; Biopsy; Budgets; Carcinoma, Transitional Cell; Cost-Benefit Analysis; Cystoscop | 2008 |
Analysis of differential PDT effect in rat bladder tumor models according to concentrations of intravesical hexyl-aminolevulinate.
Topics: Aminolevulinic Acid; Animals; Cell Line, Tumor; Chromatography, High Pressure Liquid; Disease Models | 2008 |
Hexylaminolaevulinate 'blue light' fluorescence cystoscopy in the investigation of clinically unconfirmed positive urine cytology.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma in Situ; Carcinoma, Transitional Cell | 2009 |
Cytogenetic analysis of false-positive mucosa by photodynamic diagnosis using 5-aminolevulinic acid - possible existence of premalignant genomic alterations examined by in vitro experiment.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma in Situ; Chromosome Aberrations; Cytogenetic | 2009 |
Editorial comment on: A new generation of optical diagnostics for bladder cancer: technology, diagnostic accuracy, and future applications.
Topics: Aminolevulinic Acid; Carbon Radioisotopes; Carcinoma in Situ; Diagnostic Techniques, Urological; For | 2009 |
Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden.
Topics: Adult; Aminolevulinic Acid; Carbon Radioisotopes; Computer Simulation; Cost Savings; Cystectomy; Cys | 2009 |
Raman spectroscopy of bladder tissue in the presence of 5-aminolevulinic acid.
Topics: Algorithms; Aminolevulinic Acid; Diagnosis, Differential; Discriminant Analysis; Early Detection of | 2009 |
Improved detection and reduced early recurrence of non-muscle-invasive bladder cancer using hexaminolaevulinate fluorescence cystoscopy: results of a multicentre prospective randomized study (PC B305).
Topics: Aminolevulinic Acid; Carcinoma in Situ; Clinical Trials, Phase III as Topic; Cystoscopy; Humans; Mic | 2009 |
Blue-sky thinking about blue-light cystoscopy.
Topics: Aminolevulinic Acid; Cystoscopy; Humans; Microscopy, Fluorescence; Neoplasm Recurrence, Local; Photo | 2009 |
Noninvasive transitional cell carcinoma is associated with a high occurrence of false positives in photodynamic diagnosis.
Topics: Aminolevulinic Acid; Carcinoma, Transitional Cell; Cystoscopy; False Positive Reactions; Female; Flu | 2009 |
Predictors of false positives in 5-aminolevulinic acid-induced photodynamic diagnosis of bladder carcinoma: identification of patient groups that may benefit most from highly specific optical diagnostics.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; False Positive Reactions; Female; Humans; Male; | 2009 |
Editorial comment.
Topics: Aminolevulinic Acid; False Positive Reactions; Humans; Photosensitizing Agents; Urinary Bladder Neop | 2009 |
Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Guérin immunotherapy and mitomycin C intravesical therapy.
Topics: Administration, Intravesical; Aminolevulinic Acid; Antibiotics, Antineoplastic; BCG Vaccine; Biopsy; | 2010 |
Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carbon Radioisotopes; Cystectomy; Cystoscopy; F | 2009 |
Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guérin.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Aminolevulinic Acid; Antineoplastic Agents; B | 2010 |
Regulation of 5-aminolevulinic acid-mediated protoporphyrin IX accumulation in human urothelial carcinomas.
Topics: Aminolevulinic Acid; beta-Alanine; Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone; Carcinoma, Tr | 2009 |
Editorial comment.
Topics: Aminolevulinic Acid; Carbon Radioisotopes; Cystectomy; Cystoscopy; Humans; Neoplasm Recurrence, Loca | 2009 |
[Clinical experience with transurethral resection of bladder tumor (TUR-Bt) guided by photodynamic diagnosis (PDD)].
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Aminolevulinic Acid; Disease-Free Survival; F | 2009 |
New bladder cancer removal technique reduces recurrence.
Topics: Aminolevulinic Acid; Humans; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2010 |
[Hexaminolevulinate fluorescence cystoscopy in 2009].
Topics: Aminolevulinic Acid; Carbon Radioisotopes; Cystoscopy; Fluorescence; Humans; Practice Guidelines as | 2010 |
Biodistribution of PVP-hypericin and hexaminolevulinate-induced PpIX in normal and orthotopic tumor-bearing rat urinary bladder.
Topics: Aminolevulinic Acid; Animals; Anthracenes; Antineoplastic Agents; Female; Fluorescence; Perylene; Ph | 2011 |
Photodynamic diagnosis in patients with T1G3 bladder cancer: influence on recurrence rate.
Topics: Aged; Aminolevulinic Acid; Carcinoma in Situ; Cystoscopy; Female; Follow-Up Studies; Humans; Kaplan- | 2010 |
[Photodynamic diagnosis (cystoscopy with hexaminolevulinate) in the surveillance of urothelial lesions managed with conservative treatment].
Topics: Aminolevulinic Acid; Cystoscopy; Humans; Urinary Bladder Neoplasms | 2010 |
Tissue responses to hexyl 5-aminolevulinate-induced photodynamic treatment in syngeneic orthotopic rat bladder cancer model: possible pathways of action.
Topics: Aminolevulinic Acid; Animals; Cell Line, Tumor; Photochemotherapy; Rats; Rats, Inbred F344; Signal T | 2011 |
Photo induced hexylaminolevulinate destruction of rat bladder cells AY-27.
Topics: Aminolevulinic Acid; Animals; Apoptosis; Carcinoma, Transitional Cell; Cell Line, Tumor; Flow Cytome | 2011 |
Photodynamic therapy with hexyl aminolevulinate induces carbonylation, posttranslational modifications and changed expression of proteins in cell survival and cell death pathways.
Topics: Aminolevulinic Acid; Animals; Apoptosis; Cell Line, Tumor; Cell Survival; DNA Repair; Electrophoresi | 2011 |
[Hexaminolevulinate photodynamic diagnosis in non-muscle invasive bladder cancer: experience of the BLUE group].
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Female; Humans; Male; Middle Aged; | 2011 |
[Comment to "Photodynamic diagnosis with hexaminolevulinate in Non-Muscle-Invasive Bladder Cancer. Experience of the BLUE GROUP"].
Topics: Aminolevulinic Acid; Cystoscopy; Female; Humans; Male; Urinary Bladder Neoplasms | 2011 |
Comparison between intravesical and oral administration of 5-aminolevulinic acid in the clinical benefit of photodynamic diagnosis for nonmuscle invasive bladder cancer.
Topics: Administration, Intravesical; Administration, Oral; Adult; Aged; Aged, 80 and over; Aminolevulinic A | 2012 |
[Expression of the tumormarker p16INK4a in cytology specimens of the urinary bladder. A new means for early recognition and surveillance of urothelial cancer].
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Biomarkers, Tumor; Biopsy; Carcinoma, Transitio | 2011 |
Role of hexaminolevulinate-guided fluorescence cystoscopy in bladder cancer: critical analysis of the latest data and European guidance.
Topics: Aminolevulinic Acid; Consensus; Cystoscopy; Europe; Fluorescence; Humans; Photosensitizing Agents; P | 2012 |
[Interest of flexible videocystoscopy in blue light (+Hexvix(®)) in consultation for the diagnosis of vesical tumor].
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Feasibility Studies; Female; Humans; Male; | 2012 |
Blue light cystoscopy for detection and treatment of non-muscle invasive bladder cancer.
Topics: Aminolevulinic Acid; Carcinoma in Situ; Cystoscopy; Fluorescence; Humans; Patient Selection; Urinary | 2012 |
Editorial comment.
Topics: Aminolevulinic Acid; Cystoscopy; Female; Humans; Male; Neoplasm Recurrence, Local; Neoplasm Staging; | 2012 |
Could basic research shed light on false positivity in photodynamic diagnosis?
Topics: Aminolevulinic Acid; Carcinoma in Situ; Diagnostic Techniques, Urological; False Positive Reactions; | 2012 |
Cost-effectiveness of fluorescent cystoscopy for noninvasive papillary tumors: con.
Topics: Aminolevulinic Acid; Carbon Radioisotopes; Carcinoma, Papillary; Cost-Benefit Analysis; Cystoscopy; | 2012 |
Is there a learning curve for photodynamic diagnosis of bladder cancer with hexaminolevulinate hydrochloride?
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma; Clinical Competence; Cystoscopy; False Posi | 2012 |
Oral 5-aminolevulinic acid in simultaneous photodynamic diagnosis of upper and lower urinary tract transitional cell carcinoma - a prospective audit.
Topics: Administration, Oral; Aged; Aminolevulinic Acid; Biopsy; Carcinoma, Transitional Cell; Clinical Audi | 2012 |
Editorial comment.
Topics: Aminolevulinic Acid; Cystectomy; Female; Humans; Light; Male; Neoplasm Recurrence, Local; Radionucli | 2012 |
Fluorescence diagnosis of bladder cancer: a novel in vivo approach using 5-aminolevulinic acid (ALA) dendrimers.
Topics: Administration, Intravesical; Aminolevulinic Acid; Animals; Dendrimers; Female; Microscopy, Fluoresc | 2012 |
The quality of 5-aminolevulinic acid-induced photodynamic diagnosis and transurethral resection of bladder tumors: does the urologist play a role?.
Topics: Aged; Aminolevulinic Acid; Biopsy; Cystoscopy; False Positive Reactions; Female; Humans; Male; Medic | 2012 |
'Stop going off on a tangent': a novel method for discriminating pathological from tangential fluorescence during photodynamic diagnosis cystoscopy.
Topics: Aminolevulinic Acid; Cystoscopy; Fluorescence; Humans; Photosensitizing Agents; Urinary Bladder Neop | 2012 |
Value of fluorescence cystoscopy in high risk non-muscle invasive bladder cancer.
Topics: Aminolevulinic Acid; Carcinoma, Transitional Cell; Cystoscopy; Humans; Optical Imaging; Photosensiti | 2013 |
How to avoid local side effects of bladder photodynamic therapy: impact of the fluence rate.
Topics: Aminolevulinic Acid; Animals; Apoptosis; Cystectomy; Female; Immunoenzyme Techniques; Photochemother | 2013 |
Photodynamic effect of 5-aminolevulinic acid-loaded nanoparticles on bladder cancer cells: a preliminary investigation.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Humans; Microscopy, Electron, Transmission; Nanoparticles; Ph | 2013 |
[Fluorescence cystoscopy in bladder cancer: what future?].
Topics: Aminolevulinic Acid; Carcinoma in Situ; Carcinoma, Transitional Cell; Cystoscopy; Diagnosis, Differe | 2002 |
Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions.
Topics: Aminolevulinic Acid; Biomarkers, Tumor; Biopsy; Carcinoma in Situ; Carcinoma, Transitional Cell; End | 2002 |
Determination of the maximal tumor:normal bladder ratio after i.p. or bladder administration of 5-aminolevulinic acid in Fischer 344 rats by fluorescence spectroscopy in situ.
Topics: Administration, Intravesical; Aminolevulinic Acid; Animals; Female; Microscopy, Fluorescence; Photoc | 2002 |
Do patients profit from 5-aminolevulinic acid-induced fluorescence diagnosis in transurethral resection of bladder carcinoma?
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Biopsy; Carcinoma in Situ; Fluorescence; Humans | 2002 |
Ultraviolet-excited (308 nm) autofluorescence for bladder cancer detection.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Transitional Cell; Cystoscopy; False Positi | 2002 |
Whole bladder photodynamic therapy for orthotopic superficial bladder cancer in rats: a study of intravenous and intravesical administration of photosensitizers.
Topics: Administration, Intravesical; Aminolevulinic Acid; Animals; Antineoplastic Agents; Carcinoma, Transi | 2003 |
A study of 5-aminolevulinic acid and its methyl ester used in in vitro and in vivo systems of human bladder cancer.
Topics: Administration, Topical; Aminolevulinic Acid; Animals; Biological Transport, Active; Carcinoma; Cyst | 2003 |
Fluorescence confocal microscopy and image analysis of bladder cancer using 5-aminolevulinic acid.
Topics: Administration, Intravesical; Aminolevulinic Acid; Biomarkers, Tumor; Carcinoma in Situ; Carcinoma, | 2003 |
Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study.
Topics: Administration, Intravesical; Adult; Aged; Aminolevulinic Acid; Female; Follow-Up Studies; Humans; I | 2003 |
Detection of bladder dysplasia using 5-aminolaevulinic acid-induced porphyrin fluorescence.
Topics: Aminolevulinic Acid; Carcinoma, Transitional Cell; Cystitis; Cystoscopy; Fluorescence; Humans; Photo | 2003 |
Fluorescence cytology of the urinary bladder.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma in Situ; Carcinoma, Trans | 2003 |
[Fluorescence cystoscopy using 5-aminolevulinic acid].
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Femal | 2003 |
The effect of photodynamic therapy on rat urinary bladder with orthotopic urothelial carcinoma.
Topics: Administration, Intravesical; Aminolevulinic Acid; Animals; Female; Infusions, Intravenous; Photoche | 2003 |
Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma in Situ; Cystoscopy; Female; Fluoresc | 2004 |
Investigation of sequential mitomycin C and photodynamic therapy in a mitomycin-resistant bladder cancer cell-line model.
Topics: Aminolevulinic Acid; Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Survival; Drug Interactions | 2004 |
The photodynamic diagnosis (PDD) for early detection of carcinoma and dysplasia of the bladder.
Topics: Aminolevulinic Acid; Biopsy; Carcinoma, Transitional Cell; Cystoscopy; Early Diagnosis; Fluorescence | 2003 |
Kinetics, biodistribution and therapeutic efficacy of hexylester 5-aminolevulinate induced photodynamic therapy in an orthotopic rat bladder tumor model.
Topics: Aminolevulinic Acid; Animals; Carcinoma, Transitional Cell; Disease Models, Animal; Photochemotherap | 2004 |
[Value of the photodynamic method in the diagnosis of superficial bladder tumors].
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Transitional Cell; Cystoscopy; Early | 2004 |
Lack of effect of hyperoxia on photodynamic therapy and lipid peroxidation in three different cancer cell lines.
Topics: Aminolevulinic Acid; Animals; Cell Line, Tumor; Colonic Neoplasms; Humans; Hyperoxia; Lipid Peroxida | 2005 |
[Fluorescence endoscopy in the diagnosis and treatment of superficial bladder neoplasms].
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Female; Fluoroscopy; Humans; Male; | 2005 |
Integral spectrophotometric analysis of 5-aminolaevulinic acid-induced fluorescence cytology of the urinary bladder.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Transitional Cell; Female; Humans; M | 2006 |
[Clinical experience with intravesical instillations of 5-aminolevulinic acid (5-ALA) for the photodynamic diagnosis using fluorescence cystoscopy for bladder cancer].
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Femal | 2006 |
Hexyl aminolevulinate in the detection of bladder cancer: profile report.
Topics: Aminolevulinic Acid; Carcinoma in Situ; Clinical Trials as Topic; Cystoscopy; Humans; Male; Photosen | 2006 |
Hexyl-aminolevulinate-mediated photodynamic therapy: how to spare normal urothelium. An in vitro approach.
Topics: Aminolevulinic Acid; Animals; Cell Survival; In Vitro Techniques; Microscopy, Electron, Scanning; Mu | 2007 |
Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder.
Topics: Administration, Intravesical; Adolescent; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carci | 2007 |
Detection of urinary bladder cancer with flow cytometry and hexaminolevulinate in urine samples.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Biomarkers, Tumor; Carcinoma, Transitional Cell; Cell | 2007 |
[Interdisciplinary networking for clinical and molecular questions in non-muscle invasive urothelial carcinoma of the bladder].
Topics: Aminolevulinic Acid; Biomarkers, Tumor; Carcinoma, Transitional Cell; Cooperative Behavior; Cystosco | 2007 |
[Fluorescence cytology. Improvement of urinary cytology].
Topics: Aminolevulinic Acid; Carcinoma, Transitional Cell; Cell Separation; Female; Flow Cytometry; Humans; | 2007 |
[Fluorescence cytology of the urinary bladder after instillation of 5-aminolevulinic acid].
Topics: Aminolevulinic Acid; Carcinoma in Situ; Carcinoma, Transitional Cell; Cell Division; Humans; Microsc | 2007 |
[Photodynamic diagnostic of superficial bladder carcinoma].
Topics: Administration, Intravesical; Aminolevulinic Acid; Germany; Humans; Length of Stay; Photosensitizing | 2007 |
[Editorial comment on Stepp H. et al.: fluorescence diagnosis and photodynamic therapy in urology].
Topics: Aminolevulinic Acid; Clinical Trials, Phase III as Topic; Fluorescence; Follow-Up Studies; Humans; P | 2007 |
Prof. Dr. Ramon Abascal Garcia's clear statement to fluorescence diagnosis of bladder cancer by 5- amino-levolinic acid.
Topics: Aminolevulinic Acid; Fluorescence; Humans; Urinary Bladder Neoplasms | 2007 |
[Diagnosis of urothelial carcinoma].
Topics: Aminolevulinic Acid; Biomarkers, Tumor; Biopsy; Carcinoma, Transitional Cell; Cystoscopy; Diagnostic | 2008 |
Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence.
Topics: Administration, Intravesical; Aged; Aminolevulinic Acid; Biopsy; Carcinoma in Situ; Carcinoma, Trans | 1996 |
Photodynamic diagnosis following topical application of delta-aminolevulinic acid in a rat bladder tumor model.
Topics: Administration, Intravesical; Aminolevulinic Acid; Animals; Butylhydroxybutylnitrosamine; Carcinoma; | 1994 |
[Superficial bladder tumors. Pathological and clinical review and presentation of a new diagnostic method: fluorescence photodetection of transitional epithelial carcinomas based on protoporphyrin IX induction with delta-aminolevulinic acid (5-ALA)].
Topics: Aged; Aged, 80 and over; Algorithms; Aminolevulinic Acid; Carcinoma, Transitional Cell; Cystoscopy; | 1995 |
Biodistribution and phototoxicity of 5-aminolevulinic acid-induced PpIX in an orthotopic rat bladder tumor model.
Topics: Aminolevulinic Acid; Animals; Female; Neoplasm Transplantation; Photochemotherapy; Protoporphyrins; | 1995 |
[Photodynamic diagnosis of urothelial neoplasms after intravesicular instillation of 5-aminolevulinic acid].
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Biopsy; Carcinoma | 1994 |
Intravesical instillation of 5-aminolevulinic acid: the fluorescent metabolite is limited to urothelial cells.
Topics: Administration, Intravesical; Aminolevulinic Acid; Carcinoma in Situ; Carcinoma, Papillary; Cell Lin | 1994 |
A mechanistic study of cellular photodestruction with 5-aminolaevulinic acid-induced porphyrin.
Topics: Aminolevulinic Acid; Animals; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cell Division; | 1994 |
In vivo photoproduct formation during PDT with ALA-induced endogenous porphyrins.
Topics: Aminolevulinic Acid; Animals; Female; Humans; Kinetics; Light; Mice; Mice, Nude; Neoplasm Transplant | 1993 |
Cellular fluorescence of the endogenous photosensitizer protoporphyrin IX following exposure to 5-aminolevulinic acid.
Topics: Aminolevulinic Acid; Cell Line; Flow Cytometry; Fluorescence; Humans; Photochemotherapy; Photosensit | 1995 |
Fluorescence cystoscopy following intravesical instillation of 5-aminolevulinic acid: a new procedure with high sensitivity for detection of hardly visible urothelial neoplasias.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Epith | 1995 |
Photodynamic effects of 5-aminolevulinic acid-induced porphyrin on human bladder carcinoma cells in vitro.
Topics: Aminolevulinic Acid; Carcinoma, Transitional Cell; Culture Media, Serum-Free; Dose-Response Relation | 1996 |
Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer.
Topics: Administration, Intravesical; Adult; Aged; Aminolevulinic Acid; Female; Follow-Up Studies; Humans; M | 1996 |
Chemical instability of 5-aminolevulinic acid used in the fluorescence diagnosis of bladder tumours.
Topics: Aminolevulinic Acid; Humans; Solutions; Spectrophotometry, Ultraviolet; Urinary Bladder; Urinary Bla | 1996 |
Aminolevulinic acid for photodynamic therapy of bladder carcinoma cells.
Topics: Aminolevulinic Acid; Cell Survival; Humans; Photochemotherapy; Photosensitizing Agents; Protoporphyr | 1996 |
Wavelength dependent photodynamic effects on chemically induced rat bladder tumors following intravesical instillation of 5-aminolevulinic acid.
Topics: Aminolevulinic Acid; Animals; Female; Photochemotherapy; Rats; Rats, Wistar; Urinary Bladder Neoplas | 1997 |
Clinical assessment of fluorescence cytoscopy during transurethral bladder resection in superficial bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Transitional Cell; Cystoscopes; Cyst | 1997 |
Clinical evaluation of a method for detecting superficial surgical transitional cell carcinoma of the bladder by light-induced fluorescence of protoporphyrin IX following the topical application of 5-aminolevulinic acid: preliminary results.
Topics: Administration, Cutaneous; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Aminolevuli | 1997 |
[The clinical value of fluorescence cystoscopy in the detection of superficial transitional epithelial cell carcinoma of the bladder].
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma in Situ; Carci | 1997 |
In vivo fluorescence kinetics of porphyrins following intravesical instillation of 5-aminolaevulinic acid in normal and tumour-bearing rat bladders.
Topics: Administration, Intravesical; Aminolevulinic Acid; Animals; Female; Kinetics; Photosensitizing Agent | 1997 |
Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line.
Topics: Aminolevulinic Acid; Carcinoma, Transitional Cell; Cell Survival; Dose-Response Relationship, Drug; | 1997 |
Photodynamic therapy of bladder cancer cell lines.
Topics: Aminolevulinic Acid; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cell Survival; Dose-Res | 1997 |
Biodistribution of Photofrin II and 5-aminolevulinic acid-induced protoporphyrin IX in normal rat bladder and bladder tumor models: implications for photodynamic therapy.
Topics: Aminolevulinic Acid; Animals; Dihematoporphyrin Ether; Disease Models, Animal; Female; Photochemothe | 1998 |
Fluorescence detection of flat transitional cell carcinoma after intravesical instillation of aminolevulinic acid.
Topics: Administration, Intravesical; Aminolevulinic Acid; Carcinoma in Situ; Carcinoma, Papillary; Cystosco | 1998 |
The influence of hypoxia and pH on aminolaevulinic acid-induced photodynamic therapy in bladder cancer cells in vitro.
Topics: Acidosis; Aminolevulinic Acid; Cell Hypoxia; Cell Survival; Humans; Hydrogen-Ion Concentration; Phot | 1998 |
Cell cycle phase influences tumour cell sensitivity to aminolaevulinic acid-induced photodynamic therapy in vitro.
Topics: Aminolevulinic Acid; Cell Cycle; Humans; Photochemotherapy; Photosensitizing Agents; Protoporphyrins | 1998 |
Quantitative studies of the kinetics of 5-aminolaevulinic acid-induced fluorescence in bladder transitional cell carcinoma.
Topics: Administration, Intravesical; Aged; Aminolevulinic Acid; Biopsy; Carcinoma, Transitional Cell; Cultu | 1998 |
[Fluorescence--endoscopy in carcinoma of the urinary bladder].
Topics: Aminolevulinic Acid; Cystoscopes; Humans; Neoplasm Recurrence, Local; Precancerous Conditions; Urina | 1998 |
Fluorescence cystoscopy in the diagnostics and treatment of bladder tumors.
Topics: Aminolevulinic Acid; Biopsy; Carcinoma in Situ; Carcinoma, Transitional Cell; Cystoscopes; Endoscope | 1998 |
5-aminolevulinic acid-induced fluorescence endoscopy applied at secondary transurethral resection after conventional resection of primary superficial bladder tumors.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Female; Fluorescence; Humans; Male; | 1999 |
Clinical results of the transurethreal resection and evaluation of superficial bladder carcinomas by means of fluorescence diagnosis after intravesical instillation of 5-aminolevulinic acid.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Biopsy; Carcinoma | 1999 |
Diagnosis of bladder carcinoma using protoporphyrin IX fluorescence induced by 5-aminolaevulinic acid.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Female; Fluorescence; Humans; Male; | 1999 |
Rodent fibroblast model for studies of response of malignant cells to exogenous 5-aminolevulinic acid.
Topics: 3T3 Cells; Aminolevulinic Acid; Animals; Cell Line, Transformed; Cell Transformation, Neoplastic; Ce | 1999 |
5-Aminolevulinic acid-induced fluorescence endoscopy for the detection of lower urinary tract tumors.
Topics: Administration, Intravesical; Aminolevulinic Acid; Cystoscopy; Fluorescence; Humans; Photosensitizin | 1999 |
In vivo fluence rate and fractionation effects on tumor response and photobleaching: photodynamic therapy with two photosensitizers in an orthotopic rat tumor model.
Topics: Aminolevulinic Acid; Animals; Dermatitis, Phototoxic; Disease Models, Animal; Female; Light; Microsc | 1999 |
5-Aminolevulinic acid and its derivatives: physical chemical properties and protoporphyrin IX formation in cultured cells.
Topics: Aminolevulinic Acid; Bronchi; Cell Line; Humans; Hydrogen-Ion Concentration; Kinetics; Lung Neoplasm | 2000 |
No generalized skin phototoxicity after intravesical application of 5-aminolevulinic acid for fluorescence diagnosis of superficial bladder cancer.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Dermatitis, Photo | 2000 |
Intravesical administration of 5-aminolevulinic acid (5-ALA). Safety and pharmacokinetics of 5-ALA and its metabolite protoporphyrin IX.
Topics: Administration, Intravesical; Adult; Aged; Aminolevulinic Acid; Female; Humans; Male; Middle Aged; P | 2000 |
Sensitivity analysis of the diagnostic value of endoscopies in cross-sectional studies in the absence of a gold standard.
Topics: Aminolevulinic Acid; Cross-Sectional Studies; Cystoscopy; Female; Humans; Male; Predictive Value of | 2000 |
Biosynthesis and photodynamic efficacy of protoporphyrin IX (PpIX) generated by 5-aminolevulinic acid (ALA) or its hexylester (hALA) in rat bladder carcinoma cells.
Topics: Aminolevulinic Acid; Animals; Cell Extracts; Cell Survival; Culture Media; Culture Media, Serum-Free | 2000 |
Optimization of differential photodynamic effectiveness between normal and tumor urothelial cells using 5-aminolevulinic acid-induced protoporphyrin IX as sensitizer.
Topics: Aminolevulinic Acid; Flow Cytometry; Humans; Mitochondria; Photochemotherapy; Photosensitizing Agent | 2001 |
Diagnosing cancer in vivo.
Topics: Aminolevulinic Acid; Automation; Biopsy; Colonic Neoplasms; Endoscopy; Humans; Microscopy, Confocal; | 2001 |
Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer.
Topics: Adult; Aged; Aminolevulinic Acid; Carcinoma, Transitional Cell; Female; Humans; Male; Middle Aged; N | 2001 |
Role of 5-aminolevulinic acid in the diagnosis and treatment of superficial bladder cancer: improvement in diagnostic sensitivity.
Topics: Adult; Aged; Aminolevulinic Acid; Carcinoma in Situ; Cystoscopy; Female; Fluorescence; Humans; Male; | 2001 |
[Fluorescence cytology of the urinary bladder].
Topics: Aminolevulinic Acid; Carcinoma in Situ; Carcinoma, Transitional Cell; Cystoscopy; Humans; Microscopy | 2001 |
Autofluorescence imaging to optimize 5-ALA-induced fluorescence endoscopy of bladder carcinoma.
Topics: Administration, Intravesical; Aminolevulinic Acid; Biopsy; Cystoscopy; Equipment Design; False Posit | 2001 |
Quantification of 5-aminolevulinic acid induced fluorescence improves the specificity of bladder cancer detection.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Transitional Cell; Cystoscopy; Femal | 2001 |
Significance of fluorescence cystoscopy for diagnosis of superficial bladder cancer after intravesical instillation of delta aminolevulinic acid.
Topics: Adenocarcinoma; Administration, Intravesical; Aged; Aged, 80 and over; Aminolevulinic Acid; Biopsy; | 2001 |
Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma in Situ; Chromosome Aberrations; Chromosomes | 2002 |
New aspect of photodynamic diagnosis of bladder tumors: fluorescence cytology.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Anthracenes; Carcinoma in Situ; Cystitis; Cytophotomet | 2002 |
The fluorescence biodistribution and kinetics of aminolevulinic acid induced protoporphyrin IX in the bladder of a rat model with orthotopic urothelial carcinoma.
Topics: Administration, Intravesical; Aminolevulinic Acid; Animals; Carcinoma, Transitional Cell; Female; Fl | 2002 |
Comparison of the bladder tumour antigen test with photodynamic diagnosis in patients with pathologically confirmed recurrent superficial urinary bladder tumours.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Antigens, Neoplasm; Biomarkers, Tumor; Cystosco | 2002 |
[Fluorescent endoscopy superior to white light endoscopy. Detecting cancers of the urinary bladder earlier].
Topics: Aminolevulinic Acid; Carcinoma in Situ; Carcinoma, Transitional Cell; Cystoscopy; Fluorescence; Huma | 2002 |
Comparison between 5-aminolevulinic acid photodynamic diagnosis and narrow-band imaging for bladder cancer detection.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Female; Humans; Levulinic Acids; Male; Mid | 2021 |